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ABSTRACT 
 
The conversion of one differentiated cell-type into another, challenges our 
long-held view of differentiated cells being in a fixed terminal stage of 
differentiation, incapable of reversal or change. Such conversions are most 
favourable between developmentally related cell-types such as hepatocytes 
from the liver and cells of the pancreas. The main drawback of culturing 
hepatocytes in vitro has been their limited life span and their rapid de-
differentiation in culture. However, the de-differentiation of hepatocytes, and 
the progressive diminution in the transcription levels of liver-specific genes, is 
in fact associated with a concomitant induction of a pancreatic gene 
expression profile. In this ‘primed’ state, it is possible to convert these de-
differentiated hepatocytes more efficiently into beta-like cells by the 
transduction of the pancreatic master switch gene, Pdx1, in rat, mouse and 
human hepatocytes. An extensive screen of several other key-regulatory 
pancreatic transcription factors has yielded that along with Pdx1, the 
transcription factors Neurogenin3, NeuroD, Pax4 and MafA are crucial for 
achieving efficient reprogramming. The ‘beta-phenotype’ of the cells 
generated can be further enhanced by using the extrinsic factors betacellulin, 
Activin A and nicotinamide. Many of these factors, most notably betacellulin 
can promote endocrine differentiation in favour of beta cells, as was 
demonstrated using an explant model of pancreatic development. The beta-
like cells generated by the molecular reprogramming of hepatocytes in 
addition to expressing a wide array of beta cell-specific genes, also exhibit 
many beta cell functions. The beta-like cells can process pro-insulin into the 
mature insulin protein and secrete insulin in a regulated manner in response 
to glucose stimulation. These cells therefore could serve as an attractive 
alternative for generating autologous beta cells for transplantation as a 
means of a cell-based therapy for type 1 diabetes mellitus. 
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 Chapter ONE
Introduction  
 1A MOLECULAR REPROGRAMMING OF CELLS 
 
The emergence of multicellularity was a fundamental step in the evolution of 
complex organisms. This step was facilitated by the ability to derive a 
multitude of different cell types from a single cell such as the fertilised egg. 
Initiated upon fertilisation, mammalian development proceeds through a 
hierarchical route from pluripotent embryonic stem cells of the blastocyst, via 
germlayer- and tissue-specific- progenitors to an array of ‘terminally’ 
differentiated cell-types. It was thought that this developmental pathway was 
programmed, irreversible and unchangeable. However, recent discoveries 
have shown that deviations from this hierarchical programme of 
development, is quite the norm in some organisms and during some 
pathological processes. What was observed in nature and in disease can 
now be experimentally recapitulated for therapeutic benefits. Embryonic stem 
cells can be encouraged to differentiate along specific lineages. Similarly, 
fate-committed progenitor cells and precursor cells can be altered to give rise 
to cell-types atypical of their normal developmental pathway. Furthermore, 
the long held view that terminally differentiated cells are just that; in their final 
stage of differentiation, and that this state is fixed and cells are not capable 
of reversal or change, has been challenged. The remarkable cellular 
plasticity of differentiated cells has now been demonstrated by the ability to 
reprogramme them into other cell-types (including induced pluripotent stem 
cells) by molecular and genetic manipulation. 
 
1A.1 The differentiated state of cells. 
All cells that make up an organism have a common developmental origin- the 
pluripotent cells of the inner cell mass within the blastocyst (Fig 1.1). 
However throughout development, the differentiation pathways delineate, 
committing progenitor cells to distinct fates until fully differentiated and 
functional cell-types are established. A differentiated cell is characterised by 
a distinct phenotype that demarcates it from other cells, either by functional, 
Zygote
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Inner cell mass
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Figure 1.1.  The developmental hierarchy of differentiation.  The newly 
fertilised zygote is totipotent and capable of producing all the cell types within 
the embryo as well as all the extra-embryonic tissues.  In the blastocyst the 
inner cell mass consists of cells that are pluripotent and differentiate into the 
three germlayers after gastrulation.  As development proceeds, fully 
differentiated cell types of ectodermal, mesodermal and endodermal are 
derived from the specific multipotent stem/precursor cell compartments of 
each germlayer (adapted from Gilbert, 2006 and Slack, 2006). 
 
morphological or biochemical differences. Despite the homogeneity of the 
genetic makeup of virtually all cells, morphological and functional 
heterogeneity is achieved due to differential gene expression. This 
differential gene expression is brought about by differential responses to 
gradients of morphogens mediated by transcription factors that are activated 
or repressed by the signal. The mechanisms underlying differential gene 
expression are not due to alterations in the DNA sequence itself, but due to 
epigenetic modifications providing discriminative accessibility of the genetic 
material (reviewed in Jaenisch and Bird, 2003).  
In the nuclei of all cells, DNA is compacted and packaged in the form of 
chromatin in association with proteins (Fig. 1.2). The basic repeat element of 
chromatin is the nucleosome composed of DNA wrapped around an octamer 
of histone proteins (H2A, H2B, H3 and H4). The nucleosomes wrap around 
histone H1 and are further compacted into the 30nm fibre that make up the 
active chromatin or is organised into chromosomes. Epigenetic modifications 
to the DNA or the associated histone proteins ensure that genes can be 
turned on in one lineage but off in another. Firstly DNA methylation triggers 
heritable gene silencing, either by interfering with transcription factor binding 
or by the recruitment of co-repressor complexes by methyl-CpG binding 
domain proteins (Levenson and Sweatt, 2005, Kiefer, 2007).  Secondly, post-
translational modification by acetylation, phosphorylation, ubiquitination and 
methylation of the N-terminal tails of histones can alter the structural and 
functional state of chromatin. It is believed that specific combinations of 
histone modifications are responsible for coordinating differential gene 
expression (Strahl and Allis, 2000, Li, 2002). Collectively, epigenetic marks 
ensure that for a given differentiated cell-type, in addition to expressing 
ubiquitous genes, a whole array of cell-type specific genes are expressed 
while those not characteristic of the cell-type are repressed. For example in a 
fully differentiated hepatocyte, albumin, transferrin and haptoglobin genes 
are expressed along with genes coding for liver-specific transcription factors 
that are responsible for maintaining the hepatic phenotype. Therefore, cell-
type specific transcription factor expression ultimately modulates the 
composition of the whole transcriptome of a differentiated cell. 
2nmNaked duplex DNA
“Beads-on-a-string”
& solenoid chromatin
fibres
11nm
30nm
Nucleosome
(DNA and octomer of 
H2A, H2B, H3 & H4 histones)
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Figure 1.2. Compaction of DNA and the structure of chromatin. In eukaryotic 
cells, DNA is compacted with heterodimers of core histone proteins to form a 
nucleoprotein complex called a nucleosome. The transcriptional activity of 
genes are in turn determined by the methylation and acetylation state of DNA 
and histone tails respectively. Inactive chromatin is further compacted in 
association with scaffolding protein to form chromosomes (adapted from 
Lodish et al., 2003). 
 
1A.2 The phenomenon of de-differentiation. 
De-differentiation refers to two quite distinct processes. The first is the 
process by which a terminally differentiated cell loses its cell-specific 
properties and the second, refers to the process by which the cell reverses 
the normal developmental processes and once again becomes a precursor 
or stem-like cell. The study of de-differentiation has mostly been driven by 
the curiosity to understand the mechanisms underlying the regenerative 
capabilities of various plants and vertebrates. De-differentiation is marked by 
the re-entry into the cell cycle and at the same time deviating from a 
differentiated state to a state that confers multi- or pluripotentiality (Williams 
et al., 2003). During limb and tail regeneration in urodele amphibians, 
multinucleate myofibres lose their striated nature and dissociate into 
mononucleated cells to contribute to the blastema which forms beneath the 
wound epithelium. Fluorescently-labelled and retrovirally-tagged myotubes 
implanted into the balstema change into mononucleated cells, proliferate and 
by four to six week after implantation give rise to muscle and cartilage tissue 
of the regenerating structure (Lo et al., 1993). This suggests that the 
myofibres are capable of de-differentiating and acquiring multipotentiality 
before re-differentiating into its original or an entirely novel lineage. In vivo 
de-differentiation has also been observed during the regeneration of the jaw 
(Ghosh et al., 1994), spinal cord (O'Hara et al., 1992) and cardiac muscle 
(Oberpriller et al., 1995) in amphibians. 
The de-differentiation of cells in culture has also been noted and is often 
considered a hindrance to their long term in vitro maintenance. Both 
hepatocytes and cells of the kidney epithelium are known to de-differentiate 
in long term culture (Forino et al., 2006, Guillouzo, 1986). Similarly human 
pancreatic beta cells (Ouziel-Yahalom et al., 2006), but not their murine 
counterparts (Atouf et al., 2007), can expand in vitro following a process that 
resembles an epithelial-mesenchymal transition event. Recently, attempts 
have been made to induce the de-differentiation of cells in hope of deriving 
pluripotent cells capable of re-differentiating into other lineages (Odelberg, 
2002, not reproducible). Only limited data is available on the molecular 
mechanisms that govern de-differentiation in mammalian cells. However, 
work in amphibians and plants have revealed the importance of chromatin 
decondensation and other epigenetic changes in the process of de-
differentiation (Zhao et al., 2001). Understanding the molecular mechanisms 
underlying the phenomenon is imperative in order to utilise de-differentiation 
as step in the molecular reprogramming of differentiated cells into other cell-
types. 
 
1A.3 Cell-type switching in development and disease. 
Cells pass through a hierarchy of developmental decisions during the course 
of embryonic development from stem-like cells to fully differentiated cell-
types. However, those that do not conform to this hierarchical developmental 
pathway are less common, but nonetheless are seen in nature (Fig. 1.3). 
Such changes include switching between cells of different tissue types 
(broadly referred to as metaplasia and includes the interconversion of fully 
differentiated cell-types sometimes referred to as transdifferentiation), 
derivation of cells with abnormal phenotypes (dysplasia) and also the 
reversal of the differentiated state (de-differentiation, as discussed above). 
Collectively all changes that do not conform to the normal developmental 
pathway will be referred to as cell-type conversions, cell-type switching, 
metaplastic changes or cellular reprogramming (if it is induced). Although it 
may seem unconventional to think so, metaplasias are not necessarily 
always associated with errors made during development or tissue repair. 
Though rare, the phenomenon is observed across the metazoan phylogeny. 
For example, during mammalian development, epithelial cell-type switches 
from columnar to stratified squamous and from pseudostratified to squamous 
during the development of the oesophagus and the female reproductive 
system respectively, have been long identified (Cunha, 1976, Yu et al., 
2005). In non-embryonic states, cell-type conversions are thought to be used 
as a mechanism for tissue repair which excludes the need to resort to 
undifferentiated reserves of cells such as stem cells. It is also used during 
vast tissue respecification processes associated with metamorphosis and the 
normal progression through stages of the lifecycle (Thowfeequ et al., 2007b). 
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Differentiated striated muscle cells of hydrozoan jellyfish in culture, can be 
multipotent with the ability to convert into various cell-types including smooth 
muscle cells and nerve cells positive for the neuropeptide FMRFamide (Alder 
and Schmid, 1987, Schmid et al., 1988). Tissue respecification is more 
commonplace during metamorphosis of arthropods and during regeneration 
of body parts by members of the echinoderm phylum. However, some 
vertebrates are also capable of restoring by regrowth, parts of their body that 
have been lost to injury or by autotomy.  In the process of Wolffian lens 
regeneration in urodele amphibians, cells of the dorsal iris proliferate, 
undergo de-pigmentation and re-differentiate into keratinocyte-like crystallin 
containing cells of the lens (Tsonis et al., 2004, Yamauchi et al., 1984). It is 
also possible to redirect the neuronal retina and cells of the outer cornea into 
a lens epithelium fate in this manner (Opas and Dziak, 1998). The 
homeodomain transcription factor Six3 may be the master switch gene in the 
iris-lens conversion process. Transfection of Six3 accompanied by inhibition 
of the BMP (bone morphogenic protein) signalling pathway can induce the 
transdifferentiation of the ventral iris (which does not normally take part in 
lens regeneration) into lens tissue (Grogg et al., 2005). Cellular 
reprogramming has also been suggested to play a role in amphibian limb 
and tail regeneration, where epidermal, neuronal and muscle tissues are 
replaced following amputation (Brockes and Kumar, 2002). However, most of 
the evidence suggests that the cell-type conversions in this case, are 
facilitated via a de-differentiated intermediate rather than being a direct cell-
type conversion that can be labelled as a transdifferentiation event. 
Postnatal cell-type switching is not a basic, primordial attribute of only a few 
vertebrates. Although less well understood, it has also been observed in 
mammals. Tissues that constantly renew throughout life such as hair 
follicles, the gut and blood have an adequate reservoir of dedicated adult 
stem cells.  However, many organs are not believed to maintain a resident 
undifferentiated stem cell population and either have to rely on the 
proliferation or transdifferentiation of existing differentiated cells to replenish 
the cell mass after injury. The lung for example, is an organ exposed to the 
external environment and therefore to pathogens and toxicants. Hence the 
lung epithelium needs to respond rapidly and effectively to cell damage 
repeatedly caused by these agents. During repair and maintenance of the 
lung epithelium, in addition to mobilising stem cells and promoting the 
proliferation of differentiated cells, various cell-type conversion including 
direct transdifferentiation is also thought to occur (Rawlins and Hogan, 
2006).  Following damage to the bronchiolar epithelium, ciliated cells 
respond by spreading and undergoing a sequential squamous to cuboidal to 
columnar transition and eventually change into distinct epithelial cell-types to 
repair the damaged airway epithelium.  During the process, expression of 
several key regulatory transcription factors characteristic of the developing 
lung, including β-catenin, Foxa2, Foxj1, and Sox family members are 
reactivated (Costa et al., 2001, Rawlins and Hogan, 2006). During pancreatic 
regeneration in the Vervet monkey, foci of hepatocytes are found in the 
pancreas (Wolfe-Coote et al., 1996). It is likely that the ectopic hepatocytes 
could have arisen from differentiated cells of the exocrine pancreas as has 
previously been observed in other experimental systems such as in copper-
depleted rats (Rao et al., 1986). Similarly, the reverse transformation or foci 
of acini and pancreatic ductules in the human liver have been found; but is 
associated with severe posthepatitic cirrhosis (Wolf et al., 1990).  
There are numerous examples of metaplasia in human histopathology and 
some are more clinically significant than others in that they predispose to the 
development of neoplasia.  Metaplasias are implicated in the development of 
various cancers including lung, prostate, vaginal and breast cancer 
(Auerbach et al., 1961, Bjerkvig et al., 2005, Nelson et al., 2002, Quinlan et 
al., 2007). A clinical example of cell-type switching is the premalignant 
condition of Barrett’s oesophagus or Barrett’s metaplasia. Barrett’s 
metaplasia is a known precursor to oesophageal adenocarcinoma 
(Hameeteman et al 1989). A patient is said to have developed Barrett’s when 
the normal squamous lining of the oesophagus is converted to an intestinal 
type columnar epithelium normally at the junction of the oesophagus and 
stomach (Barrett, 1957). Research suggests that the metaplasia is induced 
by chronic acid reflux from the stomach into the oesophagus (Spechler, 
2002). The master switch gene responsible for inducing Barrett’s metaplasia, 
is thought to be the Cdx2 gene, a member of the parahox cluster (Ferrier et 
al., 2005). Cdx2 is involved in intestinal epithelial differentiation and 
distinguishes the upper and lower epithelium of the alimentary canal; 
furthermore Cdx2 expression has been found to be upregulated in 
adenocarcinomas of the intestine (De Lott et al., 2005). Experiments have 
shown that ectopic expression of Cdx2 can induce intestinal metaplasia in 
the stomach (Li et al., 2005b). The exact mechanism by which metaplasia is 
induced in Barrett’s is still unclear.  
Other clinical examples where cell-type switching has been implicated 
include liver fibrosis leading to cirrhosis, interstitial fibrosis of renal disease, 
and aerosolised allergen-induced mucous metaplasia. Knowledge obtained 
from studying metaplasias and other cell-type conversions as a result of a 
natural phenomenon or as part of a disease is important for a number of 
reasons. Such studies will help answer questions regarding normal 
development, regeneration and the etiology of certain diseases. Furthermore 
it will enable us to devise potential therapeutic modalities for various 
degenerative diseases, where in addition to alleviating the symptoms may 
also make it possible to permanently replace the damaged tissue. 
 
1A.4 Inducing cell-type switching for cell-based therapies. 
Inducing the conversion of one differentiated cell type to another cell type for 
therapeutic applications holds a distinct advantage over using stem cell 
technology; as the utilisation of stem cells in cellular therapy is often 
hindered by the ethical controversies and oncogenic concerns centred 
around the use of embryonic stem cells and the practical difficulties of 
identifying and isolating adult stem cells (Samson and Chan, 2006). Early 
experiments showed that the transfection of 5-azacytidine treated mouse 
fibroblasts with cDNAs from myocyte cDNA libraries can induce their 
conversion into myoblasts (Davis et al., 1987).  cDNAs that induced muscle 
differentiation in fibroblasts have homology to the myc-like regions of MyoD 
and Myf-5. These are members of the MRF (Myogenic Regulatory Factor) 
family of transcription factors which were later found to be essential for 
myogenesis (Kitzmann et al., 1998).  It is thought that cell-type conversions 
may occur naturally and can be induced following changes in expression of 
such ‘master switch genes’. These are genes which encode transcription 
factors that induce a cell to differentiate along a particular developmental 
pathway. 
A much celebrated example of an induced cell-type conversion for which 
lineage analysis is available is the stepwise conversion of B-cells into 
macrophages. The CCAAT/Enhancer binding protein family transcription 
factors C/EBPα and C/EBPβ, can act synergistically with the transcription 
factor PU.1 in converting isolated B-lymphocytes into macrophages (Xie et 
al., 2004, Slack, 2007). This conversion is accompanied by a loss of the B-
cell specific marker CD19 and the induction of the macrophage marker 
MAC1. The presence of rearranged immunoglobulin genes in the 
reprogrammed macrophages, indicate their origin from cells that have 
already undergone normal B-cell differentiation. Furthermore, in transgenic 
mice where Cre is driven off the CD19 promoter (which permanently labels 
B-cells with the eYFP reporter), the origin of the macrophages from B-cells 
can be followed in real time (Xie et al., 2004).  
Likewise, the developmental pathways of liver and pancreas are similar; 
potentially similar enough that cell-type conversion may be induced between 
the two tissue types for therapeutic purposes using ectopic expression of one 
or a few master switch genes. In the case of treatment of liver diseases, the 
clear problem involving transplantation is the current lack of available donor 
tissue, despite the fact that liver can be obtained from living donors (Ridgway 
et al., 2005). Sources of hepatocyte-like cells for transplantation include 
salivary gland cells.  SGP-1 cells derived from duct-ligated submandibular 
salivary glands can be induced to form hepatic (AFP (α-foetoprotein) and/or 
albumin positive) clusters when cultured on type-1 collagen (Okumura et al., 
2003). Similarly, current work on the conversion of pancreatic cells to 
hepatocytes raises the possibility that liver disease could be treated using 
reprogrammed cells from the patients’ own pancreas. The conversion of the 
pancreatic cell line AR42J-B13 (B13) to a hepatic phenotype can be induced 
following addition of the synthetic glucocorticoid, dexamethasone (Dex) 
(Shen et al., 2000). Treatment with Dex causes the downregulation of the 
pancreatic marker amylase and induction of liver markers including, 
transferrin, α1-antitrypsin, transthyretin, glucose-6-phosphatase, α-
foetoprotein, cytokeratin 8, P-glycoprotein and phenol sulphotransferase. 
Later work demonstrated that not only could the new hepatocyte-like cells 
express early liver markers but also expressed genes involved with Phase I 
and II detoxification pathways, ammonia detoxification and glucose 
metabolism, indicating that the cell-type conversion was accompanied with 
the induction of genes associated with a mature phenotype after treatment 
with Dex and Oncostatin M (Burke et al., 2006, Tosh et al., 2002, Wang et 
al., 2005). It has been proposed that the molecular mechanism controlling 
the conversion of the B13 cells to hepatocytes involves the activation of the 
glucocorticoid receptor by Dex, which activates transcription of a master 
switch gene a member of the C/EBP family of transcription factors (Shen et 
al., 2000). An upregulation of C/EBPβ along with α-foetoprotein is seen 
during the Dex-induced reprogramming of primary rat pancreatic exocrine 
cells into hepatocytes (Lardon et al., 2004).  
Based on the same concept that the liver and the pancreas are 
developmentally related and that during development the two tissues are 
distinguished by the expression of one master switch gene, recent work has 
focused on the conversion of hepatocytes into pancreatic beta cells for 
diabetes therapy. Pdx1 is thought to be the master switch gene for the 
conversion of liver cells to pancreatic cells and is discussed in more detail in 
Section 1C.2. All examples of cell-type switching, be they natural or induced, 
demonstrate that the differentiated cells are not ‘fixed’ but rather retain the 
ability to undergo genetic reprogramming.  
 1B THE PANCREATIC BETA CELL 
 
The mature pancreas is both morphologically and physiologically divided into 
two distinct compartments- the exocrine pancreas and the endocrine 
pancreas. The exocrine portion is organised into acini that produce and 
secrete digestive enzymes such as amylase, and the ductal network that 
secretes bicarbonate and transports the enzymes to the intestine.  
Alternatively, the endocrine pancreas is devoted to the production and 
secretion of a variety of hormones directly into the blood stream. Within the 
endocrine compartment that comprises about 1% of the pancreas, the 
hormone-producing cells are organised into individual, highly vascularised 
and highly innervated micro-organs called the islets of Langerhans (see Fig. 
1.4). The insulin-producing beta cells are the most abundant cell-type in the 
islet (65-80%), followed by glucagon-producing alpha cells (15-20%), 
somatostatin producing delta cells (3-10%), pancreatic polypeptide-
producing PP cells (3-5%) and the ghrelin-producing epsilon cells (<1%) 
(Edlund, 2002). The shear abundance of beta cells reflects the importance of 
their function in responding synchronously to stimulatory concentrations of 
blood glucose by releasing insulin to maintain glucose homeostasis. 
Therefore it is important to know the developmental origin of the beta cell, 
how their numbers are maintained and more importantly how they function. 
 
1B.1  Developmental origins of the beta cell. 
Before exploring the mechanisms of endocrine lineage segregation and the 
origination of beta cells, it is essential to understand the fundamentals of 
early pancreatic development. Pancreatic development is a highly 
coordinated process involving morphogenesis and differentiation, 
orchestrated by extracellular signals and transcription factor interactions. 
Like the liver and the intestine, the pancreas is an organ derived from the 
definite endoderm (Slack, 1995). Following gastrulation, signals from the 
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Figure 1.4. The structure and organisation of the pancreas. The pancreas is 
located behind the stomach in the abdominal cavity. It secretes digestive 
juices into the duodenum and endocrine hormones directly into the blood 
stream via capillaries. The exocrine tissue makes up most of the pancreatic 
mass and is made up acinar, centroacinar and ductal cells. The endocrine 
portion of the pancreas comprises of the Islets of Langerhans in which the 
different endocrine cell types are grouped together (based on figures by the 
University of Wisconsin Hospital and Clinical Authority; from the website: 
http://www.uwhealth.org). 
mesoderm and ectoderm are responsible for the anterior-posterior patterning 
of the endoderm (Wells and Melton 2000). However, induction of pancreatic 
development and the commitment to a pancreatic fate is set up by an Activin 
βB- and FGF2-mediated repression of Sonic hedgehog (Shh) expression in 
the domain that becomes the prepancreatic endoderm (Hebrok et al., 1998, 
Hebrok et al., 2000; Fig. 1.5). It is believed that the signals arise from the 
adjacent mesodermal structures such as the notochord, endothelia of the 
dorsal aorta, cardiogenic mesoderm and the septum transversum (Kim et al., 
1997, Lammert et al., 2001). The competence of the foregut endoderm to 
respond to the instructive mesodermal signal is primarily mediated by the 
preceding expression of the transcription factors HNF1β, FoxA1, FoxA2, 
HNF4 and HNF6 (Onecut1), as well as GATA4, 5 and 6 (reviewed in Wilson 
et al., 2003, Cereghini, 1996, Zaret, 1999). Although, the signals are 
common to both the dorsal and ventral pancreatic anlagen, the induction 
strategies are different. While the dorsal foregut endoderm defaults to 
intestine in the absence of mesodermal signals, the default pathway for the 
ventral foregut endoderm is to become pancreatic. It is only BMP4 from the 
septum transversum working in concert with FGFs from the cardiac 
mesoderm that can drive hepatogenesis- the alternative fate of the 
bipotential precursors of the ventral foregut endoderm (Kim and MacDonald, 
2002, Rossi et al., 2001, Zhou et al., 2007). Following Shh repression, a 
consequent activation of Pdx1 expression by HNF1β and FoxA2 in the 
pancreatic precursor population is seen (Lantz and Kaestner, 2005). 
The early prepancreatic endoderm expresses two parahox transcription 
factors- Pdx1 (McKinnon and Docherty, 2001, Offield et al., 1996) and Hlxb9 
(Harrison et al., 1999). Pdx1 expression is seen in two pancreatic buds as 
well as the adjacent duodenum and antral stomach (Ohlsson et al., 1993). 
The interaction of Pdx1 with Pbx1 is thought to be important for the 
expansion of the pancreatic buds as the impairment of pancreatic 
development in the absence of Pbx1, mimics that seen in Pdx1 null embryos 
(Kim and MacDonald, 2002). The early epithelial progenitor epithelium which 
is positive for the transcription factors HNF1β, Onecut1, FoxA2 and Sox9 
(which controls progenitor cell identity by regulating the former three), 
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Figure 1.5. Schematic diagram of pancreatic development. At E8 (top left), 
the region of the midline endoderm of the dorsal pancreatic anlagen directly 
in contact with the notochord express Pdx1 whereas the adjacent Shh 
positive domains remain Pdx1 negative. These Pdx1 negative regions later 
come into contact with the cardiac mesoderm and adopt a hepatogenic fate. 
Around E9.5, the blood vessels and the septum transversum provide signals 
that direct the pancreatic gene expression in the adjacent endoderm. In the 
boxed figures, yellow represents the Pdx1 expressing domains and grey 
represents early endocrine precursor cells. These cells migrate out of the 
epithelium and cluster to form the islets of Langerhans around E12.5. The 
exocrine acini are formed from cells at the tip of the prepancreatic tubules 
(from Kim and MacDonald, 2002).  
undergoes expansion and branches into duct-like structures (Lynn et al., 
2007). This is followed by the secondary transition, which is characterised by 
synchronised waves of differentiation. Several other transcription factors 
come into play in order to determine the specification of the endocrine and 
exocrine lineages. In an analogous scheme to neuronal development, in a 
subset of cells, notch inhibition releases the Hes1 imposed repression of 
Neurogenin3 expression (Murtaugh et al., 2003). The expression of 
Neurogenin3 is scattered and transient, and regulated by an auto-repressive 
feedback loop (Fig. 1.6); however it is necessary and sufficient to initiate 
endocrine differentiation of the pancreas (Schwitzgebel et al., 2000). 
Downstream of Neurogenin3, the pro-endocrine basic helix-loop-helix 
(bHLH) transcription factor NeuroD is directly activated (Gradwohl et al., 
2000). In contrast, cells of the prepancreatic endoderm, where Neurogenin3 
expression is extinguished by persistent notch signalling, are destined to 
become the exocrine pancreas driven by the pro-exocrine transcription factor 
p48/Ptf1a (Kawaguchi et al., 2002, Rose et al., 2001). 
 
 
Figure 1.6. Lateral inhibition and the role of the Notch signalling 
pathway during beta cell development.  In endocrine precursors, on the 
removal of Hes1 imposed Neurogenin3 (Ngn3) expression NeuroD is 
activated. Ngn3 also activates the Notch ligand Delta, which in an adjacent 
epithelial cell can activate Hes1 via Notch. Thus Hes1 represses endocrine 
differentiation in this adjacent cell. Ngn3 expression itself is controlled by an 
autoregulatory feedback loop (from Skipper and Lewis, 2000). 
Once committed to an endocrine fate, the next step involves the segregation 
of the distinct endocrine lineages including beta, alpha, delta and PP. It is 
believed that the default pathway for the endocrine progenitors is to become 
alpha cells, as ectopic expression of Neurogenin3 almost exclusively results 
in this outcome (Schwitzgebel et al., 2000). However it does not mean that 
all lineages start off as glucagon-expressing cells and become multihormonal 
cells before being respecified into other lineages (see Herrera, 2000). 
Therefore additional signals are necessary to deviate the fate of the 
progenitor cells to becoming other endocrine cell-types such as beta cells 
before they go onto become alpha cells by default. This is modulated by the 
selective sequential expression of a number of transcription factors. These 
include the early factors such as Pax4, Nkx2.2 and Nkx6.1 expressed 
alongside Neurogenin3 in endocrine progenitors and the late factors 
including Pax6, Isl1, Pdx1 and MafA expressed in more mature beta cells 
(Fig. 1.7). Much of what we know about the roles of these transcription 
factors in pancreatic development has been elucidated by the study of their 
expression profiles and the phenotype of transgenic animals. For example, 
Nkx2.2 deficient mice lack fully differentiated beta cells and have reduced 
number of alpha and PP cells (Sussel et al., 1998). Nkx2.2 null mice also fail 
to express Nkx6.1. Furthermore, mice homozygous for Nkx6.1 mutations 
completely lack beta cells and double homozygous mutants for both the NK-
homeodomain transcription factors are phenotypically similar to Nkx2.2 null 
mice (Sander et al., 2000).  Collectively, these studies propose both the NK-
homeodomain transcription factors as being essential for complete beta cell 
differentiation with Nkx2.2 acting upstream of Nkx6.1. Table 1.1 summarises 
the data from other similar studies. Although most of the information relates 
to the function as known in rodents, the same transcription factors are 
implicated in the development of the human foetal endocrine pancreas (Lyttle 
et al., 2008). 
The final stage of endocrine pancreatic development involves isletogenesis 
or the organisation of the islets. It is generally accepted that the migration of 
endocrine precursors out of the endodermal epithelium, takes place prior to 
completion of their differentiation. The migration events are mediated via the 
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Figure 1.7. Gene expression during beta cell differentiation. A- the gene 
expression cascade involved in deriving differentiated pancreatic cell types 
and liver cell types from a common precursor population during development 
(amended from Samson and Chan, 2006 and Wilson et al., 2003). B.  The 
relative expression patterns of different pancreatic transcription factors 
during the differentiation of beta cells from precursor cells of the early 
pancreatic endoderm (from Servitja and Ferrer, 2004). 
Table 1.1. Transcription factors and the pancreatic phenotype genetic mouse 
models suggesting providing evidence for their importance in regulating pancreatic 
development and function. 
Factor Genetic model Phenotype References 
Hlxb9 Hlxb9
-/- 
Dorsal pancreas agenesis; reduced 
islet size and beta cell numbers in the 
ventral pancreas. 
(Harrison et al., 
1999) 
IA1/Insm1 Insm1
LacZ/LacZ 
Endocrine precursors formed but 
reduced numbers of mature insulin-
positive beta cells. 
(Gierl et al., 2006) 
Isl1 Isl1
-/- 
No dorsal endocrine cells or 
mesenchyme. 
(Ahlgren et al., 
1997) 
MafA MafA
-/- 
Post natal glucose intolerance; 
impaired secretagogue response; beta 
cell numbers not changes. 
(Zhang et al., 
2005) 
NeuroD1 NeuroD1
-/- 
Disorganised islets; secretion-defective 
acinar cells, hyperglycaemic at birth; 
perinatal mortality. 
(Naya et al., 1997) 
Ngn3 Ngn3
-/- 
Absence of intestinal and pancreatic 
endocrine lineages; abnormal acinus.  
(Gradwohl et al., 
2000) 
Nkx2.2 Nkx2.2
-/- 
Absence of differentiated beta cell; 
reduced alpha and PP cell numbers; 
increased numbers of ghrelin cells; 
hyperglycaemic at birth; perinatal 
mortality. 
(Sussel et al., 
1998) 
Nkx6.1 Nkx6.1
-/- 
Reduced islet size; reduced number of 
beta cells after secondary transition. 
(Sander et al., 
2000) 
Pax4 Pax4
-/- 
Reduced beta and delta cell numbers; 
increase in alpha and ghrelin cells 
numbers. 
(Sosa-Pineda et 
al., 1997) 
Pax6 Pax6
-/- 
Disorganised islets; absence of alpha 
cells. 
(Sander et al., 
1997) 
Pdx1 Pdx1
-/- 
Pancreatic agenesis; small pancreatic 
rudiment with few alpha cells. 
(Jonsson et al., 
1994) 
 Pdx1
+/- 
Glucose intolerance and impaired 
GSIS; reduction in beta cell mass and 
survival with age. 
(Johnson et al., 
2003) 
Ptf1a/p48 Ptf1a
-/- 
Hypoplastic pancreas; absence of 
exocrine cells in dorsal pancreas; 
normal endocrine cells and cell 
numbers. 
(Krapp et al., 
1998) 
Sox9 Pdx1-Cre/ 
Sox9
loxp/loxp 
Hypoplastic pancreas; reduced 
amylase-positive acinar cells; reduced 
proliferation of Pdx1-positive 
progenitors. 
(Seymour et al., 
2007) 
 
integrins (αvβ3 and αvβ5) regulated by mesenchymal derived TGFβ while E- 
and N- cadherins control the aggregation of the endocrine cells into islets 
(Dahl et al., 1996, Docherty, 2001, Miralles et al., 1998). At this point 
pancreatic organogenesis is complete. However it is important to note that 
most of the late transcription factors are also crucial for the postnatal 
maintenance and the functioning of the mature beta cells.  
 
1B.2  Beta cell maintenance and survival. 
Persistent expression of several late transcription factors regulate the 
expression of key beta cell genes and are important for the maintenance of 
the mature beta cell phenotype. This is clinically attested in maturity onset 
diabetes of the young (MODY) syndromes where heterozygous mutations in 
some of the genes encoding these transcription factors leads to progressive 
impairment in beta cell function and eventually diabetes (Fajans et al., 2001). 
Furthermore, recent advances in Cre-Lox technology have enabled us to 
look at the role of transcription factors in the mature beta cell independent of 
their function during development. For example, though Pdx1 is 
downregulated following the induction of pancreogenesis, Pdx1 expression 
reappears confined to more differentiated beta cells where it directly binds to 
and regulates the expression of several genes including insulin, GLUT2, 
IAPP and Nkx6.1 (Cerf, 2006, Docherty et al., 2005). Similarly, the 
transcription factor NeuroD is thought to regulate glucokinase expression 
(Moates et al., 2003) while MafA plays a key role in beta cell function (Zhang 
et al., 2005). Foxa2 on the other hand, is an upstream regulator of both Pdx1 
and the ATP-sensitive K+ channel, Kir6.2 (Sund et al., 2001). Emerging 
evidence also suggests the importance of the FoxO proteins in maintaining 
the beta cell phenotype. FoxO-dependent mechanisms are thought to 
enhance beta cell survival and help them accomplish their endocrine function 
by: 1- increasing their resistance to oxidative stress. 2- conditioning beta 
cells to cope with changes in fuel abundance (reviewed in Glauser and 
Schlegel, 2007). Since, beta cell-specific deletion of most of these genes 
only results in a diminution but not a complete loss of beta cell function, a 
considerable degree of redundancy is apparent within the transcriptional 
network governing the mature beta cell.  
 
1B.3  Beta cell replication and neogenesis. 
An organism needs to be able to control its beta cell mass in accordance 
with its insulin needs. A stable and sufficient pancreatic beta cell mass is 
necessary for efficient functioning of the endocrine pancreas. Beta cell 
hypertrophy can increase beta cell mass without the necessity of making 
new cells. However, new beta cells can be formed either by the mitotic 
division of pre-existing beta cell (replication) or by the differentiation of a pool 
of undifferentiated precursor/stem cell population (neogenesis). Much 
controversy still lingers regarding which of these two mechanisms remain 
accountable for the origin of the majority of beta cells in adult life. 
The rate of replication of beta cells in the adult pancreas is generally low (2-
3% per day) but can undergo dynamic shifts to compensate for changes in 
body mass or during pregnancy to match increased insulin demand 
(Ackermann and Gannon, 2007, Bouwens and Rooman, 2005, Finegood et 
al., 1995). Using a lineage tracing model to label the initial beta cell 
population with human placental alkaline phosphatase, it has been shown 
that beta cell replication dominantly contributes to beta cell homeostasis in 
the adult (Dor et al., 2004) as well as during beta cell regeneration following 
beta cell loss (Nir et al., 2007). Several other studies have independently 
confirmed this (Teta et al., 2007). The importance of beta cell proliferation in 
the maintenance of the adult beta cell mass has also been shown in cyclin 
D2-/- mice. In these mice, the islets show normal prenatal development but in 
the adults the beta cell mass is almost undetectable (Georgia and Bhushan, 
2004, Kushner et al., 2005).  
The minimal role of progenitor cells especially in beta cell regeneration does 
not remain undisputed. It is accepted that in the foetus 10-20% of the beta 
cells arise by beta cell duplication but the remaining 80% or more is 
attributed to neogenesis from undifferentiated precursors (Bouwens and 
Rooman, 2005). The presence of putative precursor/stem cells in the adult 
pancreas has been suggested (Weir and Bonner-Weir, 2004), however their 
localisation and possible contribution to beta cell homeostasis remains 
undetermined. Recent studies have shown, that in the partial duct ligated 
pancreatic injury model, regeneration occurs via neogenesis of beta cell from 
a Neurogenin3 positive progenitor (O'Neill et al., 2008, Xu et al., 2008). In the 
case of type 2 diabetics, beta cell neogenesis seems to be the predominant 
mechanism for beta cell mass regeneration while the beta cell replication 
rates remain relatively unchanged. Nonetheless, the neogenesis of beta cells 
from precursor cells in the undisturbed healthy adult pancreas remains 
debatable (Butler et al., 2003). 
 
1B.4  Insulin- from gene to secretory granules. 
In the adult, insulin is a protein that is produced almost exclusively in the 
beta cells of the islets of Langerhans, notwithstanding the low levels of extra-
pancreatic insulin that has been detected in the brain (Devaskar et al., 1994), 
thymus (Pugliese et al., 1997), salivary (Vallejo et al., 1984) and lachrymal 
glands (Cunha et al., 2005). The well characterised function of the insulin 
released from the beta cells is to induce most of the body's cells (including 
myocytes and adipocytes) to take up glucose from the blood, storing the 
excess as glycogen in the liver and muscle, and minimise the use of fat as 
an energy source. However the role of the extra-pancreatic insulin is unclear. 
It has been suggested that it may play a role in the hormonal communication 
networks necessary to maintain overall energy balance or help establish 
immune tolerance (Hay and Docherty, 2006, Porte et al., 2005). 
Most mammals have one copy of the insulin gene (ins). In the case of 
humans, the INS gene is located on chromosome 11 at position p15.5 
(Harper et al., 1981). However few species including the rat and the mouse 
have two non allelic-variants of the insulin gene, namely ins1 and ins2, of 
which ins2 corresponds to the single copy in other species. It is thought that 
ins1 was retroposed from the partially processed ins2 mRNA (Hay and 
Docherty, 2006, Shiao et al., 2008). Both the ins genes share strong 
homology to each other and for this reason are believed to be subjected to 
the same regulatory pathways (Roderigo-Milne et al., 2002). The ins gene is 
small, consisting of three exons and two introns with the sequence 
immediately upstream of the transcription initiation site being defined as the 
ins promoter (German and Wang, 1994). Control of insulin gene expression 
is largely exerted at the transcriptional level through well defined elements 
located within this promoter region that bind to beta cell restricted as well as 
ubiquitous transcription factors (Fig. 1.8). The compactness of the ins 
promoter and the close proximity of the regulatory elements requires 
complex additive and synergistic interactions between the binding factors in 
order to achieve efficient transcription regulation. Furthermore, overlapping 
of regulatory elements introduces another level of control through binding 
competition between transcription factors (Docherty et al., 2005).  The highly 
conserved A, E and C boxes act as cis-acting elements with no significant 
transcriptional activity of their own, but can dramatically boost ins promoter 
activity once bound by the transcription factors Pdx1, the E47/NeuroD 
heterodimer and MafA respectively (Docherty et al., 2005). The formation of 
functional transcriptional activator complexes are completed by the non-DNA 
binding co-activator-mediated stabilisation of the DNA-bound transcriptional 
factors (Qiu et al., 2002). Several upstream transcription factors such as 
Nkx2.2 are not essentially part of the transcription complex. However they 
regulate ins gene expression by influencing the expression of factors that are 
part of the complex (Ohneda et al., 2000a). 
 
 
 
Figure 1.8. The rat ins1 promoter. The well characterised DNA elements 
(between C2 and A1) of the rat insulin promoter are shown in grey. The 
major transcription factor complexes known to bind to these elements and 
activate the promoter are also shown (amended from Chakrabarti and 
Mirmira, 2003). 
A further level of regulation of the ins gene is provided by the long-term 
nutritional and hormonal control of transcription. Glucose for instance, 
influences ins gene expression by affecting Pdx1 in multiple ways. Glucose 
can promote the nuclear inclusion of Pdx1, acutely stimulates Pdx1 binding 
to elements A1-A3 within the ins promoter and increases the activation 
potential of the Pdx1 activation domain (MacFarlane et al., 1994, Petersen et 
al., 1998). The cyclic binding of MafA and NeuroD to the ins promoter are 
however unhindered by changes in glucose concentration (Barrow et al., 
2006). Fatty acids on the other hand inhibit ins transcription. Fatty acid 
metabolism results in de novo ceramide synthesis which can directly inhibit 
Pdx1 nuclear translocation and MafA gene expression (Hagman et al., 2005, 
Poitout et al., 2006). Once transcribed, the stability of the ins mRNA can be 
affected by several other factors such as somatostatin, glucose and L-
leucine (Docherty and Clark, 1994, Philippe, 1993).  
Successful translation of the ins mRNA results in the large precursor 
preproinsulin molecule which is bound to the ribosome. Following the 
association of the ribosome with the endoplasmic reticulum (ER) and 
subsequent ER entry via the sec61 translocon, the signal peptide is cleaved 
releasing the proinsulin molecule into the ER. Glucose can increase the rate 
of transfer of the free ribosomes bearing the nascent preproinsulin from the 
cytoplasm to the ER membrane (Wolin and Walter, 1988). The proinsulin 
molecule consists of the distinct carboxy-terminal A- and amino-terminal B- 
chains linked together by the connecting peptide (C-peptide). Proinsulin 
undergoes post-translational preoteolysis in ER and during the formation of 
the insulin secretory granule at the trans-Golgi network, to yield the mature 
functional hormone, insulin (Fig. 1.9). Proinsulin processing is a multi-step 
process. Firstly, the action of type 1 (prohormone convertase (PC) 1/3) and 
type 2 (PC2) endopeptidases cleave at the B-chain/C-peptide junction and 
the C-peptide/A-chain junction respectively. This is followed by the removal 
of the exposed basic amino acids at the C-terminus by the exoproteolytic 
action of carboxypeptidase E (Halban, 1994, Hutton, 1994). The remaining 
A- and B-chains are bound together by disulphide bonds and condensation  
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Figure 1.9. The enzymatic processing of insulin. Mature insulin protein is 
derived from preproinsulin molecule via serial steps of cleavage involving  
several endopeptidases (prohormone convertases, PC) and exopeptidases 
(carboxypeptidase E) . The connecting c-peptide is removed and the A and B 
chains are linked by disulphide bonds (based on figures in Halban, 1994). 
of the insulin molecule takes place. The secretory granules (containing 
mature insulin) accumulate in the cytoplasm and are stored until a stimulus 
for secretion is received. Multiple levels of regulation from the transcription of 
the ins gene to post-translational modifications of the proinsulin molecule, 
ensure that a sufficient amount of functional and mature insulin is always 
available to meet demand. The efficient mobilisation of this insulin by the 
beta cells is the next step essential for maintaining glucose homeostasis. 
  
1B.5  Beta cell function.  
The two features that underlie the adequate functioning of a fully-
differentiated beta cell are the ability to sense changes in external glucose 
concentration and the ability to release the required amount of stored insulin 
accordingly. In comparison to glucose signalling in yeast and plants, glucose 
signalling in mammalian pancreatic beta cells requires extensive glucose 
catabolism (reviewed in Rolland et al., 2001). Glucose is transported into the 
beta cell through GLUT2, a facilitated glucose transporter. Glycolysis then 
takes place inside the cell, where phosphorylation, initiated by the enzyme 
glucokinase (with an islet specific homolog), acts as the rate limiting step for 
the reaction. However, neither GLUT2 nor glucokinase act as direct glucose 
sensors. Instead it is the increase in the ATP:ADP ratio as a result of 
glycolysis that inhibits the hetero-octomeric ATP-dependent transmembrane 
K+-channel (composed of the Kir6.2 subunits and the sulphonylurea receptor 
(SUR1) subunits) which causes membrane depolarisation (Dunne, 2000).  
Consequently, voltage gated Ca2+ channels open and Ca2+ flows into the 
beta cell. The intracellular Ca2+ concentration is further increased by IP3 
(inositol 1,4,5-triphsophate)-mediated Ca2+ induced Ca2+ release from ER 
stores. A significant increase in the cytosolic Ca2+ concentrations then 
causes the insulin secretory vesicles to move towards the plasma 
membrane, dock, fuse and release their content into the circulating blood by 
exocytosis (Pertusa et al., 1999; Fig. 1.10). Both glucose metabolism and 
Ca2+ levels oscillate resulting in pulsatile but synchronised insulin secretion 
by all the beta cells with a periodicity of 3-6 minutes (Gilon et al., 2002). It is 
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Figure 1.10. The glucose sensing and insulin secretion mechanisms in the 
pancreatic beta cell.  Glucose that is internalised into the cell via the Glut2 
transporter is phosphorylated mainly by glucokinase during glycolysis. This 
results in the production of ATP from ADP and a resultant increase in the 
ATP/ADP ratio which in turn inhibits ATP-sensitive K+ channels causing 
membrane depolarisation (∆Ψ). This is thought to activate voltage-gated 
Ca2+ channels leading to IP3-mediated Ca2+-induced Ca2+-release from 
Ca2+ stores in the endoplasmic reticulum. The increase in intracellular Ca2+ 
levels causes the fusion of the insulin secretory granules with the plasma 
membrane in a regulated manner. Secretory granules are formed by the 
condensation of the secretory product in the trans-Golgi network. The initial 
sorting event is followed by granule fusion, vesicular budding and maturation. 
Insulin protein that is not sorted in this manner appears to be secreted 
constitutively. Membrane proteins associated with both regulated and 
constitutive exocytosis are thought to be recycled back to the trans-Golgi 
network (based on figures in Rolland et al., 2001 and Hutton, 1994). 
through this regulated insulin secretion pathway that most of the insulin of a 
fully-differentiated beta cell is secreted. However, some insulin is secreted by 
the beta cells through the constitutive insulin secretion pathway without 
stimulation by glucose. It is now widely accepted that low levels of 
constitutive insulin secretion is necessary for the beta cell to maintain 
sensitivity to glucose and also for the glucose-stimulated regulated insulin 
release (Srivastava and Goren, 2003).  
In addition to glucose and insulin itself, several other factors modulate 
glucose-stimulated insulin secretion. They include circulating fatty acids 
(Stein et al., 1996), acetyl CoA and protein kinase C levels (Yaney et al., 
2000). Furthermore, transcription factors such as MafA can play an important 
role in regulating insulin secretion. Although the regulation might not be 
direct, it is possibly mediated by the ability of the transcription factors to 
influence the expression of many genes such as Glut2 and glucokinase that 
are involved in glucose-stimulated insulin secretion. For example, MafA has 
been implicated as a key regulator of insulin release since MafA-deficient 
mice show impaired glucose-stimulated insulin secretion and are glucose 
intolerant (Zhang et al., 2005). Similarly, a modest reduction in Pdx1 levels 
can result in the dysregulation of normal glucose sensing and insulin release 
in beta cells by affecting glycolysis, mitochondrial stability as well as 
intracellular Ca2+ mobilisation (Brissova et al., 2002).  Such changes can 
manifest in the form of diabetes mellitus. 
 
1C DIABETES MELLITUS 
 
Diabetes mellitus is a multifactorial disease characterised by disordered 
glucose metabolism resulting in high blood glucose levels or hyperglycaemia. 
It can be broadly classified as those caused by an insufficient production of 
insulin (type 1 diabetes mellitus and maturity-onset diabetes of the young/ 
MODYs) and those due to the diminished response of the body to insulin 
(type 2 diabetes mellitus and gestational diabetes). While the MODYs are 
caused by autosomal dominant inheritance of mutations in individual genes 
(Hnf4α, glucokinase, Hnf1α, Pdx1, Hnf1β and NeuroD), polygenic recessive 
mutations underlie the susceptibility to type 1 and type 2 diabetes. Since it is 
type 1 diabetes that is primarily associated with beta cell failure and loss, it 
will be dealt with in more detail. In its various forms, diabetes affects over 
200 million people worldwide, of which 10% of cases correspond to type 1 
diabetes (Wild et al., 2004).  
 
1C.1  Pathophysiology of Type 1 diabetes 
Type 1 diabetes is regarded as an autoimmune disease whereby the beta 
cells of the body are destroyed by autoimmune attack. The trigger for the 
autoimmune attack is not yet identified, but a possible induction by viral 
infections has been postulated (Oldstone et al., 1991). Various other 
environmental triggers including dietary factors such as (antibodies raised 
against) cow’s milk proteins, vitamin D3 deficiency and pharmacological 
agents have also been suggested (reviewed in Knip and Akerblom, 1999). 
However it is the complicated interplay between environmental triggers and 
genetic disease predisposition that leads to the progression to clinical type 1 
diabetes.  
Following the autoimmune destruction of the beta cells, the deficiency of the 
hormone insulin, results in inefficient glucose homeostasis and 
hyperglycaemia. When blood glucose concentrations overshoot the renal 
threshold, incomplete reabsorption of glucose, results in glycosuria and 
polyuria, leading to polydipsia. Polyuria, polydipsia and polyphagia manifest 
as the classical triad symptoms of diabetes. Prolonged hyperglycaemia can 
lead to long term complications of diabetic retinopathy, nephropathy, 
neuropathy and cardiomyopathy. It is believed that non-enzymatic 
glycosylation of proteins under herperglycaemic conditions underlies many of 
the chronic complications of diabetes. Increases in the amount of endothelial 
surface glycoproteins lead to basement membrane disruption and damage to 
the vasculature primarily in the retina, renal glomeruli and macrovessels 
(King et al., 1994, Brownlee, 2001, Nathan, 1996). Glycosylation of 
erythrocyte proteins (haemoglobins), plasma protein (albumin, low-density 
lipoproteins and immunoglobulins), nerve proteins (myelin-associated 
proteins), lens proteins (crystallins), and some extracellular matrix 
components (collagens) can further exacerbate the complications (Kennedy 
and Baynes, 1984). There is growing evidence to suggest that in addition to 
hyperglycaemia, some of the complications might also be caused due to 
altered fatty acid, protein and nitric acid metabolism, altered NAD+/NADH 
ratios and insulin deficiency itself (Brownlee, 2001, Nathan, 1996).  
Despite the individual mechanisms involved, many of the complications of 
diabetes are chronic and if left untreated patients can succumb to death by 
heart failure and/or ischemic stokes. Therefore developing a therapy and a 
potential cure for diabetes as a means of alleviating effects of 
hyperglycaemia is of paramount importance. 
 
1C.2  Therapies for type 1 diabetes. 
Insulin dependency of type 1 diabetic patients requires exogenous insulin 
supplementation to control hyperglycaemia. This is the most widely used 
means of controlling blood glucose levels in type 1 diabetics as well as late-
stage type 2 diabetics with reduced beta cell mass (Limbert et al., 2008). 
However, exogenous administration of insulin does not ensure satisfactory or 
continuous control of blood glucose. Hyperglycaemia and hypoglycaemia 
events are common due to incorrect dosage.  Therefore, ideal therapies and 
potential cures for type 1 diabetes are aimed towards the rejuvenation or the 
replacement of the depleted beta cell mass.  
Restoring the regenerative capacity of the pancreas, and in particular beta 
cell rejuvenation, is an interesting avenue of research for a potential diabetes 
therapy. As already mentioned above (in Section 1B.3) the mechanism by 
with the beta cell mass is regulated postnatally is still debatable. Although 
beta cell replication may be the predominant mechanism for beta cell 
maintenance in the normal adult pancreas, the situation could prove to be 
different in the type 1 diabetic pancreas (as is the case for the type 2 diabetic 
pancreas). In several studies, various extrinsic factors have been utilised to 
promote beta cell proliferation and neogenesis in vitro. Human islets have 
been expanded in vitro using a combination of serum-free culture media, 
growth factors and insulinotropic agents such as nicotinamide (Beattie et al., 
2002, Gao et al., 2003). However, a combination of senescence and de-
differentiation in culture leads to the loss of beta cell function in long term 
culture and after mass expansion. Glucagon-like peptide 1 (GLP1) can inhibit 
apoptosis and increase the proliferation of beta cells both in vitro and in vivo 
thus proving to be a potential candidate to be used for diabetes therapy 
(Brubaker and Drucker, 2004). Similarly, administration of a combination 
therapy of EGF and gastrin has been shown to enhance the expansion of the 
beta cell mass in vivo in non-obese diabetic (NOD) mice (Suarez-Pinzon et 
al., 2005). However, the protection of the rejuvenated beta cell mass from 
ongoing autoimmune destruction is a challenge and requires rigorous 
immunomodulatory regimes.  
An alternative to regenerating the beta cell mass is to find functional 
substitutes for the beta cells lost to autoimmune attack. One option is to 
transplant islets isolated from cadaveric pancreata. Islet transplantation using 
the Edmonton protocol has enabled many type 1 diabetic patients to achieve 
long-term insulin independence and restore normoglycaemia. The protocol 
involves the isolation of islets of the donor using enzymatic digestion, prior to 
infusion into the patient’s portal vein (Shapiro et al., 2000). Islet 
transplantation is however not a cure for type 1 diabetes and by 5 years after 
transplantation only 10% of patients attain glycaemic control with the 
average duration of insulin independence being 15 months (Ryan et al., 
2005). Compared to whole pancreas transplantation, islet transplantation is 
technically simpler, has lower morbidity and allows the harvested islets to be 
stored long-term in cryopreservation if immediate utilisation is not required. In 
spite of this, allogenic transplantations necessitate strict immunosuppressive 
therapies, frequently accompanied by an array of adverse side effects 
making it unattractive, especially for paediatric applications. Moreover, the 
source of islets is limited by the number of donors, which is exacerbated by 
the fact that the Edmonton protocol requires cells (11000 islets per kg of 
body weight of patient) from up to three donors for successful transplantation 
(Limbert et al., 2008). The scarcity of pancreatic tissue from human donors 
has spurred the search for alternative sources of beta cells for 
transplantation. Xenogenic tissue such as porcine islets are more readily 
available and has been considered a good source of cells for transplantation 
since the generation of transgenic pigs lacking xenogenic surface antigens 
(Phelps et al., 2003). However the transmission of xenozoonotic viruses still 
remains a possibility.  
The use of in vitro-derived cells for transplantation engenders the relatively 
novel discipline of cell-based therapies for degenerative diseases. The ‘non-
beta’ sources of insulin-producing cells can be broadly divided into four 
categories: the use of, 1- insulin-producing cell lines, 2- insulin-producing 
cells derived from embryonic stem cells, 3- insulin-producing cells 
differentiated from adult stem cells and progenitor cells, 4- use of cells 
derived from differentiated cells either by direct molecular reprogramming or 
by using induce-pluripotent stem cell technology. Most of these studies are 
still in their infancy in regards to clinical application and have only been 
tested in rodent models.  
Strict criteria have been laid down to outline what unequivocally 
characterises a complete in vitro differentiation event of a ‘non-beta’ cell into 
an autologous beta cell safe for clinical applications (Lechner and Habener, 
2003).  Firstly, the original source of cells from which the beta cells are to be 
derived should be fully characterised. Upon deriving the autologous beta 
cells in vitro, the following  criteria needs to be met: 1- the expression of 
beta-, islet- and endocrine-specific markers (other than insulin) should be 
demonstrated, 2- the presence of insulin secretory granules should be 
confirmed by ultramicroscopic studies, 3- in vitro, beta cell function in terms 
of glucose responsiveness, the responsiveness to other secretagogues and 
incretins and electrophysiological properties should be reminiscent of their 
natural counterparts, 4- in vivo, a reproducible and durable attenuation of the 
diabetic phenotype should be demonstrated following the transplantation of 
the autologous beta cells along with the reappearance of the diabetic 
phenotype upon their removal. Additionally, the tumourigenicity of the end 
product as well as the immune response towards the transplanted cells 
should be thoroughly examined.  
With these criteria in mind, one source for deriving insulin-producing cell 
lines that is commonly used, is the pancreatic beta cells themselves. As 
stated previously the long-term culture of isolated beta cells is thwarted by 
their de-differentiation in culture and loss of beta cell properties. However, 
reversibly immortalised beta cell lines (such as NAKT-15) can now be 
created from isolated human beta cells and maintained in vitro by retrovirus-
mediated insertion and subsequent excision of the immortalising genes 
simian virus 40 large T-antigen (SV40T) and human telomerase reverse 
transcriptase (hTERT) from the genome (Narushima et al., 2005). Similarly 
the human PANC-1 cell line and the rat ARIP cell line can be induced to 
differentiate into insulin-secreting endocrine cells by exposing them to GLP1. 
However this does require the expression of Pdx1 which is not normally 
expressed in the PANC-1 or ARIP cells (Hui et al., 2001). The surrogate 
beta-like cells generated in this manner can rescue alloxan- and/or 
streptozotocin-induced diabetic mice after transplantation. Irrespective of 
how closely a modified cell line resembles primary beta cells, all of their 
phenotypic features are not defined. Therefore one should approach with 
caution when using such cells for cell based therapy. 
The derivation of insulin-producing cells from embryonic stem (ES) cells has 
also been achieved with variable success (reviewed in Docherty et al., 2007). 
The first studies utilised the nature of ES cells to spontaneously differentiate 
into a large variety of cell types. Using a cell trapping strategy, the 
spontaneously generated insulin expressing cells were selected by driving 
the neomycin resistance gene off the ins promoter (Soria et al., 2000). A 
more directed approach to differentiating ES cells has also been employed 
such as using a modified protocol for ES cell to neuron differentiation, by 
deriving an enriched population of nestin-postive intermediates from 
embryoid bodies. By manipulation and supplementation of the culture 
medium (Lumelsky et al., 2001), ectopic expression of Pax4 (Blyszczuk et 
al., 2004) and PI3K inhibition (Hori et al., 2002), insulin-positive cells have 
been derived from ES cells. However, the levels of expression of insulin in 
these beta-like cells were inadequate and the efficiency of the protocols in 
terms of the number of cells generated was in each case extremely low. 
Therefore recently, a more directed approach to ES cells to beta cell 
differentiation has been pursued, recapitulating the normal developmental 
biology of the pancreas. Using such an approach, ES cell differentiation is 
directed through various checkpoints corresponding to undifferentiated ES 
cells, definitive endoderm, posterior foregut endoderm, pancreatic endoderm, 
islet precursors and finally differentiated beta cells, each expressing a unique 
array of markers specific to that particular stage (Fig. 1.11). Subsequent 
studies have used directed differentiation of human ES cells, first to generate 
definite endoderm then endocrine hormone expressing islet cells including 
beta cells, which when transplanted were capable of restoring 
normoglycaemia in diabetic mice (D'Amour et al., 2005, D'Amour et al., 2006, 
Kroon et al., 2008). Nonetheless, the turmurogenic potential of ES cells in 
giving rise to teratomas and teratocarcinomas in humans makes them a less 
desirable option for clinical application.  
 
Figure 1.11. A protocol for deriving endocrine cells from human ES 
cells. The figure schematically outlines how human ES cells can be 
differentiated in vitro into hormone-expressing endocrine cells. The culture 
media composition and growth factor supplementation at each stage is given 
in the yellow boxes. The protocol involves five stages of differentiation and 
aims to achieving a specific identifiable endodermal intermediate at the end 
of each stage. The lower panel indicates the markers characteristic of each 
stage of differentiation (D'Amour et al., 2006).  
Adult stem cells and progenitor cells are present in the body throughout life 
and are more ethically sound than ES cells, constituting an attractive source 
of cells for cell therapy. However, adult stem cells are rare, have low 
proliferative rates and reside in stem cell niches that are hard to identify. 
Pancreatic stem or progenitor cells have been isolated from adult ducts and 
islets by a combination of flow cytometry and clonal analysis identified by the 
expression of Neurogenin3, c-met and/or nestin (Seaberg et al., 2004, 
Suzuki et al., 2004). Alternatively insulin-expressing cells have been derived 
from more well defined extra-pancreatic stem/progenitor cells such as 
mesenchymal stem cells (MSC). Despite the low levels of insulin production, 
MSC-derived beta-like cells are still capable of rescuing diabetes in 
streptozotocin-treated mice (Tang et al., 2004). Transplanted MSC 
themselves have been shown to enhance the number of endogenous beta 
cells in non-obese diabetic severe combine immunodeficient (NOD/SCID) 
mice (Lee et al., 2006).  
The use of differentiated cells for the generation of insulin producing beta-like 
cells often fails to fulfil the rigorous criteria that define a bone fide 
transdifferentiation event. Yet it is still of immense interest to cell-based 
therapeutic modalities. Functional beta-like cells have also been generated 
from cultured adult exocrine pancreatic cells treated with leukaemia inhibitory 
factor (LIF) and epidermal growth factor (EGF) (Baeyens et al., 2005). 
Similarly by over-expressing Neurogenin3, Pdx1 and MafA, adult murine 
pancreatic exocrine cells have been converted into beta-like cells that can 
ameliorate hyperglycaemia (Zhou et al., 2008). Furthermore, based on the 
concept that liver and pancreas arise from the same region of the developing 
embryo, recent work has focused on the conversion of hepatocytes to beta 
cells. Most approaches have been based on over-expression of Pdx1, the 
master gene controlling pancreatic development. A modified form of the 
Pdx1 homolog Xlhbox8 carrying the VP16 transcriptional activation domain 
from Herpes simplex, has been used to convert liver to pancreas in 
transgenic Xenopus tadpoles. The Xlhbox8-VP16 construct was driven off 
the transthyretin (TTR) promoter in order to direct expression in the liver and 
contained a GFP tag under the pancreatic elastase promoter (Beck and 
Slack, 1999, Horb et al., 2003). Transient expression of Xlhbox8-VP16 may 
induce formation of ectopic whole pancreas, in an otherwise normal animal, 
giving rise to both endocrine and exocrine cell-types (Horb et al., 2003). It is 
thought that the appearance of ectopic pancreata in this case is the result of 
a metaplastic conversion of at least partially differentiated liver cells rather 
than simply changing the developmental fate of undifferentiated endodermal 
cells. This investigation also discovered that the same construct could also 
induce similar effects in the human hepatoma HepG2 cell line (Li et al., 
2005a). Pdx1 can also induce the expression of pancreatic genes in many 
other cell-types including foetal liver progenitor cells and in a liver stem line- 
the WB cells (Zalzman et al., 2003, Tang et al., 2006). In vivo transformation 
of hepatocytes into insulin-producing cells has been successfully achieved 
by the intravenous injection of adenoviruses encoding Pdx1 (with and without 
VP16) and/or various other key regulatory pancreatic transcription factors 
including NeuroD, Neurogenin3 and MafA (Ber et al., 2003, Imai et al., 2005, 
Kaneto et al., 2005a, Kaneto et al., 2005b, Koizumi et al., 2004, Kojima et al., 
2003, Shternhall-Ron et al., 2007). Beta-like cells produced from liver cells 
were able to rescue streptozotocin induced diabetes in mice. Likewise, adult 
rat and human hepatocytes have been transformed in vitro and subsequently 
transplanted into diabetic mice, correcting hyperglycaemia for various 
lengths of time (Sapir et al., 2005, Meivar-Levy et al., 2007). Compared to 
the in vivo approaches, in vitro transformation of cells has the added 
advantage of overcoming the narrow tropism of the viruses especially for 
organs such as the liver. It also reduces vector toxicity by minimising 
systemic infections. 
The derivation of induced pluripotent stem (iPS) cells from both adult mouse 
(Takahashi and Yamanaka, 2006, Okita et al., 2008) and human (Takahashi 
et al., 2007) somatic cells could potentially serve as an easily accessible and 
immunotolerant source of cells to generate beta cells in vitro for 
transplantation. Nevertheless, understanding the immunological causes of 
diabetes is an area of research that should be addressed alongside the 
search for new sources of beta cells for cell-replacement therapy. New 
avenues of research that are being actively pursued in regards to a 
immuno/cell-therapy for type 1 diabetes include monocyte derived dendritic 
cells and autologous cord-blood infusion, and autologous nonmyeloablative 
haematopoietic stem cell transplantation. 
 
1D AIMS AND OBJECTIVES.  
 
The work outlined in this thesis was aimed to develop a protocol for the 
generation of fully differentiated beta-like cells by the in vitro molecular 
reprogramming of primary hepatocytes. 
The objective was to identify the specific culture conditions, the transcription 
factors and extrinsic factor combinations necessary for such a hepato-
pancreatic conversion. The cells derived by hepato-pancreatic 
reprogramming should be able to closely resemble bone fide beta cells in 
terms of gene expression and protein synthesis as well as function. 
Therefore based on their performance in functional tests, additional 
rectifications and amendments to the protocol were undertaken to improve 
the quality of the beta cell phenotype achieved. 
Chapter TWO
Materials and
Methods  
2A MATERIALS 
 
All chemicals were dissolved in distilled water unless stated otherwise in the 
manufacturer’s instructions. See Appendix A for a full list of all commercial 
suppliers. 
 
2A.1 General laboratory chemicals 
NaCl, KCl, ethylenediaminetetraacetic acid (EDTA), ethanol, methanol, 
isopropanol, acetone, chloroform, paraformaldehyde (PFA) and Tris(hydroxyl 
methyl) aminomethane (Tris Base) were purchased from Fisher Scientifics.  
CaCl2, CsCl, K2HPO4, sodium azide, D-glucose, D-sucrose, formaldehyde, 
phenol red, Tween-20, Triton x-100, tricine, glycine, sodium dodecylsulphate 
(SDS) and 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES),  
were all obtained from Sigma. Electrophoresis grade agarose (Invitrogen) 
and phosphate buffered saline (PBS; Autogen-Bioclear) were also used. 
 
2A.2 Laboratory equipment 
Spectrafuge 16M (Jencon-PLS) was used as the routine bench-top 
centrifuge. Allegra® 25R swinging bucket centrifuge, L-80 Ultracentrifuge 
(Beckman) and ALC PK110 centrifuge (Thermo) were used for specific 
purposes (see 2B: methods). SSM3 mini-gyro rockers, Denley Spiramix 5 
rollers and a PMS-1000 Bio-Gen platform shaker (Jencon-PLS) were used 
during long incubation steps. 
For microscopy, MZ75 dissection microscopes, a DMIRB inverted 
microscope, a DMRB microsope (all Leica) and LSM 510 and LSM 510-
META confocal microscopes (Zeiss) were used (see 2B.13 for details). A 
DU® 530 UV/Vis Spectrophotometer (Beckman) was used to measure DNA 
and RNA concentrations. A Spectra Rainbow Thermo microplate 
spectrophotometer (Tecan) was used to measure protein concentration. 
2A.3 Cell culture reagents and media 
Table 2.1. Tissue culture cell lines and their passaging densities. 
Cell lines Passage Source 
Rat insulinoma (RIN-5F) 1/5 
European Collection of Cell 
Cultures, Porton Down, UK 
Murine insulinoma (MIN6) 1/3 
Human embryonic kidney 
epithelium (HEK293) 
1/12 
Rat pancreatic exocrine 
(AR42J-B13) 
1/10 
Itaru Kojima, Junetendo University 
School of Medicine, Tokyo, Japan 
Bipotential mouse 
embryonic liver (BMEL) 
1/15 
George Yeoh, University of 
Western Australia, Pert, Australia 
 
Table 2.2. Composition of media used for cell culture. 
Media Composition 
Hepatocyte 
Attachment 
Medium 
William’s Medium E (Sigma) with 10% (v/v) FBS, 10U/ml 
penicillin, 100µg/ml streptomycin and 2mM L-glutamine 
Hepatocyte 
Differentiation 
Medium (KS) 
Keratinocyte Serum Free Medium (KSFM; Gibco) 
supplemented with 2mM L-glutamine, 10U/ml penicillin, 
100µg/ml streptomycin, 100µg/ml amphotericin B, 50µg/ml 
gentamycin, 50µg/ml bovine pituitary gland extract (bPGE) 
and 5ng/ml human recombinant EGF (rhEGF).  
Hepatocyte 
Differentiation 
Medium (KdS) 
Same as KS medium, supplemented with 10nM 
dexamethasone. 
Hepatocyte  
De-
differentiation 
Medium (DS) 
Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma) 
supplemented with 10% (v/v) FBS, 2mM L-glutamine, 
10U/ml penicillin, 100µg/ml streptomycin, 100µg/ml 
amphotericin B, 50µg/ml gentamycin, 50µg/ml bPGE and 
5ng/ml rhEGF. 
Dissection 
Medium 
Minimal Essential Medium Eagle’s with Hank’s salts 
(MEM-E; Sigma) and 10% (v/v) FBS. 
Embryonic 
Pancreas 
Culture Medium 
Basal Medium Eagle’s with Earle’s salts (BME; Sigma), 
20% (v/v) FBS, 2mM L-glutamine, 10U/ml penicillin and 
100µg/ml streptomycin. 
RIN-5F Culture 
Medium 
RPMI1640 Medium (Sigma), with 10% (v/v) FBS, 2mM L-
glutamine, 10U/ml penicillin and 100µg/ml streptomycin. 
MIN6 Culture 
Medium 
High glucose (25mM) DMEM with 10% (v/v) FBS, 2mM L-
glutamine, 10U/ml penicillin and 100µg/ml streptomycin. 
HEK293 & B13 
Culture Medium 
DMEM with 10% (v/v) FBS, 2mM L-glutamine, 10U/ml 
penicillin and 100µg/ml streptomycin. 
BMEL Growth 
Medium 
William Medium E with 10% (v/v) FBS, 2mM L-glutamine, 
10U/ml penicillin, 100µg/ml streptomycin, 100ng/ml 
amphotericin B, 30ng/ml IGF2, 20ng/ml human 
recombinant EGF, 10µg/ml insulin (humulin; Sigma) 
 
Heat-inactivated foetal bovine serum (FBS; GibcoTM/Invitrogen) was used 
routinely for all cell culture media, except with HEK293 cells where γ-
irradiated FBS was used instead. Stock solutions of 200U/ml penicillin, 
2mg/ml streptomycin, 40mM L-glutamine (Sigma), 2mg/ml amphotericin B, 
gentamycin, trypsin-EDTA (GibcoTM/Invitrogen) were used. 1mM 
dexamethasone was made up in 100% ethanol and stored at -20°C. 0.4% 
(w/v) trypan blue (Sigma) in 0.81% (w/v) NaCl, 0.06% (w/v) K2HPO4 was 
diluted 1:1 to assess cell viability. 
 
2A.4 Adenoviral vectors 
Table 2.3. List of adenoviral vectors used for gene transduction. 
Adenoviral construct Titre (iu/ml) Source 
Ad-CMV-Null 2.0 x 108 
Harry Heimberg, Vrije Universiteit, 
Brussels, Belgium. 
 
Ad-CMV-Pdx1-eGFP 1.0 x 1010 
Ad-CMV-Pdx1VP16-eGFP 1.2 x 1011 
Ad-CMV-HA-Ngn3-eGFP 7.7 x 1011 
Ad-CMV-Pax4 3.8 x 1010 
Ad-CMV-Pax6 3.7 x 1010 
Ad-CMV-HA-Nkx6.1-eGFP 4.6 x 1010 
Ad-CMV-Nkx2.2 7.0 x 1010 
Ad-CMV-IA1-eGFP 1.3 x 1012 
Ad-CMV-NeuroD 5.2 x 1011 Vector Biolabs. 
Ad-CMV-Sox9-IRES-eGFP 5.2 x 1010 
Made from a plasmid construct from 
Neil Hanley, University of 
Southampton, Southampton, UK. 
Ad-CMV-p48-IRES-GFP 9.9 x 109 
James Dutton, Stem Cell Institute, 
Minneapolis, MN, USA. 
Ad-CMV-p63 7.6 x 1011 Wei-Yuan Yu, University of Bath, UK. 
Ad-RSV-GFP 1.0 x 1010 
Emma Regardsoe, University of 
Oxford, Oxford, UK. 
Ad-CMV-LacZ 7.0 x 109 
Andrew Byrnes, University of Oxford, 
Oxford, UK. 
Ad-CMV-LIP 1.8 x 1011 
Hiroshi Sakaue, Kobe University, 
Kobe, Japan. 
Ad-CMV-MafA-eGFP 2.8 x 108 
Takaaki Matsuoka, Osaka University, 
Osaka, Japan. 
Ad-TTR-Xlhbox8 1.5 x 1012 Mark Hornsey, University of Bath, 
Bath, UK. Ad-TTR-Xlhbox8VP16 1.3 x 1012 
 
CMV- Cytomegalovirus promoter; RSV- Rous-sarcorma virus promoter, TTR- transthyretin 
promoter; eGFP- enhanced green fluorescent protein; HA- haemagglutinin tag. 
 
  
2A.5 Antisera for immunocytochemistry 
Table 2.4. List of primary antibodies used for immunocytochemistry. 
Antibody Species Supplier Dilution 
α-foetoprotein (AFP) rabbit DAKO 1:100 
Albumin rabbit DAKO 1:100 
Amylase rabbit Sigma 1:200 
Carbamoyl phosphate 
synthetase (CPS) 
rabbit Gift
a 
1:1000 
Chromogranin A rabbit DAKO 1:100 
C-peptide rabbit Acris 1:100 
Cytokeratin 19 mouse Gift
b 
1:1 
Cytokeratin 20 mouse Abcam 1:100 
E-cadherin rat Epitomics 1:100 
Ghrelin rabbit Phoenix 1:50 
Glucagon mouse Sigma 1:100 
Glut2 rabbit Biogenesis 1:100 
Glutamate synthetase mouse Transduction Labs 1:200 
Haemagglutinin mouse Santa Cruz 1:100 
Haptoglobin rabbit Sigma 1:100 
HNF4α rabbit Santa Cruz 1:100 
Insulin guinea pig DAKO 1:300f, 1:100g 
Insulin mouse Sigma 1:300f, 1:100g 
MafA rabbit Abc am 1:100 
NeuroD goat Santa Cruz 1:100 
Neurogenin3 rabbit Gift
c 
1:100 
OV6 mouse Gift
d 
1:200 
Pancreatic Polypeptide rabbit Zymed 1:50 
Pdx1 rabbit Gift
e 
1:100 
PECAM-1 rat BD Pharmingen 1:100 
PGP9.5 rabbit AbD Sero Tec 1:50 
Phospho-histone 3 rabbit Upstate 1:200 
Smooth muscle actin 
(SMA)-Cy3 conjugate 
mouse Sigma 1:300 
Somatostatin rabbit DAKO 1:100 
Sox9 rabbit Chemicon 1:100 
Thy1 rabbit Santa Cruz 1:50 
Transferrin rabbit DAKO 1:500 
Transthyretin rabbit DAKO 1:100 
UDP-glucuronosyl 
transferase (UGT) 
sheep Cypex 1:200 
Vimentin mouse Sigma 1:100 
 
a- Wouter Lamers, University of Amsterdam, Amsterdam, The Netherlands; b- Birgit Lane, Institute of Medical 
Biology, Singapore; c- Michael German, UCSF, CA, USA; d- Stewart Sell, Ordway Research Institute & Wadsworth 
Centre, Albany, NY, USA; e- Jonathan Slack, University of Bath, UK; f- for pancreas; g- for all other tissue. 
Table 2.5. List of secondary antibodies used for immunocytochemistry. All 
secondary antibodies were used at a dilution factor of 1 in 200. 
Antibody Species Conjugate Supplier 
Anti-rabbit IgG 
goat 
TRITC 
Vector 
Laboratories 
FITC 
donkey HRP 
Anti-mouse IgG horse 
Texas Red 
FITC 
AMCA 
HRP 
Anti-sheep IgG rabbit Texas Red 
Anti-rat IgG rabbit FITC 
Anti-goat IgG rabbit FITC 
Anti-guinea pig IgG 
goat FITC 
rabbit TRITC Sigma 
goat HRP Abcam 
 
TRITC- tetramethylrhodamine isothiocyanate; FITC- fluorescein isothiocyanate; HRP- horse radish 
peroxidase; AMCA- aminomethylcoumarin acetate. 
The conjugated compounds Amanita phalloides phalloidin-TRITC (Sigma) 
and Dolichos biflorus agglutinin (DBA)-FITC (Vector Biolabs) were used at 
dilutions of 1/1000 and 1/400 respectively. 4,6-diamidino-2-phenylindole 
(DAPI, Sigma) was used at 1:1000 to visualise the nuclei. 
 
2A.6 Antisera for western blot analyses. 
Table 2.6. List of primary & *HRP-conjugated secondary antibodies used.  
Antibody Supplier Species Dilution 
Insulin Santa Cruz rabbit 1:100 
Glucagon Sigma mouse 1:2000 
Amylase 
Sigma 
rabbit 
1:2000 
Somatostatin 1:500 
Ghrelin Phoenix Pharmaceuticals 1:5000 
HNF4α Santa Cruz 1:1000 
Pdx1 Gift
a
 1:100 
Ptf1a Abcam 1:300 
Sox9 Chemicon 1:1000 
pStat3Tyr705 Cell Signalling 1:1000 
CK19 Gift
b 
mouse 
1:1000 
α-tubulin Sigma 1:4000 
*Anti-rabbit IgG 
Vector Laboratories 
donkey 1:2000 
*Anti-mouse Sheep 1:2000 
IgG 
2A.7 Primers for polymerase chain reaction. 
The PCR primers were designed using the online Primer3TM software (Rozen 
and Skaletsky, 2000) and purchased from MWG Primers service, UK.   
Table 2.7. List of PCR primers and their annealing temperatures Tm. 
 
Gene Forward/ Reverse (5’ to 3’) 
Tm/ 
°C 
Product/ 
bp 
R
a
t 
α1-antitrypsin (AAT) 
TGTCCCCTATGACCATCACC/ 
TCACTGTCTGGCCTGTTGAG 
56 376 
Albumin 
GCCCTACCCACAAAGCCTCAG/ 
AGCCCCTTCATATCACAGAGCA 
56 543 
Alpha-foetoprotein (AFP) 
ACCAAGTGTGGATTCTCAGG/ 
ATTGATGCTCTCTTTGTCTG 
54 276 
Amylase 
GCCTACTGACAGAGCCCTTG/ 
TGGTCCAATCCAGTCATTCA 
58 200 
Beta-actin 
TCCGTAAAGACCTCTATGCC/ 
AAAGCCATGCCAAATGTCTC 
56 477 
Cdx2 
TCCCTAGGAAGCGAAGTGAA/ 
CTGCGGTTCTGAAACCAAAT 
57 187 
C/EBPα 
GTTCCACATCGCACACTGCG/ 
TGACCAAGGAGCTCTCAGGC 
55 426 
Chromogranin A 
ACTAAGGTGATGAAGTGTGT/ 
TCTCTACAGTGTCCTTGGAG 
58 353 
Chymotrypsin (Crtb) 
GATCGCGAGGTCTTTAGAA/ 
CATCGACGTTGGGTGACAC 
55 298 
CK19 
ACCATGCAGAACCTGAACGAT/ 
CACCTCCAGCTCGCCTTAG 
59 312 
c-kit 
AGCAAGAGTTAACGATTCCGGAG/ 
CCAGAAAGGTGTAGGTGCCTCCT 
60 340 
Carbamoyl phosphate 
synthetase 1 (CPS1) 
CGTCCAAGATTCCTTGGTGT/ 
ATGGAAGAGAGGCTGGGATT 
57 158 
Elastase 1 
GGAACCATCCTGGCTAACAA/ 
ACACACCATGGTCGTCTTCA 
59 170 
FoxA3 
GGCTTGTACACGGAAAGGAA/ 
TCATTGAAGGACAGCGAGTG 
57 226 
Ghrelin 
CCCAAGCTTAGGCCATGGTGTC/ 
CCGGAATTCCAGTGGTTACTTGTT 
62 212 
Glucagon-like peptide 1 
receptor (GLP1-R) 
TCTCTTCTGCAACCGAACCT/ 
CTGGTGCSGTGCSSGTGTCT 
58 351 
Glucagon 
GACCGTTTACATCGTGGCTG/ 
GGTTCCTCTTGGTGTTCATCA 
58 247 
Glucokinase (islet-specific/ 
isl-GCK) 
AGGCCACCAAGAAGGAAAAG/ 
TTGTCTTCACGCTCCACTGC 
65/60 265 
Glucokinase (liver-specific/ 
liv-GCK) 
GAGCCCAGTTGTTGACTCTG/ 
TTGTCTTCACGCTCCACTGC 
65/60 364 
Insulin 1 
ACCTTTGTGGTCCTCACCTG/ 
CCAGTTGGTAGAGGGAGCAG 
56 230 
Insulin 2 
AGTGCCAAGGTCTGAAGGTC/ 
CAGCACCTTTGTGGTTCTCA 
58 163 
Isl1 
CGGGAGGATGGGCTTTTCTG/ 
AGCTGCTTTTGGTTGAGCACAG 
56 211 
Table 2.7.  (continued). 
R
a
t 
Islet Amyloid Polypeptide 
(IAPP) 
GGCTGTAGTTCCTGAAGCTT/ 
AAGGTTGTTGCTGGAGCGAA 
58 260 
Kir6.2 
ACCACGCTGGTGGACCTCAAG/ 
GCACCACCTGCATATGAATGG 
58 481 
MafA 
TCAACGACTTCGACCTGATG/  
GGGCAGAGTGATGATGGTG 
58 209 
Nestin 
TGCAGCCACTGAGGTATCTG/ 
CAGTTCCCACTCCTGTGGTT 
60 449 
NeuroD 
CTTGGCCAAGAACTACATCTGG/ 
GGAGTAGGGATGCACCGGGAA 
59 228 
Neurogenin3 
CTTCACAAGAAGTCTGAGAACA/ 
CTGCGCATAGCGGACCACAGCT 
58 211 
Nkx2.2 
CAGCAGCGACAACCCCTAC/  
AAGAGCACTCGGCGCTTCC 
58 203 
Nkx6.1 
ATGGGAAGAGAAAACACACCAG/  
TAATCGTCGTCGTCCTCCTCG 
58 279 
Pancreatic Polypeptide (PP) 
AACAGAGGGCTCAATACGAA/ 
GAGACAGAAGGGAGGCTACA 
56 212 
Pax4 
CTGCCTGTGCTGGAAGAAT/ 
TAGGTTGATGGCGCTTGTC 
58 231 
Pax6 
GAGACAGATTACTCTCCGAGG/  
ACCACACCTCTATCCTTGCTTAGG 
59 464 
Pdx1 
TCGCTGGGAACGCTGGAAC/ 
CTTTGGTGGATTTCATCCACG 
58 223 
PGP9.5 
GCCCAGCATGAAAACTTCAG/ 
AGGGGACAACTTCTCCGTTT 
57 209 
Prohormone convertase 1/3 
(PC1/3) 
TCAGGGAATGGGGGTCGTCAAG/ 
CCAAATCGGCTGTTCACCATCAAG 
63 400 
Prohormone convertase 2 
(PC2) 
CTGAGGCTGGTGTGGCTAC/ 
AGCTGGCGTGTTTGCATTA 
57 366 
SDF1a 
ATTCTTTGAGAGCCATGTCGC/ 
CCTTGAGCTGAGTGACTCTCG 
60 638 
Somatostatin (SS) 
ACCCCAGACTCCGTCAGTTT/ 
CTCCAGCCTCATCTCGTCCT 
60 173 
Sox9 
TGAAGAAGGAGAGCGAGGA/ 
CAGAGCTTGCCCAGAGTCTT 
57 245 
Sulphonylurea Receptor 1 
(SUR1) 
AAGATCATGCACTTGTCTACT/ 
AGACAGCAGGAACAGCGGTGT 
58 591 
Surfactant associated 
binding protein-B (SURF-B)  
CTGTGCCAAGAGTGTGAGGA/ 
TGGCTTTGGGTTTAATCTGG 
59 201 
Thy1 
GCAGATGTCCCGAGGACAGA/ 
GGCAGTCCAGTCGAAGGTTCT 
56 187 
Vimentin 
CACCAACGAGAAGGTGGAAT/ 
GTGCCAGAGAAGCATTGTCA 
58 349 
M
o
u
s
e
 
Albumin 
GCAGAGGCTGACAAGGAAAG/ 
TTCTGCAAAGTCAGCATTGG 
56 182 
Beta-actin 
TACGCATGTCAACGTCACAC/ 
AAGAGCTATGAGCTGCCTGA 
55 159 
Betacellulin 
CCAAGCAGTACAAGCATTACTG/ 
GAACACCACCATGACCACTATC 
60 184 
CK19 
AAGACCATCGAGGACTTGCG/ 
CTATGTCGGCACGCACGTCG 
62 545 
E-cadherin 
GCTGGACCGAGAGAGTTA/ 
TCGTTCTCCACTCTCACAT 
57 380 
ErbB1 
GTGCCCCCGAAACTCGTGGTGAC/  
CTAGAGGGGAGTGCGCGTGAAAG 
55 272 
Table 2.7.  (continued). 
M
o
u
s
e
 
ErbB4 
CGGACGGCGGCGGAGAAGG/ 
GTGGCGGGGGAGGTGGTAGAA 
60 303 
Insulin 1 
TAGTGACCACCTATAATCAGAG/ 
ACGCCAGGTCTGAAGGTCC 
56 217 
Insulin 2 
AGGTCTGAAGGTCACCTGCT/ 
CCCTGCTGGCCCTGCTCTT 
56 212 
Kir6.2 
CCAAGCCCAAGTTTAGCATC/ 
TGGGGCCSGAAATAGCATAG 
58 235 
SUR1 
TGAAGCAGACCAACGAGATG/ 
GCAATGGGGATAGCTGTGTT 
56 222 
Vimentin 
ATGCTTCTCTGGCACGTCTT/ 
AGCCACGCTTTCATACTGCT 
57 268 
H
u
m
a
n
 
Albumin 
CTCAAGTGTGCCAGTCTCCA/ 
TGGGATTTTTCCAACAGAGG 
58 272 
Beta-actin 
AGAAAATCTGGCACCACACC/ 
GGGGTGTTGAAGGTCTCAAA 
58 142 
Insulin 
AGCCTTTGTGAACCAACACC/ 
CGGCCAAGTTCTTCAACAAT 
58 245 
Kir6.2 
GAGATCATCGTCATCCTGGAA/ 
GTAGGCTGTGGTCCTCATCAA 
58 221 
SUR1 
TGACCTCCATCTCCAACTCC/ 
TGGATCTGGATCTTCCCTTG 
58 195 
Vimentin 
CCCTCACCTGTGAAGTGGAT/ 
TCCAGCAGCTTCCTGTAGGT 
58 261 
 
2B.8 Extracellular factors and other compounds. 
Table 2.8 Concentrations of compounds used for various treatments. 
Compound [Stock] [Working] Supplier 
Alloxana 1M 5mM 
Sigma 
Betacellulin 10mg/ml 10ng/ml 
Growth hormone 25ng/ml 10nM 
Metforminb 1M 10mM 
Nicotinamide 2M 20mM 
Prolactin 7mg/ml 500ng/ml 
NaC4H5O2 (butyrate) 10mM 0.5mM 
Streptozotocinc 250mM 2.5mM 
Trichostatin A 10mM 20µM 
Zebularine 10mM 100µM 
γ-secretase inhibitor IV 25mM 25µM 
Calbiochem 
PI3K inhibitor (LY294002) 10mM 10µM 
Activin A 1mM 10nM 
R&D 
Systems 
 
BMP4 10µg/ml 10ng/ml 
EGF 100µg/ml 50ng/ml 
FGF7/KGF 10µg/ml 10ng/ml 
FGF10 25µg/ml 100ng/ml 
TGF-α 100µg/ml 10ng/ml 
TGF-β1 10µg/ml 10ng/ml 
VEGF 10µg/ml 50ng/ml 
 
a- 1,3-Diazinane-2,4,5,6-tetrone; b- N,N-dimethylimidodicarbonimidic diamide; c- 1-methyl-1-nitroso-3-[2,4,5-
trihydroxy-6- (hydroxymethyl) oxan-3-yl]-urea. 
2B  METHODS 
 
2B.1  Hepatocyte Isolation 
All laboratory animals used were kept under standard laboratory conditions, 
at 25°C, on a 12:12 h light-dark cycle and given ad libitum access to food 
and water. The animal studies were performed under the regulations of the 
UK Home Office Licence and the use of human material was undertaken with 
the approval of the University of Bath Ethics Committee. 
2B.1.1  Rat hepatocytes 
The method for rat hepatocyte isolation is based on a modification of the two-
step collagenase perfusion technique previously described by Tosh et al. 
(1988). Rats of the albino Wistar strain, weighing 280g-320g (University of 
Bath) were anesthetised with 4.5% isoflorane (Baxter Healthcare Ltd., UK) in 
oxygen, flowing at a constant rate of 1500ml/minute. When the rat was fully 
anaesthetised (indicated by a lack of the pedal reflex), the animal was 
maintained so, with 3% isolfluorane delivered via a face mask. The animal 
was placed supine on a flat tray and the abdominal fur was disinfected with 
70% ethanol. Laparotomy was performed by making a ‘U’ shaped incision 
from the lower abdomen to the lateral aspects of the rib cage. The skin was 
folded over the chest, fully exposing the viscera. The intestine was then 
displaced, to reveal the portal vein. The portal vein was elevated by placing a 
flat matchstick underneath it and excess adipose tissue was removed with 
the blunt side of a curved forceps. A non-absorbable suture was loosely tied 
around the portal vein (4-0; EthiconTM Mersilk). An 18GA cannula 
(BDVenflon, Franklin Lakes, NJ) was inserted into the portal vein (see Fig. 
2.1A) 3-5mm distal to the suture and the inner metal stylet of the cannula 
was then removed, while slightly advancing the cannula into the vein. The 
suture was then firmly tightened around the cannula and the abdominal 
blood vessels were cut along with the spinal cord, whereupon the death of 
the animal occurs by exsanguination. The cannula was connected to the 
pump and perfusion was initiated with perfusion buffer 1 [0.05 (w/v) KCl in 
10mM HEPES buffer, 5mM D-glucose, 200µM EDTA, 0.001% (v/v) phenol 
red, in 500ml of sterile phosphate buffered saline (PBS), pH 7.4] pre-warmed 
to 39oC. The inferior vena cava was then cut and the abdominal blood 
vessels clamped with a Spencer-Well’s artery forceps, thereby establishing a 
continuous flow (25-30ml/minute) of the buffer from the cannula in the portal 
vein, through all the lobes of the liver and out through the vena cava into the 
thoracic cavity. After perfusing the liver with 250ml of perfusion buffer 1, 
perfusion was continued with 200ml of pre-warmed perfusion buffer 2 [0.05 
(w/v) KCl in 10mM HEPES buffer, 20mM HEPES buffer, 5mM D-glucose, 
1mM CaCl2, 0.001% (v/v) phenol red, in 500ml of sterile PBS, pH 7.4] in 
which 50mg of type 2 collagenase (Worthington, Lakewood, NJ)  was 
dissolved. 
The above procedure isolates a total population of viable hepatocytes which 
includes cells from the periportal, intermediate and perivenous zones of the 
hepatic acinus. In order to isolate enriched populations of periportal and 
perivenous hepatocytes, 6-8ml of a 4mg/ml solution of digitonin (Sigma, 
made up in 150mM NaCl, 6.7mM KCl., 50mM HEPES, pH7.5 by heating to 
55°C) was injected through the thoracic portion of the vena cava (the hepatic 
vein drains into the vena cava) or portal vein respectively. For periportal 
isolations, when the selective zone 2 and 3 destruction pattern of the 
perivenous hepatocytes by digitonin was apparent, the perfusate was 
switched back to perfusion buffer 1 and the perfusion was carried on as 
usual in the orthograde (portal to caval) direction (Fig. 2.1C). For perivenous 
isolations, when selective zone 1 destruction pattern of the periportal 
hepatocytes was visible, the digitonin was washed away by perfusion with 
perfusion buffer 1 in the retrograde direction (caval to portal) for 10 minutes 
before resuming the perfusion in the orthograde direction as before (Fig. 
2.1D).   
Following perfusion, the whole liver was removed and dissociated in a class 
II microbial safety cabinet using two pairs of curved forceps. The cells were 
filtered through a 70µm mesh (Gore-Tex, Newark, DE) and dead and dying 
cells were removed by serial differential centrifugation at 50g for 2 minutes 
 Figure 2.1 Steps in the procedure for isolation of A- total hepatocytes from rats, 
B- total hepatocytes from mice, C- periportal hepatocytes from rats and D- 
perivenous hepatocytes from rats. [svc- superior vena cava; ivc- inferior vena cava; 
hpv- hepatic portal vein]. 
each time in perfusion buffer 2 or attachment media [William’s Medium E 
(Sigma), 10% (v/v) foetal bovine serum (FBS), 100units/ml penicillin, 
100µg/ml streptomycin and 2mM L-glutamine]. The cell viability was 
determined at 85% viable using 0.4% (w/v) trypan blue (Sigma). The 
hepatocytes were inoculated in attachment media at a final density of 
4.5x105 cells/ml into 35mm, 60mm and 100mm vented plastic culture dishes 
(Nunclon). The cells were left to attach for 5-6hours at 37°C in 5% (v/v) CO2 
and then transferred to the different culture media.  
2B.1.2  Mouse hepatocytes 
Hepatocyte isolation from CD1, Rosa26 LacZ and C57BL/6 Alb-Cre x R26R 
LacZ mice (University of Bath, UK) were carried out as described above for 
the rat but with the following modifications. Extra care was taken while 
anaesthetising C57BL/6 Alb-Cre x R26R LacZ mice as they were notably 
more sensitive to isoflorane compared to the other strains. After displacing 
the intestine, excess abdominal fat around the inferior vena cava was 
removed with the blunt side of a curved forceps. A flat matchstick was then 
inserted underneath the vena cava just posterior to the renal veins. A non-
absorbable suture was loosely tied around the vena cava and a 24GA 
cannula (Terumo) connected to the perfusion tubing was inserted into the 
vena cava and advanced just anterior to the renal veins (Fig. 2.1B). The 
inner metal stylet was removed making sure there were no air bubbles in the 
cannula and the suture was tightened around it. The portal vein was then cut 
and the perfusion tubing was reconnected to the cannula maintaining a flow 
rate of 5-12ml/minute. The liver was initially perfused with 100ml of perfusion 
buffer 1 followed by 8-10 minutes of perfusion with perfusion buffer 2 
(containing 50mg of type 2 collagenase per 150ml of buffer). 
After dissociation of the liver, the cells were filtered through a 100µm mesh 
and viable hepatocytes were isolated by serial differential centrifugation as 
described above. Generally more centrifugation steps are needed compared 
to rat hepatocytes and the viability of the cells can be judged under the 
microscope after each step. The hepatocytes were inoculated in attachment 
media and left to attach for 5-6 hours.  
2B.1.3  Human hepatocytes 
Human hepatocytes were obtained from the UK Human Tissue Bank (De 
Montfort University, Leicester, UK). The hepatocytes were isolated by in vitro 
perfusion of liver resections from male and female donors between the ages 
of 66 and 70. Human hepatocytes were incubated overnight in attachment 
media before being transferred to their respective culture media.  
 
2B.2  Embryonic pancreas dissections 
Embryos were obtained from CD1 strain albino mice (University of Bath, UK) 
11.5 days postcoitum (dpc). The day of the vaginal plug was considered as 
0.5dpc. The pregnant female mice were killed by cervical dislocation and the 
uteri were surgically removed by the horn of the uterus. The uteri were 
transferred to 100mm Petri dishes containing ice-cold phosphate buffered 
saline (PBSA) where individual uteri were separated using surgical scissors. 
The embryos were removed from their deciduas using fine forceps. The 
embryos were then transferred to 60mm Petri dishes containing dissection 
medium (see Table 2.2).  The gut was dissected out of the body with fine 
forceps. Using a tungsten needle, the liver buds and the dorsal pancreatic 
bud were removed from its location in the posterior region of the stomach 
adjacent to the duodenum, (see Fig. 2.2). The pancreata and liver buds were 
collected for tissue culture in 35mm Petri dishes containing the dissection 
medium.  
The cultures were set up as described in Percival and Slack (1999) with the 
following modifications. In a tissue culture hood, subbed glass coverslips 
(Fisher Diagnostics), which have been sterilised by baking for 2 hours at 
180oC, were placed in 35mm Petri dishes. To culture pancreatic buds for 
immunohistochemistry, a 40µl drop of 50µg/ml bovine plasma fibronectin 
(Invitrogen) was placed at the centre of each coverslip and left to dry. 2ml of 
the embryonic pancreas culture medium (See Table 2.2) was added to each 
Petri dish. A plastic cloning ring of 3mm internal diameter was then placed 
over the fibronectin-coated area of each coverslip and the pancreatic buds 
  
Figure 2.2 Steps in the dissection of the dorsal pancreatic bud from E11.5 
mouse embryos. A- E11.5 mouse embryo; B- decapitation of the embryo; C to F- 
opening up of the embryo and removal of the internal viscera; G- separation of the 
liver from the stomach; H- separation of the dorsal pancreatic bud from the base of 
the stomach; J- the dorsal pancreatic bud before (J’) and after attachment (J’’) onto 
the fibronectin coated coverslip. [œ- oesophagus; t- trachea; lb- lung buds; h- heart; 
liv- liver; st- stomach; duo- duodenum; panc- dorsal pancreatic bud; mes- pancreatic 
mesenchyme; epi- pancreatic epithelium].  
A B C 
F E D 
G H J’ 
J’’ 
h 
œ/t 
lb 
liv 
st 
duo 
panc panc 
epi mes 
  
were dropped into the centre of each cloning ring. To ensure the spreading 
of the tissue during culture, the pancreatic buds were oriented using fine 
tungsten needles, so that they were in the centre of the cloning rings with 
their cut face lying down. To culture pancreatic buds for protein extraction 
and protein assays, up to six buds were cultured on the same coverslip 
wholly coated with fibronectin. 
 
2B.3  Cell Culture 
2B.3.1  Primary cultures of hepatocytes 
The hepatocytes were cultured in different culture media as indicated in 
Table 2.2, at 37°C in 5% (v/v) CO2 for up to 8 days. The cultures were set up 
in 35mm dishes containing glass coverslips, 60mm and 100mm dishes for 
immunocytochemistry, RNA extraction and protein extraction respectively. 
The media was changed every two days. Whenever swapping between 
different media, the cells were briefly rinsed with pre-warmed PBS before the 
new media was added. The different extracellular factor treatments were 
initiated 24 hours after attachment, unless stated otherwise (see Table 2.8). 
2B.3.2  Culture of cell lines: maintenance, storage and revival 
A number of different cell lines were used as positive controls for various 
genes that were being investigated. Table 2.2 summarises the different 
culture media for the murine insulinoma cell line MIN, rat insulinoma cell line 
RIN-5F, the rat pancreatic-exocrine AR42J-B13 cell line, human embryonic 
kidney epithelial cell line HEK293 and the bipotential mouse embryonic liver 
cell line BMEL. All the cell lines were passaged by the same method when 
70-80% confluent. The cells were washed with PBS and then trypsinised with 
5ml of trypsin-EDTA for 3-5 minutes at 37°C. The trypsin was neutralised 
with an equal volume of supplemented medium and the cells were re-
suspended and centrifuged at 1000 rpm in a bench top PK110 centrifuge 
(ALC Intl., Milan, Italy) for 4 minutes. The supernatant was removed and the 
  
cell pellet re-suspended in 1ml of fresh medium. The cell suspension was 
reseeded in 15ml of fresh medium in 75cm2 flasks after making the 
necessary passaging dilutions for the specific cell line (see Table 2.1). 
For cell storage, after centrifugation the cell pellets were stored in cryovials 
containing 1ml freezing medium [10% (v/v) dimethyl sulfoxide (DMSO; VWR 
International) in FBS] and then frozen in an isopropanol freezing chamber at 
-80°C overnight before being transferred to liquid nitrogen for long-term 
storage. The cells were revived by rapid thawing in a 37°C water bath, re-
suspending the pellet in 1ml of fresh medium, followed by centrifugation at 
1000 rpm for 4 minutes (except for RIN-5F and MIN6 cells which were put 
into culture straight after thawing). The new pellet was re-suspended in 1ml 
of fresh medium and then inoculated in 15ml of medium in 75cm3 flasks. The 
medium was changed the following day and every other day thereafter. 
2B.3.3  Maintenance of embryonic organ cultures 
All organ cultures were maintained for 7 to 10 days at 37°C in 5% CO2. 
On day 1, the cloning rings were removed and the culture medium was 
changed every 24 hours then on. For betacellulin treated samples, 
10ng/ml of human recombinant betacellulin (Sigma) was added to the 
culture medium after the cloning rings were removed. 
 
2B.4  Lineage tracing of hepatocytes in culture 
Hepatocytes of C57BL/6 Alb-Cre x R26R LacZ mice were used to trace the 
lineage hepatocytes in culture (Postic and Magnuson, 2000, Soriano, 1999). 
For X-gal staining, the cultures were fixed at day 8 after isolation, in 0.5% 
glutaraldehyde in PBS for 5 minutes at room temperature (RT) and stained at 
37°C in 5-bromo-4-chloro-3indolyl-β-D-galactopyranoside (X-gal), 2mM 
MgCl2, 5mM potassium ferricyanide, 5mM potassium ferrocyanide, 0.01% 
sodium deoxycholate, 0.02% Nonidet P-40 in PBS (pH 7.3) for 6 hours. 
Cultured hepatocytes of Rosa26 LacZ mice, expressing bacterial β-
  
galactosidase ubiquitously(Zambrowicz et al., 1997), and CD1 wild type mice 
also fixed at day 8, were used as positive and negative controls, respectively. 
 
2B.5  Adenovirus preparation and titration 
HEK293 cells were grown in vented 75cm2 flasks (as previously described in 
2B.3.2) until 70% confluence. 10µl, 1µl, 0.1µl and 0.01µl of virus stocks were 
added to the flasks and incubated at 37°C. Approximately 50% of the cells 
detach within 2-4 days, as a result of the cytopathic effect (CPE) of the virus 
and is indicative of good viral infection. The cells were harvested simply by 
shaking the flasks, collecting the media and centrifuging at 1000 rpm for 4 
minutes. The resulting pellet was re-suspended in 1ml of HEK293 culture 
medium (see Table 2.2) and the cells were lysed by subjecting the cell 
suspension to four rapid freeze/thaw cycles, alternating between a dry 
ice/ethanol mixture and a 37°C water bath. The pre-stocks of the viruses 
were stored at -80°C. 
For further amplification of the virus, HEK293 cells were grown in vented 
225cm3 culture flasks and infected with 125µl, 12.5µl and 2µl of the viral pre-
stocks to ascertain the optimal volume (i.e. giving 50% CPE in 2-4 days) of 
pre-stock to add to each flask. Eight 225cm3 flasks were infected with this 
optimal volume of viral pre-stock. 2-4 days later, the cells from all eight flasks 
were harvested and centrifuged at 2000 rpm for 10 minutes. The pellet was 
re-suspended in 5ml 100mM Tris-HCl, pH 8.0, and subjected to 4 rapid 
freeze/thaw cycles and centrifuged at 1000 rpm for 5 minutes. The 
supernatant was mixed with 0.6 times the volume of sterilised supersaturated 
CsCl [(Sigma); in 100mM Tris-HCl, pH8.0] and divided into two centrifuge 
tubes (Beckman). The tubes were sealed after discarding all air from the 
tubes and centrifuged at 65000 rpm for 4 hours at 22°C on an L-80 
Ultracentrifuge (Beckman). The step gradient of the supersaturated CsCl 
solution concentrates the virus as a prominent bluish-white band, which was 
collected via a 25GA needle into a 10ml syringe. The virus was mixed with 
supersaturated CsCl and re-centrifuged at 65000 rpm overnight at 22°C. The 
new virus band was extracted as before and made up to 2.5ml with 10mM 
  
Tris-HCl, pH7.5, and passed through an equilibrated PD-10 SephadexTM G-
25 M desalting column (Amersham Biosciences). The column removes any 
CsCl and allows the virus to flow through. The virus particles were purified by 
filtering through a 0.22µm filter.  
For the titration of the virus, a 12 well plate was seeded with HEK293 cells 
and grown to 70% confluence. The cells were infected at 37°C with 100µl of 
10-2, 10-3, 10-4, 10-5, 10-6 and 10-7 dilutions of virus in separate wells with the 
last five dilutions in duplicate. After 48 hours of infection, the medium was 
discarded, the plate was aspirated and the cells were fixed at -20°C for 10 
minutes with ice-cold 100% methanol. The titration was carried out according 
to instructions provided with the Adeno-XTM Rapid Kit (Clontech 
Laboratories) which uses a mouse anti-hexon to immunocytochemically 
localise the viral hexon protein expressing infected cells. A 3,3’-
diaminobenzidine (DAB) chromogen kit (Vector) was used for development 
of the immunostaining. The infected cells were stained brown and the titre 
was estimated as the number of infectious units (iu)/ml: 
d

Titre mliu
×
×
=
1.0
573
_
)/( ,  where 
_
  is the mean number of infected cells per field 
at 20x objective magnification (10x eyepiece) for the viral dilution factor d. 
 
2B.6  Adenoviral infections 
Table 2.3 summarises all the viruses used. The adenoviruses were initially 
diluted in DS medium to 1x108 iu/ml. 72 hours after isolation, the hepatocytes 
were infected in the serum-containing DS medium at a total multiplicity of 
infection (M.O.I.; number of virus particles per cell) of 20-50 for 1 hour at 
37°C. During multiple infections the individual M.O.I. for each virus was kept 
constant, using the Ad-Null virus to moderate the total M.O.I. Cells were 
maintained after infection for 5 more days before RNA and protein isolation 
or fixation for immunostaining was carried out. GFP expression in the cells 
was visualised under a Leica DMIRB inverted microscope, for GFP tagged 
viruses 24 hours after infection to assess the efficiency of infection. 
  
2B.7  Qualitative and quantitative RT-PCR 
2B.7.1  RNA extraction 
The same RNA extraction protocol was used for the isolated of RNA for both 
qualitative and quantitative RT-PCR. Total RNA was extracted from cells on 
60mm culture dish per each condition, using TRI REAGENTTM (Sigma) 
according to manufacturer’s instructions. The RNA pellets were dissolved in 
DEPC-treated [0.0001% (v/v) diethylpyrocarbonate; Sigma] RNase-free 
water. The concentration of the extracted RNA was measured in µg/µl on a 
Beckman Spectrophotometer. Only RNA samples with 260nm/280nm 
absorbance ratio between 1.8 and 2.0 were used for reverse transcription. 
4µg of RNA was treated with 0.1U/µl of RQ1 RNase-free DNase I (Promega) 
at 37°C for 30 minutes to get rid of any genomic DNA contamination. The 
DNase was inactivated by incubating at 65°C for 10 minutes. 
2B.7.2  Reverse transcription 
Messenger RNA (mRNA) was isolated from 2µg of DNAse-treated total RNA 
by using the SuperScriptTM First-Strand Synthesis System for RT-PCR 
(Invitrogen) which involved the incubation of RNA with 0.5µg of Olido(dT)12-18 
oligonucleotides and 10mM dNTP mix at 65°C for 5 minutes. Complementary 
DNA (cDNA) was synthesised at 42°C for 52 minutes, using 10U/µl 
SuperScriptTM II reverse transcriptase enzyme, 2U/µl RNaseOUTTM and 
10mM dithiothreitol (DTT). The mRNA-cDNA hybrids were degraded by 
incubating with 0.1U/µl RNase H at 37°C for 20 minutes. All reagents for 
reverse transcription were obtained from Invitrogen. 
2B.7.3  Polymerase chain reactions 
The PCR reactions were carried out with 50ng of cDNA, 500ng of sense 
(forward) and antisense (reverse) primers (see Table 2.7 for a full list of 
primers) and 20µl of PCR ReddyMixTM Master Mix (AbGene, UK), in a DNA 
thermal cycler using the following conditions: denaturation at 94°C for 60 
seconds, amplification at the annealing temperature Tm (see Table 2.7) for 
  
60 seconds and elongation at 72°C for 60 seconds for 25-35 cycles. The rat 
GCK primer sequences were obtained from Heimberg et al. (1996), where 
PCR reactions were performed for 10 cycles of  94°C, 60 seconds; 65°C, 
90seconds; 72°C, 90 seconds followed by 20 cycles of 94°C, 30 seconds; 
60°C, 60seconds; 72oC, 90 seconds. The PCR products were analysed by 
electrophoresis on a 1.0-1.5% agarose gel alongside 100bp and 1kb DNA 
ladders (Invitrogen). 
For quantitative real-time PCR, 50ng of cDNA, 500ng of sense and antisense 
probes were mixed with 10µl of 1x SYBR®Green Taq ReadyMixTM (Sigma) in 
LightCycler® capillaries (Roche, Germany). Real-time PCR was performed 
on the Roche LightCycler® 1.5 and the thermal cycling parameters were set 
as 45 cycles of denaturation at 95°C for 30 seconds, amplification at Tm for 5 
seconds and elongation at 72°C for 20 seconds, followed by cooling at 40°C 
for 2 minutes. For real-time PCR all samples were amplified in triplicate.  
2B.7.4  Data analysis for quantitative real-time PCR 
The relative amounts of mRNA were calculated using the TC∆∆  method. The 
TC  value of a gene is the cycle number during the PCR at which a certain 
threshold T of amplification is reached. The TC  values were generated using 
the Roche LightCycler® software after the completion of the reaction. The 
mean TC  values ( TC
_
) were calculated for the amplification of both, the 
target gene of interest (target) and a house keeping reference gene such as 
beta-actin (reference) for either a positive control or a non-treated control 
(control) and all the experimental samples (experimental).  
Then,         )(
_
)arg(
_
referenceTettTT CCC −=∆ , and  
)(exp)( erimentalTcontrolTT CCC ∆−∆=∆∆ . 
The level of mRNA of the gene of interest relative to that of the reference 
gene and normalised to the control was expressed as TC ∆∆ , where   is the 
efficiency of the reaction taken as the exponent of amplification.  
  
For calculation purposes it was assumed that 2= , based on the 
theoretical dynamics of a PCR; unless the efficiency of the reaction was 
significantly lower, in which case the primers were redesigned. All 
comparisons were made with the TC ∆∆ for the control which was equal to 1, 
(as 0)( =∆∆ controlTC ), thus giving the result as the fold increase or decrease 
compared to the control. 
 
2B.8  Immunocytochemistry. 
Cells were fixed in 4% (w/v) paraformaldehyde (VWR International), pH7.4, 
in PBS for 20-30 minutes at room temperature (RT) or in ice cold 1:1 
acetone:methanol for 5 minutes. Pancreas and liver organ cultures were 
fixed in MEMFA (3.8% (v/v) formaldehyde, 0.15M MOPS, 2mM EGTA, 1mM 
MgSO4, pH7.4) for 20 minutes at RT. Antigen retrieval was performed in 1x 
citrate buffer or 1x EDTA buffer (Lab Vision) at 37oC for 1 hour where 
necessary. Samples were permeablised in PBS with 0.1% (for cells) or 1% 
(for organ cultures) (v/v) Triton x-100 (Sigma) for 20 minutes and then 
blocked in 2% (w/v) blocking buffer (Roche, UK) for 1-2 hours. The samples 
were then incubated overnight at 4oC with the indicated dilutions of the 
primary antibodies (Table 2.4). The samples were washed in PBS and then 
incubated at RT for 2 hours in the dark with the appropriate fluorochrome-
conjugated secondary antibody (Table 2.5), avoiding simultaneous 
incubation with possible cross-reacting antibodies. When using 
fluorochrome-conjugated primary antibodies, lectins or phalloidin the 
samples were incubated at RT for 2 hours in the dark with the appropriate 
dilution of the conjugated compound. After several washes with PBS, the 
samples were mounted on superfrost slides (Mensel-Gläser, Braunschweig, 
Germany) using Gel-MountTM mounting medium (Biomeda, Foster City, CA). 
Where horseradish peroxidase (HRP)- conjugated secondary antibodies 
were used, the endogenous peroxidase activity was quenched by two 15 
minute incubations at RT in 0.3% (v/v) H2O2 in methanol just after 
permeablisation. The samples were developed using a DAB immunolabelling 
kit (Vector) according to manufacturer’s instructions. For cell counting 
  
experiments, prior to mounting the coverslips were incubates with 500ng/ml 
4,6-Diamidino-2-phenylindole (DAPI; Sigma, UK) for 20 minutes.  Positive 
controls for all the primary antibodies used and the no primary controls for all 
the secondary antibodies are included in the Appendix B. 
The same procedure as described above was followed for the 
immunofluorescent staining of freshly isolated hepatocytes in suspension. 
The staining was carried out in 1.5ml Eppendorf tubes which were pre-
incubated with 2% blocking buffer at RT for 30 minutes to prevent antibody 
binding to the plastic. All the incubation steps were done on a bench-top 
nutator. After each step the cells were re-pelleted by centrifugation at 
1000rpm for 4 minutes and then re-suspended in the subsequent solution.  
 
2B.9  Tissue processing and histology 
Adult and embryonic tissue used as positive controls for different antibodies 
were initially fixed in 4% (w/v) paraformaldehyde for 2 hours at 4°C followed 
by 3 serial PBS washes for 15 minutes each. The tissue was processed in a 
Leica TP1020 tissue processor, overnight through a series of 70-100% (v/v) 
ethanol and then histoclear (Fisher Scientific). The samples were 
impregnated in paraffin wax at a Leica EG1160 embedding station and then 
sectioned using a Leica RM2155 microtome into 5µm thick ribbons collected 
onto Menzel-Gläzer Polysine slides (Thermo Scientifics) which were dried 
overnight at 38°C. Before immunohistochemistry, the sections were de-
waxed in histoclear and then rehydrated though an ethanol series. 
For cryosectioning, the fixed samples were sequentially incubated with 5%, 
15% and 30% (w/v) sucrose in PBS at 4°C on rollers, until the tissue attained 
neutral density with each solution. The samples were mounted with Optimal 
Cutting Temperature (OCT) compound (Leica) on a trough of dry ice and 
isopropanol. The frozen blocks were cut into 10-15µm thick sections using a 
Leica CM1850 cryostat run at -20°C to -27°C and collected onto pre-warmed 
SuperFrost Plus® glass slides (Thermo Scientific).  The slides were washed 
in PBS at RT prior to immunostaining, to dissolve the OCT mounting media. 
  
2B.10  Protein extraction and Western blot analysis 
2B.10.1 For all proteins larger than 10kDa 
Tissue samples and cells were washed in ice-cold PBS, transferred to lysis 
buffer [150mM NaCl, 1mM EDTA, 2mM dithiothreitol (DTT; Sigma), 20mM 
HEPES, 1% (v/v) Triton x-100, pH7.6] containing 1:100 protease inhibitor 
cocktail for mammalian tissues (Sigma) and the supernatant was collected 
from cellular debris by centrifuging at 4oC on 13,000rpm for 10 minutes. 
Protein concentrations in the lysates were assayed using the Bio-Rad protein 
assay based on the Bradford dye-binding procedure. If necessary the sample 
solutions were further concentrated by ultrafiltration using a Centricon YM-
100 Centrifugal Filter Device (Millipore). The samples were stored at -80oC. 
The protein lysates were mixed with equal volumes of 2X sample 
buffer [125mM Tris-HCl (pH6.8), 4% (w/v) sodium dodecyl sulphate 
(SDS), 20% (v/v) glycerol, 0.2mM DTT and 0.02% (w/v) bromophenol 
blue (all Sigma)] and then heated on a 100oC heat block for 5 minutes. 
A volume of sample corresponding to 10µg of protein alongside a 
Precision Plus Protein Rainbow StandardTM ladder (BioRad) was 
subjected to sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS PAGE) on 4-20% gradient, 10% or 15% Tris-HCl 
CriterionTM Precast Gels (BioRad) in 1 x running buffer [25mM Tris, 
192mM glycine and 0.1% (w/v) SDS] at 200V. The protein from the 
gels were then electrophoretically transferred to a nitrocellulose 
membrane (Pall) by blotting for 2 hours at 200mA in 1 x transfer buffer 
[25mM Tris-HCl, 192mM glycine and 20% (v/v) methanol]. The 
membranes were stained in Ponceau S (Sigma) to visualise the bands 
and then blocked in 5% (w/v) skimmed milk (Marvel) in PBS with 0.1% 
(v/v) Tween-20 (PBST; Sigma). Incubation with the primary antibodies 
(Table 2.6) was done overnight at 4oC with gentle constant agitation on 
a bench top rocker at 70 rpm.  After stringent washes in PBST, the 
membranes were incubated with the secondary antibodies (Table 2.6) 
  
for 2 hours at RT. The immunoreactive proteins were visualised by the 
ECL or ECL plus Western blotting analysis systems (Amersham) 
followed by autoradiography on HyperfilmTM (Amersham), or 
colorimetrically by using a DAB immunolabelling kit according to 
manufacturer’s instructions (Vector). All antibodies were prepared in 
3% (w/v) skimmed milk (Marvel) in PBST except when a biotinylated 
secondary had to be used, in which case they were prepared in 5% 
(w/v) bovine serum albumin (BSA: Sigma) in PBST. 
The membranes were stripped with stripping buffer [62.5mM Tris-HCl, 
100mM β-mercaptoethanol and 2% (w/v) SDS, pH6.7] for 30 minutes 
at RT in a fume hood and re-probed if necessary. The membranes 
were washed with distilled water, dried and stored, wrapped in cling 
film at 4°C for future use. 
2B.10.2 For insulin and other proteins smaller than 10kDa 
Protein was extracted from de-differentiated hepatocytes and RIN-5F cells by 
lysing and homogenising the cells in 0.18M HCL in 35% (v/v) ethanol 
containing 1:100 protease inhibitor cocktail for mammalian tissues (Sigma). 
A total of 400µl of lysis reagent was used per 100mm dish. The cell lysates 
were rotated overnight at 4oC, centrifuged at 13,000 rpm and the 
supernatants were stored for future use at -80oC. The HCl in the cell lysate 
was neutralised using equimolar NaOH before the protein content was 
measured using the Bio-Rad protein assay as described above. A total of 
50µg of protein (10µg for RIN-5F), mixed with an equal volume of 2 x sample 
loading buffer [200mM Tris-HCl (pH 6.8), 40% (v/v) glycerol, 1% (w/v) SDS, 
0.01% (w/v) Coomassie Brilliant Blue R250] was denatured by heating to 
100oC for 5 minutes. The proteins were then separated on a pre-cast 
CriterionTM 16.5% Tris-Tricene gel (Bio-Rad, Watford, UK) in running buffer 
[0.1M Tris-Hcl, 0,1M Tricene and 0.1% (w.v) SDS)] along side an ultra-low 
range molecular weight marker (1.06-26.6kDa; Sigma). The blot was run at 
50V for 10 minutes followed by 120V for 90 minutes, both at RT. The protein 
  
bands were then transferred onto a polyvinylidene fluoride (PVDF) 
membrane (Bio-Rad) with a current of 50V for 30 minutes at 4oC in 1x 
transfer buffer [25mM Tris-HCl, 192mM glycine and 20% (v/v) methanol]. 
The membranes were blocked and probed as mentioned above (2B.10.1). 
Rabbit polyclonal anti-insulin antibody was used at a concentration of 1:100 
followed by anti-rabbit HRP (1:1000) and developed using the ECL Western 
blotting analysis system followed by autoradiography. 
The ultra-low range molecular marker and the total protein on the 
membranes were visualised by using a Coomassie stain. After blotting, the 
gels were fixed in a Tris-Tricene gel fixative [0.2% (v/v) glutaldehyde, 30% 
(v/v) ethanol and 0.2M sodium acetate] for 1 hour at RT with gentle rocking 
and then stained with Coomassie staining solution [0.025% (w/v) Coomassie 
Brilliant Blue R250, 40% (v/v) methanol. 7% (v/v) acetic acid] overnight at RT 
with gentle agitation on a rocker. Background stain was removed by serial 10 
minute washes in de-staining solutions I [40% (v/v) methanol and 7% (v/v) 
acetic acid] and II [5% (v/v) methanol and 7% (v/v) acetic acid]. The stained 
gels were stored at RT in de-staining solution II with 1% (v/v) glycerol. 
 
2B.11  Glucose Stimulated Insulin Secretion (GSIS) 
Cells cultured in 10mm dishes were washed with PBS and then incubated 
with 10ml of phenol red-free normal glucose (5.5mM) or high glucose 
(25mM) DMEM with 100units/ml penicillin and 100µg/ml streptomycin, for 1 
hour at 37°C. The media was collected and then concentrated using a 
Centricon YM-3 Centrifugal Device (nominal molecular weight cut-off limit of 
3kDa; Millipore) by centrifuging at 4000 g for 40 minutes on a swinging 
bucket centrifuge. Approximately 200µl of protein concentrate was recovered 
and mixed with 1:100 proteinase inhibitor cocktail. The insulin concentration 
of the concentrated media and cell lysates (see 2B.10.2) was measured 
using an ultra-sensitive rat insulin ELISA kit (Mercodia) according to 
manufacturer’s instructions. All the standards and samples were analysed in 
triplicate.  
  
Any insulin lost during the protein extraction process was determined by 
spiking the initial lysis buffer with a known concentration of insulin while 
extracting the total protein from differentiated hepatocytes (that otherwise do 
not contain insulin), and measuring the percentage recovered after the 
extraction process. The total insulin content of cells was calculated as the 
amount of insulin per total amount of protein, accounting for any insulin lost 
during the extraction process. The amount of insulin released into the media 
was expressed as the percentage of total insulin content of cells released 
during the one hour period of glucose stimulation.  
 
2B.12  Quantification of C-peptide levels 
The C-peptide content of cell lysates were measured using a high precision 
Rat C-peptide ELISA kit (Mercodia) according to manufacturer’s instructions. 
A total sample volume of 10µl was used per well and all the samples were 
measured in triplicate and the experiment was repeated three times. The C-
peptide content of cells were calculated as pmoles of c-peptide per gram of 
total protein. Any samples with a measurement below the threshold detection 
limit for the kit (i.e. ≤100pmol/L) was discounted. 
 
2B.13  Image processing 
Images of cells in culture, were collected on a DMIRB inverted microscope 
using a SPOTTM camera operated with the SPOTTM Advanced software. 
Fixed and stained fluorescent specimens were observed under the Leica 
DMRB microscope. Zeiss LSM 510 and LSM 510-META microscopes were 
used for confocal microscopy (the latter was used for high magnification 
images where the DAPI staining had to be collected along with other 
fluorochromes). For measurements of cell size and area, the measuring tools 
on the Zeiss LSM Image Browser software were used. The final figures were 
assembled using Adobe Photoshop 7.0 software. 
 
  
2B.14  Statistics 
All numerical results are expressed as the mean ± SEM. The statistical 
significance between different values were determined with a student’s t-test 
performed using the GraphPad PrismTM 3.02 software.  
 
  
Chapter THREE
Hepatocyte 
De-differentiation
& the Induction of
Pancreatic Genes  
  
 BACKGROUND 
 
Hepatocytes are highly differentiated epithelial cells that constitute up to 80% 
of the liver mass (Mitaka, 1998). They have several major functions that help 
maintain body homeostasis. Hence, primary hepatocytes (both rodent and 
human) maintained in culture have been used as an in vitro model system for 
the study of xenobiotic metabolism, liver physiology, as well as 
understanding the biology of certain viral pathogens and parasites (Elaut et 
al., 2006). Cultured hepatocytes are also proving to be an attractive 
candidate to make cell-based extracorporal liver support systems (Court et 
al., 2003). However, the use of primary hepatocytes for any form of in vitro 
experimentation or therapeutic application has long been hindered by their 
limited life-span and de-differentiation in culture (Guillouzo, 1986). The 
distinguishing feature of the phenomenon of de-differentiation is the 
withdrawal from a given differentiated state and in the case of plants, 
invertebrates and amphibians, the attainment of a state that confers 
pluripotency (Odelberg et al., 2000, Zhao et al., 2001, Grafi, 2004). In 
hepatocytes however, de-differentiation is characterised by a progressive 
loss of liver-specific gene expression, function and distinct hepatocyte 
morphology. Such changes have been attributed to the diminished 
expression of liver-enriched transcription factors upon isolation. This in turn 
is due to the loss of signals emanating from the extracellular matrix, blood 
and via intercellular contacts with nonparenchymal cell types that otherwise 
maintain the hepatic phenotype in vivo (reviewed in Elaut et al., 2006).  
With the recent description of a culture medium that can maintain the hepatic 
phenotype in long-term culture (Li et al., 2007), it is possible for the first time 
to directly compare differentiated and de-differentiated hepatocytes in vitro. 
The experiments described in this chapter will aim to assess the changes 
that take place during the process of hepatocyte de-differentiation. 
Furthermore the resulting potentiality of the de-differentiated hepatocytes, in 
particular of becoming pancreatic, will also be addressed. 
 
  
3.1 Isolation and characterisation of primary rat hepatocytes. 
Primary rat hepatocytes were isolated as described in Chapter 2 (2B.1.1) 
and the viability was estimated at greater than 85% using trypan blue 
exclusion test, to be considered suitable for culture. Freshly isolated 
hepatocytes, if viable have uninterrupted shiny membranes and the nuclei 
are often visible (Fig. 3.1A). The occurrence of cell surface blebbing was 
common, partly due to oxidative stress during the isolation process and the 
high Ca2+ content of perfusion buffer 2. However, since cell surface blebbing 
is Ca2+-dependent, and if the blebbing was not too extensive, the majority of 
the cells recovered during the first few hours of culture in the attachment 
medium. Once the cells attach to the glass or plastic substrates of the culture 
dish, the cells flatten out and the hepatic morphology is evident (Fig. 3.1B). 
Hepatocytes are hexagonal in shape with the majority being binucleate and 
bile cannaliculi are often seen between adjacent hepatocytes in culture. 
To ascertain the purity of the initial hepatocyte population, freshly isolated 
hepatocytes were fixed and the expression of various cell-type specific 
markers was examined by immunocytochemistry (Fig. 3.2). The results 
indicate that the initial starting population is a relatively pure population of 
parenchymal hepatocytes all expressing the hepatocyte-enriched iron 
transporter protein transferrin. The hepatocyte population comprised cells 
from both the periportal and perivenous zones of the liver, indicated by the 
differential expression of the urea cycle enzymes, carbamoyl phosphate 
synthetase (CPS) and glutamine synthetase (GS) respectively. The 
proportions of CPS and GS positive cells (Fig. 3.3) found in the isolated 
hepatocytes were reminiscent of that found in vivo, in the liver. The cells 
stained negatively for the endothelial marker PECAM-1, the connective 
tissue marker smooth muscle actin, the non-parenchymal liver cell marker 
Thy1 and the (intra-hepatic) duct-specific lectin (DBA) binding α-N-
acetylgalactosamines, confirming that there was no contamination by any of 
these cell types in the isolate (Fig. 3.2D-G). 
The only contaminating cell-type found was a sub-population of cells positive 
for the intermediate filament vimentin, which comprised of 0.039 ± 0.009% of 
  
the total cells (Figs 3.2H & 3.3). These cells were most often found within 
clumps of hepatocytes and their numbers were reduced by ensuring a single 
cell suspension of hepatocytes was obtained during the centrifugation steps. 
After attachment and by 24 hours into culture, all the hepatocytes have 
typical hepatocyte morphology as previously described, and express an 
array of hepatocyte-specific proteins (Fig. 3.4). They include the plasma 
proteins albumin and transthyretin, the oxyhaemoglobin binding glycoprotein 
haptoglobin, the iron transporter protein transferrin and the liver-specific 
enzymes UDP-glucuronosyltransferase (UGT), CPS and GS. The expression 
of such proteins is a hallmark feature of a differentiated hepatocyte.  
 
3.2 De-differentiation of primary rat hepatocytes. 
The isolated hepatocytes were cultured long term (up to 11 days) in either 
the KS medium to maintain the differentiated state or the DS medium to 
initiate de-differentiation. Hepatocytes cultured in the KS medium, 
maintained their hepatic morphology, whereas those cultured in the DS 
medium underwent de-differentiation and showed rapid loss of their hepatic 
epithelial-like morphology (Fig. 3.5A-B). During the 7 day culture period in 
the DS medium, the cells became more elongated and attained a 
mesenchymal morphology, which was associated with a dramatic 
rearrangement of their actin cytoskeletal network (Fig 3.5C). The change in 
morphology was apparent from day 2 onwards. 
In addition to the change in morphology, by day 7, de-differentiation was also 
accompanied by the loss of hepatic gene expression including albumin, 
transferrin, UGT and the liver enriched transcription factor hepatic nuclear 
factor 4α (HNT4α) which were otherwise maintained under KS culture 
conditions (Fig. 3.6).  Following de-differentiation, genes that were not 
typically expressed in hepatocytes were also induced. Such genes included 
vimentin, smooth muscle actin and cytokeratin 20 (CK20). A population of 
cells with DBA binding sites also appeared after de-differentiation.  
  
Following the cells through the course of de-differentiation over 8 days 
revealed that the loss of the hepatic gene expression and the induction of 
non hepatic genes were not sudden but gradual (Fig 3.7). By day 3, while the 
expression of the Glut2 transporter was being lost from hepatocytes, there 
was already overt expression of vimentin and CK20 which concurrently 
increased during the next 5 days of culture.  
 
3.3 Lineage analysis during de-differentiation. 
Whenever a change of phenotype is observed in cultured cells, as during de-
differentiation, it is necessary to demonstrate that the effect is not due to 
selection of a small population of contaminating cells. This is because a 
rapidly growing minority of cells could become a significant proportion of the 
total cells after an 8 day culture period. There is indirect evidence to suggest 
that the mesenchymal-like cells were derived from the epithelial hepatocytes 
during the de-differentiation process (Fig. 3.8). For example, low residual 
levels of transferrin, UGT and HNF4 protein expression was seen in de-
differentiated cells at day 7, long after the change in morphology had taken 
place. Furthermore, some de-differentiated cells that were expressing 
vimentin or smooth muscle actin were also binucleate- which is a feature 
common to hepatocytes but atypical of fibroblasts or other mesenchymal cell 
types. However, to draw more conclusive evidence to demonstrate that the 
de-differentiated cells arose from hepatocytes, a lineage tracing experiment 
was devised.  
The low efficiency with which primary hepatocytes can be transfected with 
any conditional labelling construct made it necessary that, transgenic 
animals were employed for lineage analysis. The impracticability of 
generating transgenic rats and the fact that mouse hepatocytes also show 
the same de-differentiation phenomenon as rat hepatocytes (discussed later 
in Section 3.8), meant that Alb-Cre R26R LacZ mice could be used for the 
lineage tracing experiments. In the Alb-Cre R26R LacZ mice, Cre 
recombinase is expressed only in cells that have activated the albumin 
promoter but not in other cell-types. The Cre excises the stop sequence from 
  
the R26R gene, leading to the permanent expression of the E. coli β-
galactosidase gene under the control of the cytomegalovirus (CMV) 
promoter. The non-hepatocyte cells that might be present in small numbers 
in the original culture will not be labelled in this way as an active albumin 
promoter is specific to the hepatocyte population. Hepatocytes were isolated 
from these mice as described in Chapter 2 (2B.1.2), and cultured in the DS 
medium. The cells were fixed and stained with X-gal to visualise β-
galactosidase expression. By day 8 of culture, the vast majority of cells with 
mesenchymal morphology were X-gal positive and therefore derived from 
hepatocytes that once expressed albumin, rather than having arisen from a 
sub-population of a contaminating cell-type (Fig. 3.9). Hepatocytes from 
Rosa26 LacZ mice that express bacterial β-galactosidase ubiquitously and 
those from CD1 wild type mice were used as positive and negative controls 
respectively, for the X-gal staining. A few of the cells with mesenchymal-like 
morphology were X-gal negative, but this is also true on the positive control 
cultures set up from Rosa26 LacZ mice in which all cells express β-
galactosidase constitutively from the same promoter. The lack of X-gal 
staining in all cells could be due to a number of factors. The recombination at 
the R26R locus may not be 100% efficient, or the β-galactosidase levels in 
some cells may fall below the detection threshold of the X-gal staining or 
there may be a downregulation of the R26R locus during de-differentiation. 
  
3.4 Hepatocyte de-differentiation resembles an epithelial-
mesenchymal transition event. 
Epithelial-mesenchymal transition (EMT) is a phenomenon that is associated 
with organogenesis during development and the initiation of metastatic 
cancer. During EMT, epithelial cells lose their epithelial phenotype, become 
more mesenchymal like and show increased cell mobility. EMT has also 
been observed in vitro in cells that undergo rapid expansion by cell 
proliferation.  
The de-differentiation of hepatocytes cultured in the DS medium is 
characteristic of an EMT. In vivo, hepatocytes are normally mitotically 
  
quiescent and stay under G0 arrest. However they are unique among 
differentiated parenchymal cells in that, they retain the ability to proliferate 
when triggered to do so. This underlies the remarkable regenerative capacity 
of the liver in response to acute injuries that diminish hepatic mass. During 
de-differentiation, in addition to losing their epithelial morphology and 
becoming mesenchymal-like, the hepatocytes also started to proliferate by 
re-entering the cell cycle at the G1 mitotic phase. This can be seen as an 
increase in the number of cells expressing phosphorylated histone 3, which 
plays a role in chromatin remodelling and chromosome condensation 
associated with cell cycle re-entry (Fig. 3.10). However, during the de-
differentiation process an equal number of cells were seen undergoing 
replication, both before and after becoming vimentin positive (Fig. 3.11).  
The other feature characteristic of an EMT, which was also observed in de-
differentiated hepatocytes was increased cell mobility. Cells were cultured in 
KS and DS medium. 24 hours after attachment, a 1cm2 area of cells from the 
centre of the coverslip was scraped off using a cell scraper. The cells were 
washed to get rid of any floating and partly attached cells, the media was 
changed and the cultures were continued for 10 more days. In the KS 
medium, where the hepatocytes maintained their differentiated state, only 
minimal cell migration and subsequent invasion of the clear area was seen 
even at 10 days after cell scraping. In the DS medium, where hepatocytes 
de-differentiated, the cells were more mobile. Cell migration was observed at 
2 days after cell scraping and by day 10, almost 50% of the clear area was 
occupied by migrating cells (Fig 3.12). However, limited cell mobility can also 
be induced in 2 day KS cultures by treating the cells with 10ng/ml TGF-β1 
that has been shown to induce EMT in other primary culture systems (Forino 
et al., 2006). 
 
3.5 De-differentiation and the induction of pancreatic gene 
expression. 
In addition to losing the hepatic gene expression and gaining vimentin 
expression, hepatocytes cultured under DS conditions also started to 
  
express a pancreatic gene expression profile (Fig. 3.13). The pancreatic 
genes that were induced included several characteristic of endocrine beta 
cells, such as the transcription factor Pdx1, the genes for the hormones 
insulin (ins1 and ins2) and islet amyloid polypeptide (IAPP), the 
neuroendocrine secretory protein chromogranin A and the genes encoding 
the two subunits of the pancreatic beta cell K+-ATP channel- sulphonylurea 
receptor 1 complex (SUR1 and Kir6.2). Genes characteristic of a more 
mature beta cell phenotype, such as pancreatic glucokinase (islet GCK), 
were also induced while the gene encoding the liver-specific isoform of the 
enzyme (hepatic glucokinase; liver GCK) was downregulated in a 
complementary fashion. The pancreatic exocrine maker amylase was also 
expressed when cells were cultured in the de-differentiation medium. 
In order to determine if it was only a pancreatic gene expression profile that 
was being induced following de-differentiation and not that of any other 
endoderm-derived organ, the expression of lung and intestine specific genes 
were investigated. However, neither the gene encoding the lung-specific 
pulmonary surfactant associated protein B (Sftp-B), nor the marker for 
intestinal-type differentiation- the caudal type homeobox transcription factor 2 
(cdx2)- were induced as a consequence of de-differentiation (Fig 3.14). 
The cells cultured in the DS medium, by day 8, comprise a heterogeneous 
population (Fig. 3.15). There are three types of vimentin positive cells that 
are noticeable in this population: 1- mesenchymal like cells derived from de-
differentiated hepatocytes; 2- large multinucleate cells (with 3 or more nuclei) 
formed either by the fusion of de-differentiated cells or incomplete 
cytokinesis following karyokinesis during hepatocyte replication; 3- a few 
contaminating cells remaining from the initial isolation that are much smaller 
in size than the other cells. To distinguish whether the pancreatic genes 
(such as insulin) were being induced in the de-differentiated hepatocytes and 
not in the contaminating population, the cells were cultured in the KS 
medium for 3 days to suppress fibroblast growth prior to initiating de-
differentiation in the DS medium. This culture routine removed of most of the 
small vimentin positive cells arising from the initial contaminantion (Fig. 
3.16A-B). The resulting population still showed the induction of ins1 gene at 
  
levels comparable to hepatocytes that were cultured in the DS medium 
continually for 5 or 8 days (Fig. 3.16C), suggesting that the pancreatic genes 
were being induced, at least in part, in the de-differentiated hepatocytes 
rather than predominantly in the contaminating population. 
 
3.6 The reversibility of the de-differentiated phenotype. 
To determine if the de-differentiated phenotype was reversible, hepatocytes 
were cultured under de-differentiating DS conditions for 3 days and then 
transferred to the KS medium and maintained under these conditions for a 
further 5 days (Fig. 3.17).  Initially after the transfer, the de-differentiation (as 
indicated by vimentin expression) and the levels of the induced pancreatic 
genes were downregulated. However, this suppression of gene expression 
was only temporary and by 3 days after transfer to KS conditions, de-
differentiation had resumed although at a much slower rate compared to 
those cells cultured throughout in the DS medium. More dramatic was the 
upregulation of liver gene expression (as seen by levels of albumin and cps) 
in de-differentiated hepatocytes following the transfer to the KS medium. The 
expression of the liver genes appeared to be more sustained during the 5 
day culture period that followed in the KS medium. Therefore, the de-
differentiated phenotype is not entirely reversible. Although liver-specific 
genes can be re-induced, a true hepatic phenotype cannot be achieved just 
by swapping the media and without the use of other exogenous factors.  
 
3.7 Are progenitors induced during hepatocyte de-differentiation? 
During embryonic development, pancreatic and liver lineages arise from 
different progenitors derived from a common endodermal domain. After the 
completion of organogenesis, it is widely accepted that some cells with 
progenitor-like properties reside within the organs well into adult life in order 
to contribute to tissue mass during post-embryonic organ growth and innate 
regenerative responses of the body. Markers for such tissue-specific 
  
progenitors have been identified and several more have been proposed. In 
order to find out if any of these hepatic or pancreatic progenitor markers 
were induced during the de-differentiation process, after loss of the hepatic 
phenotype and prior to the induction of the pancreatic phenotype, RT-PCR 
was carried out (Fig. 3.18). The expression of the embryonic liver markers 
alpha-foetoprotein (AFP) and stromal cell derived factor 1a (SDF1a), and the 
oval cell marker c-kit were all seen during de-differentiation. Additionally, the 
genes encoding the protein gel product 9.5 (PGP9.5) and the winged helix 
transcription factor FoxA3 (or Hnf3γ) were also expressed. These genes are 
otherwise expressed in the early endodermal epithelium and neuroendocrine 
progenitors. Nestin- a postulated marker for pancreatic progenitors, CK19- a 
marker of the pancreatic ductal epithelium in which the beta cell precursors 
are thought to reside and Sox9- a transcription factor expressed in cells from 
which the pancreatic endocrine cells are derived, were all induced following 
de-differentiation. 
The expression of both the progenitor markers and the differentiated 
pancreatic cell-type markers at common time points does not necessarily 
imply co-expression. The total population might comprise cells at several 
different stages of differentiation. The progenitor markers that can be seen at 
an immunodetectable level are the pancreatic and hepatic oval cell maker 
OV6 and the early pancreatic progenitor marker, Sox9 (Fig. 3.19). Both these 
proteins were only detected in de-differentiated hepatocytes in the DS 
medium and not in freshly isolated hepatocytes or hepatocytes maintained in 
the KS medium. This suggests that a heterogeneous hepatic/pancreatic 
progenitor-like population is produced during de-differentiation. 
 
3.8 Induction of pancreatic genes in de-differentiated mouse and 
human hepatocytes. 
It is important to establish whether the de-differentiation phenomenon and 
the induction of pancreatic genes observed with rat hepatocytes extends to 
other rodent hepatocytes (e.g. from the mouse) and more importantly to 
human hepatocytes. Mouse and human hepatocytes can be cultured under 
  
KS and DS conditions as previously described for the rat hepatocytes. 
Mouse hepatocytes are slightly larger than rat hepatocytes (Fig. 3.20 A and 
B) and in the DS medium, the mouse hepatocytes also lose their hepatic 
morphology and gene expression. The downregulation of hepatic gene 
expression is accompanied by the induction of vimentin expression and also 
of several pancreatic genes including ins1, Kir6.2 and SUR1 (Fig. 3.21).  
Freshly isolated human hepatocytes were found to contain more lipid than 
the rodent hepatocytes partly due to the age of the human cell donors. 
Although human hepatocytes started to express vimentin following culture in 
the DS medium, the change in morphology of the human hepatocytes was 
not as pronounced as that for rat hepatocytes undergoing de-differentiation 
(Fig. 3.32). However, a similar loss of liver gene expression was seen both at 
mRNA and protein levels (Figs 3.23 and 3.24). By day 7, the expression of 
albumin, transferrin, UGT and HNF4 were all downregulated. It was also 
observed that, unlike for the rodent hepatocytes the KS medium was not 
sufficient enough to maintain high levels of hepatic proteins in human 
hepatocytes cultured for 7days (Fig. 3.23). However, the induction of 
pancreatic gene expression following de-differentiation was also observed in 
human hepatocytes, but the levels of induction was slightly lower compared 
to de-differentiated rodent hepatocytes (Fig. 3.24). 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
DISCUSSION 
The morphological changes that are initiated upon hepatocyte isolation and 
during their subsequent culture have been previously described (Guillouzo, 
1986). The ascertaining the homogeneity of the initial population is vital and 
it has confirmed that the phenotypic changes seen, both in morphology and 
gene expression are directly due to de-differentiation of hepatocytes. 
Furthermore, the changes associated are too rapid to be accounted for by 
selective overgrowth of a very small population of undifferentiated 
precursors. For example, the most abundant contaminant is the vimentin 
positive cells at 4 cells per 10000 hepatocytes. These would need to divide 
13 times, in the total absence of division by the hepatocytes, before they 
became a majority of the culture. The PH3 staining indicated that this was 
not the case. We have also confirmed the phenomenon of hepatocyte de-
differentiation by the lineage tracing with Alb-Cre R26R LacZ cells, which 
shows that most of the cells at 8 days are derived from the original 
hepatocytes. Therefore it is important to understand the mechanisms that 
provoke de-differentiation of hepatocytes and how it applies to our system. 
Epithelial-mesenchymal transition events that resemble hepatocyte de-
differentiation have also been reported for several other cell-types such as 
pancreatic beta cells and kidney tubular epithelial cells maintained in long-
term primary culture (Gershengorn et al., 2004 (remitted), Ouziel-Yahalom et 
al., 2006, Forino et al., 2006). The potential molecular mechanisms 
underlying the de-differentiation processes involve disruption of the in vivo 
mechanisms that maintain the differentiated phenotype. For hepatocytes 
these can be divided into, 1- soluble endogenous substances, growth factors 
and hormones circulating in the blood, 2- autonomic hepatic innervations, 3- 
the extracellular matrix, and 4- intercellular communication mediated via 
paracrine factors and cell junctions (such as adherens junctions and 
connexin containing gap junctions). Most of the above mentioned 
mechanisms can influence the transcriptional regulation of hepatic genes by 
directly or indirectly interacting with nuclear receptors and recruiting liver-
enriched transcription factors such as HNFs, C/EBPs and DBP (Cereghini, 
  
1996, Lekstrom-Himes and Xanthopoulos, 1998, Hayhurst et al., 2001). Most 
liver-specific promoters have consensus sequences to which these 
transcription factors bind to, in order to regulate gene expression and 
ultimately hepatic function. Thus the liver is an organ which highlights the 
importance of the histoarchitecture, the soluble environment and the 
transcriptional machinery in maintaining a differentiated phenotype in vivo.  
During the hepatocyte isolation process and subsequent dissociation of the 
liver, the collagenase-mediated digestion of the extracellular matrix and the 
disruption of normal tissue integrity triggers de-differentiation (Elaut et al., 
2006). Hepatic ischemia/reperfusion (I/R) injury is also considered one of the 
major causes of hepatocyte de-differentiation, during the isolation process 
itself (Fondevila et al., 2003). Our protocol for liver perfusion in situ and prior 
oxygenation of the perfusion buffers minimises the duration of oxygen 
deprivation. Nonetheless the hepatocytes are still susceptible to I/R injury. 
This can account for the slightly low levels of hepatic mRNA in freshly 
isolated and 24 hour cultured hepatocytes compared to RNA isolated from a 
non-perfused liver. The presence of PH3 positive cells as early as 24 hour 
into cultures could also be explained by I/R stress, as the G0 to G1 phase 
transition can take place during the isolation itself (Su et al., 2002).  
The other phenotypic alterations seen during the culture of hepatocytes 
under DS conditions can be summarised as the change in morphology, 
induction of vimentin expression and further downregulation and near 
abolition of hepatic gene expression. During culture as a monolayer, 
hepatocytes depolarise partly due to the loss of tight and gap junctions, and 
also the absence of gradients of signals that otherwise maintain cell polarity 
(Arterburn et al., 1995, Luttringer et al., 2002). Under these depolarised 
conditions, the need for the cells to re-establish connectivity and adapt to the 
new culture environment calls for major changes to the cytoskeletal 
architecture resulting in a physical change in cell shape (Baker et al., 2001). 
This was seen as the cells changed morphology by cytoskeletal 
rearrangement (visualised by phalloidin binding) and became more fibroblast 
or mesenchymal-like when cultured in the DS medium.  
  
In addition to changes in morphology, acquisition of vimentin expression is 
considered a sign of de-differentiation. Unlike the cytokeratins which are 
epithelial intermediate filaments, vimentin is an intermediate filament 
primarily expressed in cells of mesenchymal origin (Traub, 1985). The 
reason for the induction of vimentin expression in de-differentiated 
hepatocytes remains obscure. However it is known that in hepatocytes the 
keratins are found attached to desmosomes and hemidesmosomes at points 
of cell-cell and cell-extracellular matrix adhesion sites respectively in order to 
maintain epithelial integrity. Following isolation, such adhesion junctions are 
lost. Thus the induction of vimentin expression (and this could also apply to 
the acquisition of smooth muscle actin expression) might relate to cells 
adapting to new conditions of being cultured in a more two-dimensional and 
flattened monolayer compared to the three dimensional environment in vivo. 
There is evidence to suggest that the vimentin filaments are laid along the 
existing cytokeratin filaments before completely replacing them (Pagan et al., 
1996). The results also indicate that where hepatocytes clusters were 
present, the cells in the periphery changed morphology most drastically, had 
lamellar projections and showed highest levels of vimentin expression, while 
cells at the centre of clusters remained more epithelial like. This is in line with 
the evidence that the cells at the centre with the most cell-cell contacts, 
maintain their cytokeratins, compared to those at the periphery. Vimentin 
expression might also explain the increased cell motility seen in DS cultured, 
as vimentin is a more dynamic intermediate filament compared to the 
cytokeratins. It is yet uncertain, which factors in the KS medium enables the 
cells to override most of these effects in order to maintain a differentiated 
state and the expression of liver enriched transcription factors long-term. 
However, it was observed that cell death during the first 24 hours of 
cultivation is greater under serum-free KS conditions perhaps favouring the 
survival of epithelial clusters with greater cell-cell contacts as opposed to 
individual cells with no cell-cell contacts (which otherwise survive under 
serum-containing DS conditions). This can be seen in Fig. 3.12, where the 
nuclei appear more clustered in KS cultures. The reversibility of the de-
differentiated phenomenon on swapping to KS medium from DS can also be 
  
explained by such a selection of epithelial clusters against individual de-
differentiated cells under KS conditions. 
In addition to I/R stress, the absence of growth factors (including FGFs and 
EGF) that might otherwise maintain the hepatic phenotype, contribute to the 
further downregulation of hepatic gene expression. However, why a 
pancreatic gene network and not any other gene network is induced 
following the immediate departure from a hepatic state remains an enigma. 
Once scenario is that the de-differentiated cells recapitulate normal 
endodermal differentiation during embryonic development. As previously 
mentioned (in Chapter 1), during embryonic development the default 
pathway for the bipotential population of cells in the foregut endoderm is to 
attain a pancreatic fate (Deutsch et al., 2001). During in vitro culture 
however, FGF, BMP and Wnt signals that otherwise push the progenitor cells 
into a hepatic fate would not be present. Therefore in the absence of such 
signals, the cells, once de-differentiated, can follow their default 
differentiation pathway to become pancreatic. However, we have to bear in 
mind that neither are the signals essential for true pancreatic differentiation 
present in our undefined culture medium to the best of our knowledge. This 
is presumably why the transcriptional levels of the pancreatic genes in de-
differentiated hepatocytes are low compared to any fully differentiated 
pancreatic cell-type. The other possibility is that pancreatic gene activation 
takes place as a consequence of chromatin remodelling during de-
differentiation itself. Recent evidence suggests that in the liver, most 
pancreatic promoters are in a bivalent state of methylation with both 
activating and repressive histone modifications present concurrently (Ulupi 
Jhala, UCSD; unpublished). This would make the activation of such 
promoters in hepatocytes much easier compared to any other non-pancreatic 
cell-type. If this is true for the de-differentiated hepatocytes, activation of 
pancreatic genes might simply be a consequential outcome of the chromatin 
remodelling during de-differentiation and pancreatic promoters preferentially 
becoming more accessible to the transcriptional machinery. In a comparable 
situation, it has been shown that treatment of bone marrow cells with 
  
trichostatin A, which opens chromatin by inhibition of histone deacetylases, 
can provoke some pancreatic gene expression (Tayaramma et al., 2006).   
In addition to the activation of pancreatic genes, a number of genes that 
define pancreatic and liver progenitors are also expressed during de-
differentiation. Therefore we cannot entirely rule out the possibility of the 
attainment of pancreatic gene expression by a sequential procession down a 
differentiation hierarchy. That is, from an undifferentiated, to a progenitor and 
finally a differentiated state. This can be attributed to the absence of 
particular signals such as FGFs and BMPs, and potentially (though not 
definitely) the presence of other signals. However the exact lineage down 
which the cells expressing the pancreatic genes are derived from de-
differentiated hepatocytes, cannot be known for certain, unless 
immunodetectable levels of the progenitor-specific and pancreas-specific 
proteins are obtained. This would also enable us to elucidate the true 
heterogeneity of the de-differentiated and ‘re-differentiating’ population and 
discern which markers are co-expressed at different stages of differentiation.  
Finally, with a view to possible future uses of de-differentiated hepatocytes to 
produce beta-like cells for transplantation, it is important to establish whether 
the same effects occur in human cells. The results show that the 
phenomenon of de-differentiation can be confirmed for human hepatocytes. 
The only elementary difference was that an overt cytoskeletal rearrangement 
and morphological change was not seen as for the rodent hepatocytes. One 
possibility is that human vimentin protein is able to maintain the integrity of 
the cytoplasm and cytoskeletal interactions at a different level compared to 
that of rodents. Such differences are commonplace between human and 
rodent cells in primary culture. For example, the reverse is true for beta cells 
in culture whereby cultured human beta cells undergo an EMT while those 
from mice do not (Billestrup and Otonkoski, 2008). Despite the conservation 
of morphology, pancreatic genes were still being induced. However, the 
reprogramming from hepatic to pancreatic is far from complete. Moreover, 
unfavourable expression of pancreatic exocrine genes were also seen at low 
levels. Thus, the next steps involved enhancing the expression of the already 
induced pancreatic genes, particularly in favour of a beta cell phenotype. 
  
Chapter FOUR
Transcription Factors &
the Enhancement of the
Pancreatic Phenotype
 
  
BACKGROUND 
An intricate, pervasive, and combinatorial interplay of several sequence-
specific DNA binding factors or transcription factors ensure that the right 
genes are expressed in the right cells, at the right time during embryonic 
development. The robust spatio-temporal patterns of gene expression 
generated by multiple transcription factor-DNA interactions, ultimately 
orchestrate cellular differentiation and tissue organisation essential for 
organogenesis (Chen and Rajewsky, 2007). The pancreas like the liver and 
the intestine, is derived from the definitive endoderm (Slack, 1995). Firstly 
the expression of the master regulator of pancreatic development, Pdx1, 
marks a precursor cell population for pancreatic development within the 
foregut endoderm. Then a hierarchical cascade of pancreatic developmental 
transcription factor expression, in the pancreatic progenitor cells, gives rise 
to the endocrine and exocrine cell populations and the distinct cell types 
within each of these populations (Jensen, 2004, Wilson et al., 2003). For 
example, transcription factors such as Neurogenin3 and NeuroD are 
essential for early endocrine lineage determination (Chakrabarti and Mirmira, 
2003, Jensen, 2004, Watada, 2004). Furthermore, sequential expression of 
Nkx2.2, Pax4, Nkx6.1, Pdx1, Pax6 and MafA determine insulin producing 
beta cell fate, while others such as Brn4, Arx1, Nkx6.2 and MafB promote the 
glucagon producing alpha cell fate (Chakrabarti and Mirmira, 2003, Jensen, 
2004, Samson and Chan, 2006).  
Understanding the transcription factor hierarchy involved in pancreatic 
development and maturation of beta cells has proved useful in 
reprogramming other cell types such as hepatocytes into beta cells for 
diabetes therapy. In theory, this can be achieved by the over-expression of 
pancreatic transcription factors in hepatocytes. However, the genetic 
transformation of hepatocytes both in vivo and in vitro has been rather 
challenging. In recent years, recombinant adenoviruses have become an 
attractive gene delivery vehicle for primary cells such as hepatocytes (Fig. 
4.1). Adenoviruses can enter cells, facilitated by the coxsakievirus B and 
adenovirus receptor (CAR) that normally functions as a cell-cell adhesion 
  
molecule on the basolateral surface of epithelial cells (Honda et al., 2000, 
Howitt et al., 2003). The ability to grow recombinant viruses to high titres, the 
high capacity for transgene insertion, the non-integrating nature of the 
transgene to the host genome, and the efficient transduction of quiescent 
and dividing cells make adenoviruses a popular gene delivery vehicle for 
molecular reprogramming purposes (McConnell and Imperiale, 2004). 
 
 
Previously, several different groups have independently transduced 
hepatocytes both in vivo and in vitro using adenoviral vectors encoding 
pancreatic transcription factors such as Pdx1 (eg:- Ber et al., 2003, Sapir et 
al., 2005), Neurogenin3, NeuroD (Kaneto et al., 2005b), and MafA (Kaneto et 
al., 2005a), achieving varying degrees of insulin expression and diabetes 
rescue. Using in vitro adenovirus-mediated genetic manipulation of cultured 
cells and their subsequent transplantation minimises the adaptive immune 
responses and systemic toxicities that are otherwise associated with a 
systemic in vivo administration of adenoviruses (reviewed in Liu and Muruve, 
2003). However an ideal combination of transcription factors for efficient and 
reproducible hepatic to beta cell conversion, thus far has not been 
elucidated. Furthermore, much doubt still remains regarding the feasibility of 
adenoviral infections in hepatocytes, the stability of the newly acquired 
phenotype following transcription factor over-expression, as well as the 
importance of the individual pancreatic transcription factors themselves. This 
chapter will attempt to answer such questions using the cultured rat 
hepatocyte model.  
Figure 4.1. A schematic illustration of the structure of an 
adenoviral particle (adapted from Shenk, 1996). 
  
 
4.1 Optimisation of adenoviral infections. 
Freshly isolated hepatocytes are readily infected with adenoviruses. 
However cell mortality due to the cytopathic effect of the adenovirus was 
high during the early stages of culture. Therefore to avoid this, the primary 
hepatocytes were allowed to recover in culture for 3 days after isolation prior 
to adenoviral infection. Since the ultimate aim was to transduce hepatocytes 
with multiple pancreatic transcription factors, the probability of infection with 
individual adenoviruses during a multiple infection was determined. In order 
to do this, three viruses, each with a different reporter, were used. They 
were: Ad-CMV-GFP coding for the green fluorescent protein (GFP) which 
can be detected by fluorescence, Ad-CMV-LacZ with the E. coli β-
galactosidase gene detectable by X-gal staining and Ad-CMV-HA-Ngn3 with 
the haemagglutinin tag (-HA-) that can be detected by immunocytochemistry 
using an anti-HA antibody. When visualised 5 days after a multiple infection, 
more than 90% of cells were infected with one, two or all three viruses and it 
was easy to detect those cells infected with more than one viral type (Fig. 
4.2A-B).  
The multiplicity of infection (M.O.I.) is the theoretical number of virus particles 
per cell; making the two assumptions that all the cells have an equal 
probability of being infected and that all the virus particles based on the 
measured titre are infectious. When the cells were infected with a single 
adenovirus (Ad-CMV-GFP) at an M.O.I. of 4 (i.e. a mean of 4 adenoviral 
particles per cell), 86% of the cells were infected (Fig. 4.2C). The observed 
ratio of infection by single and multiple viruses, during double and triple 
infections is summarised in the form of Venn diagrams in Fig. 4.2C. The 
infectibility of the three viruses were slightly different from the expected 
values (i.e. an equal proportion of the total infected cells to be infected by 
each virus). Such differences in infectibility can be accounted for by 
inaccuracies in determining the viral titres as well as the reduction in viral 
titres since titration and during long-term storage. Although the infectibility of 
Ad-CMV-HA-Ngn3 was considerably lower compared to the other two 
viruses used at the same M.O.I., a total of 7% of cells were infected with all 
the three viruses during a multiple infection. This was a significant proportion 
  
 
of the total cells and the probability can be further improved by increasing the 
M.O.I. 
In order to find out the probability of infection by each virus during sequential 
infections, once again three different viruses were used. The hepatocytes 
were first infected with Ad-CMV-GFP on day 3 after isolation, followed by Ad-
CMV-LacZ and Ad-CMV-HA-Ngn3 on days 4 and 5 respectively (Fig. 4.3A). 
The cells were maintained for 3 more days before analysis. The number of 
cells infected with the first virus outnumbered those infected with the other 
two (74% compared with 47% and 21%). Similarly, cells co-infected with the 
first two viruses were more than those infected with any other combination. 
The percentage of cells infected with all three viruses after a sequential 
infection was also 2% less than with a simultaneous infection (Fig 4.3B). The 
differential infectibility of the adenoviruses mentioned above can partly 
account for these differences. However it is also possible that the 
hepatocytes develop some form of resistance to adenoviral infection after 
each subsequent infection, by the internalisation of the tight-junction 
coxsackievirus-adenoviral receptors (CAR) for instance. 
As outlined in chapter 3, the isolated hepatocyte population consists of 
hepatocytes from both the periportal and perivenous zones of the liver.  
Periportal and perivenous hepatocytes express the enzymes CPS and GS 
respectively. Enriched populations of periportal and perivenous hepatocytes 
can be isolated by digitonin-mediated selective destruction of the liver prior to 
collagenase perfusion (see chapter 2 2B.1.1 and Fig. 2.1). Following the 
destruction of the perivenous cells with digitonin, a relatively pure population 
of CPS expressing hepatocytes can be obtained with no perivenous 
hepatocytes present (Fig. 4.4C-D). In the contrary, perivenous isolations 
have some periportal contamination (Fig. 4.4E-F), but the number of GS 
expressing cells are significantly increased compared to a normal 
hepatocytes isolation (Fig. 4.4A-B). To test if both periportal and perivenous 
hepatocytes can be infected with adenoviruses, cells from an enriched 
perivenous isolation was used as it contains comparable numbers of both 
CPS and GS expressing cells. The cells were infected with Ad-CMV-LacZ on 
the third day after isolation at an M.O.I. of 4 and then the cells were fixed and 
  
 
stained with X-gal as well as antibodies for CPS and GS (Fig. 4.5). The 
results indicate that both the CPS and GS expressing populations are 
infectible with adenoviruses with equal efficiency. 
As a final step in the optimisation of adenoviral infections, the adenoviruses 
to be used were tested to see if cells transduced with the viruses could 
produce the protein encoded for by the virus. It is sometimes possible that 
during serial viral amplification steps, mutations and di-cistronic 
rearrangement can occur in the viral construct, making the gene of interest 
non-functional while still keeping the reporter intact. Thus the reporter is a 
good indicator of infectibility but not necessarily of an effective virus. Using 
immuocytochemistry, Pdx1, Neurogenin3, NeuroD, Sox9 and MafA coding 
viruses (those viruses coding for proteins with antibodies available against 
them) were confirmed as being able to produce immunodetectable levels of 
these transcription factors in hepatocytes infected with them (Fig 4.6). 
 
4.2 Enhancement of the pancreatic phenotype by Pdx1. 
Previous work has suggested that the transduction of the master switch gene 
for pancreas development, Pdx1, can induce the expression of pancreatic 
genes such as insulin in cultured hepatocytes. Since insulin can be induced 
by de-differentiation alone, it was important to know how much of an effect 
Pdx1 transduction itself had on hepato-pancreatic reprogramming. 
Hepatocytes were cultured under DS conditions that trigger de-differentiation 
and KS conditions that maintain the hepatic phenotype. The hepatocytes 
were infected on day 3 with Ad-CMV-Pdx1-eGFP at a total M.O.I. of 20. RNA 
was isolated from the cells 5 days after and the levels of insulin 1 were 
compared to those in non-infected hepatocytes by real time RT-PCR (Fig. 
4.7). Freshly isolated hepatocytes and hepatocytes cultured in the KS 
medium up to 8 days do not express any insulin. In the contrary, those 
cultured in the DS medium show induction of insulin as a result of de-
differentiation alone. However, the levels of the induced insulin expression 
were further enhanced by Pdx1 transduction by 9.8 fold in DS medium. 
Furthermore, insulin expression can also be induced by Pdx1 at low levels in 
  
 
hepatocytes cultured in the KS medium. Therefore, though Pdx1 can induce 
pancreatic gene expression itself, de-differentiation synergises the effect of 
Pdx1. The levels in both KS and DS cells were nonetheless 106 fold lower 
than insulin 1 levels in RIN cells (Fig. 4.7). 
To further ascertain if this enhancement of pancreatic gene expression was 
due to Pdx1 and not an artefact of viral infection, exogenous protein 
expression or transcription factor over-expression, both KS and DS 
hepatocytes were infected with Ad-CMV-null (empty vector with no protein 
coding gene), Ad-CMV-GFP and AD-CMV-p63 (a non-pancreatic 
transcription factor) respectively (Fig. 4.8). An induction of pancreatic gene 
expression (including that of insulin 1, insulin 2, endogenous Pdx1, SUR1, 
Kir6.2, chromogranin A, IAPP, amylase and islet-specific glucokinase) in KS 
hepatocytes was only seen with Pdx1 and not with any of the other viruses. 
Similarly, an enhancement of the already induced pancreatic gene 
expression in DS hepatocytes was seen only with Pdx1. It was also observed 
that Pdx1 transduction further facilitated the de-differentiation process in DS 
hepatocytes and  induced de-differentiation in KS hepatocytes by the 
downregulation of hepatic gene expression (seen as reduced levels of 
albumin and liver-specific glucokinase). This downregulation of hepatic gene 
expression was not replicable with any of the other viruses. However, none 
of the viruses, including Pdx1, were capable of affecting the levels of 
vimentin expression. 
Similar to rat hepatocytes, de-differentiated human hepatocytes can also be 
infected with the Ad-CMV-Pdx1-eGFP virus with good efficacy (Fig. 4.9A).  
Pdx1 transduction can induce pancreatic gene expression in human 
hepatocytes cultured under KS conditions and further enhance the induced 
pancreatic genes such as insulin, Kir6.2 and SUR1 in human hepatocytes 
cultured under DS conditions (Fig. 4.9B). 
The CMV promoter is a strong promoter that can be expressed ubiquitously 
irrespective of cell type. As discussed in Chapter 3, the cells cultured under 
DS conditions comprise a mixed population with a majority of de-
differentiated hepatocytes and also few cells derived from the initial vimentin 
expressing contaminants. To find out, if the effect of Pdx1 was specifically on 
  
 
the hepatocytes and not on any of the non-hepatic contaminating cell types, 
the Ad-TTR-Xlhbox8 virus was used, where the Xenopus laevis Pdx1 
homolog, Xlhbox8, was driven off the hepatocyte specific transthyretin (TTR) 
promoter. With this virus a similar enhancement of insulin 1 expression was 
seen as with the Ad-CMV-Pdx1 virus (Fig. 4.10). However, the levels of 
enhancement was slightly reduced, possibly because the TTR promoter is 
weaker compared to the CMV promoter and furthermore the downregulation 
of hepatic genes (including transthyretin) would have already been initiated 
by day 3 which is when infections are carried out. Nonetheless the effects 
are enough to conclude that the observed effect of Pdx1 (and Xlhbox8) is on 
de-differentiated hepatocytes and not predominantly on any other cell type.   
It has been suggested that the effect of a transduced gene can be enhanced 
by using a construct containing the VP16 trans-activating domain from the 
Herpes simplex virus, downstream of the gene of interest. When de-
differentiated hepatocytes were infected with Ad-CMV-PdxVP16 and Ad-
TTR-Xlhbox8VP16, the levels of insulin 1 mRNA were increased compared 
to those infected with Ad-CMV-Pdx1 and Ad-TTR-Xlhbox8 respectively (Fig. 
4.11). However, the increase was not statistically significant for Xlhbox8. 
 
4.3 Determining an optimal transcription factor combination for 
hepato-pancreatic reprogramming. 
During development, Pdx1 is the earliest transcription factor to mark the 
endodermal domain for pancreatic organogenesis. However, several other 
key regulatory transcription factors play vital roles in delineating the different 
pancreatic lineages including that for beta cells, alpha cells and exocrine 
cells. To find out which of these transcription factors are vital for the effective 
molecular reprogramming of de-differentiated hepatocytes into pancreatic 
beta-like cells, an extensive screen of different pancreatic transcription 
factors with pro-endocrine expression profiles was carried out. The screening 
strategy involved, transducing de-differentiated hepatocytes with different 
combinations of candidate transcription factors on day 3 after isolation. The 
10 transcription factors included in the screen were Pdx1, Neurogenin3, 
  
 
NeuroD, Nkx2.2, Nkx6.1, Pax4, Pax6, IA1, Sox9 and Ptf1a (p48). All the viral 
infections used for the transcription factor screening were performed with an 
individual M.O.I. of 5 for each transcription factor with the total M.O.I. always 
moderated at 50 using the Ad-CMV-null virus. The effect of each 
combination was scored based on the relative amount of insulin 1 mRNA, 
analysed by real time RT-PCR. When used individually, Pdx1, Neurogenin3 
and NeuroD were the only transcription factors to enhance the amount of 
insulin 1 expression by 9.8-, 7.8- and 7.3-fold respectively. All possible 
combinations of 1, 2, 7, 9 and 10 viruses were tested (a full list of data is 
included in Appendix C). The results showed that no single combination gave 
a considerably high level of insulin 1 expression in de-differentiated 
hepatocytes compared to the others The mean level of insulin 1 expression 
for all the combinations tested was 8.85x10-6 times the amount in the adult 
rat pancreas. However, a few combinations repeatedly scored much higher 
than the other combinations (i.e. more than the predetermined arbitrary 
threshold of 2x10-5 times the amount in the adult rat pancreas). In all the 
combinations that scored higher than this predetermined threshold, above 
the average, Pdx1 was present (Fig. 4.12). Apart from Pdx1, the transcription 
factors Neurogenin3, NeuroD and Pax4 frequently appeared in the high 
scoring combinations at frequencies greater than 77.8%. The combination of 
these four transcription factors (Pdx1, Neurogenin3, NeuroD and Pax4) were 
selected as the ideal combination, as infections with more than four viruses 
reduces the probability of being infected with all the viruses and also 
increases the competition by the transcription factors to occupy pancreatic 
promoters, making it less efficient. 
De-differentiated hepatocytes transduced with the combination of Pdx1, 
Neurogenin3, NeuroD and Pax4 showed 2- and 1.3-fold increase in the 
amount of insulin 1 and insulin 2 respectively compared to de-differentiated 
hepatocytes transduced with Pdx1 alone (Fig. 4.13). The same trend was 
observed at the protein level for insulin, with the highest expression being in 
de-differentiated hepatocytes transduced with all the four transcription 
factors, compared to those infected with Pdx1 alone (Fig. 4.14). 
 
  
 
4.4 The feasibility of sequential transcription factor transductions. 
 The sequential expression of pancreatic transcription factors during the 
development of the mouse embryo is well documented. However, the 
information regarding embryonic pancreatic development in the rat is more 
limited. Pancreata were dissected from rat embryos at stages 11.5 to 22.5 
days post dp (dpc) and 1 day post partum (dpp). The levels of expression of 
the transcription factors Isl1, NeuroD, Ngn3, Nkx2.2, Nkx6.1, Pax4, Pax6 and 
Pdx1 were analysed by RT-PCR (Fig. 4.15). The expression pattern was 
similar to that established for mouse pancreatic development with Isl1, Pdx1 
and Neurogenin3 expression occuring much earlier on compared to other 
transcription factors such as Pax4 or Nkx6.1. 
 The sequence of transcription factor expression during a hepato-pancreatic 
conversion was examined after de-differentiated hepatocytes were 
transduced with Pdx1 (Fig. 4.16). The pattern was similar to that during 
normal pancreatic development, with Isl1, Pdx1, Neurogenin3 and NeuroD 
again being expressed much earlier compared to Pax4, Pax6, Nkx2.2 and 
Nkx6.1. However, the expression pattern did not exactly resemble that of 
normal pancreatic development. The endogenous Pdx1, Neurogenin3 and 
NeuroD were seen to be expressed in a biphasic manner, being 
downregulated between day 7 and 10 before being upregulated again. 
 In an attempt to mimic the developmental expression pattern of Pdx1, 
Neurogenin3, NeuroD and Pax4, de-differentiated hepatocytes were 
transduced sequentially with Pdx1 on day 3 after isolation, Neurogenin3 on 
day 4, and NeuroD and Pax4 on day 5 (each at an M.O.I. of 10). However, 
sequential infections reduced the viability of cells and the number of 
transformed cells that survived up to day 8 (Fig. 4.17A). Furthermore, there 
was a 2.7-fold reduction in the levels of insulin 1 (Fig. 4.17B). This data 
suggests that it is necessary to take measures to reduce the cytopathic 
effects of the adenovirus on hepatocytes, if sequential infections are to be 
carried out successfully 
  
  
 
4.5 Facilitating de-differentiation and chromatin accessibility prior to 
adenoviral transduction. 
While de-differentiation facilities the molecular reprogramming process, there 
are several other factors that antagonise the effects of Pdx1 and the 
molecular reprogramming from a hepatic to a pancreatic phenotype. Firstly, 
liver-enriched transcription factors play an important role in maintaining the 
hepatic phenotype by ensuring hepatic gene expression is sustained. Such 
liver-enriched transcription factors include C/EBPα and β, HNF1α and 4α, 
DBP and RXRα (Costa et al., 2003, Hayhurst et al., 2001). Although the 
expression of most of these transcription factors are downregulated during 
the course of de-differentiation, the process of de-differentiation and initiation 
of pancreatic gene expression can be further enhanced by minimising the 
effects of such liver-enriched transcription factors. Secondly, the identity of 
each cell-type is maintained by its unique gene expression profile. Epigenetic 
modifications ensure that genes that define the cell type (such as hepatic 
genes in hepatocytes) are expressed and remain active, while those non-
characteristic of the cell type (such as pancreatic genes in hepatocytes) 
remain inactive. Such epigenetic changes include but are not restricted to 
DNA methylation and post-translational histone modifications, which can 
pack the DNA at the promoter regions of inactive genes so as to make them 
inaccessible to transcription factors. Therefore, cellular reprogramming 
requires the remodelling of these epigenetic marks. Recently there has been 
mounting interest in the use of DNA demethylating agents and histone 
deacetylase inhibitors to activate genes by mediating global epigenetic 
changes in chromatin structure. 
With the aim of facilitating and speeding up the de-differentiation process 
prior to pancreatic transcription factor transduction, hepatocytes cultured in 
the DS medium were infected with the Ad-CMV-LIP virus 24 hours into 
culture. LIP encodes the liver inhibitory protein- a dominant-negative isoform 
produced by alternative splicing of C/EBPβ mRNA. Even at sub-
stoichiometric proportions, LIP can heterodimerise with LAP (liver activation 
protein isoform of C/EBPβ) thereby negating the transactivation capabilities 
of LAP (Descombes and Schibler, 1991, Ossipow et al., 1993).  Hepatocytes 
  
 
over-expressing LIP showed more rapid changes in morphology compared to 
uninfected cells, becoming mesenchymal like within 2 days after infection 
(Fig. 4.18A-B). In an attempt to bring about chromatin remodelling and 
increase the accessibility of pancreatic promoters to pancreatic transcription 
factors, Ad-CMV-LIP infected, de-differentiated hepatocytes were treated 
with 100µM zebularine starting at 24 hours into culture. Zebularine is an 
effective inhibitor of DNA methylation. Zebularine attenuated the rapid 
morphology change brought about by LIP and allowed the infected 
hepatocytes to sustain an epithelial morphology for much longer (fig. 4.18C). 
However neither LIP transduction nor zebularine treatments were capable of 
enhancing the effect of Pdx1 on its own or in combination with Neurogenin3, 
NeuroD and Pax4, analysed in terms of insulin 1 expression (Fig. 4.18D). In 
fact, zebularine treatments notably reduced the amount of insulin 1 
expression.  
 
4.6 Using MafA to further promote the beta cell phenotype. 
One of the pancreatic transcription factors that was not included in the initial 
screen (see 4.3) was the basic-leucine zipper transcription factors MafA. It is 
expressed later on during pancreatic development around E13.5, only in 
those insulin positive cells that go onto mature into islet beta cells (Matsuoka 
et al., 2004). Therefore MafA is thought to be essential for the maturation of 
beta cells in the differentiation process. When MafA was included in the 
transcription factor combination along with Pdx1, Neurogenin3, NeuroD and 
Pax4, a 1.56 fold increase in insulin 1 gene expression was seen compared 
to the combination that did not include MafA (Fig. 4.19). Insulin protein 
expression was also analysed by immunocytochemistry using a peroxidase 
conjugated secondary and DAB staining, as this protocol is known to be 
more sensitive than immunofluorescence. However, even with MafA, the 
levels of insulin protein expression were far too low to be 
immunocytochemically detectable (Fig. 4.20). 
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Figure 4.5. Both perivenous and periportal hepatocytes can be transduced
with adenoviral constructs. An enriched population of perivenous rat
hepatocytes (with contaminating periportal hepatocytes) was isolated using
digitonin-mediated selective destruction of the periportal zone. The cells
were cultured in KS medium and then infected with the Ad-LacZ virus on day
3 after isolation (A). The infected cells are seen in blue by X-gal staining. The
infected cells include both GS (red) positive perivenous hepatocytes and CPS
(green) positive periportal hepatocytes (B) showing the infectibility of both
populations. Note that LacZ appears blue by X-gal staining and under
transmitted light (A); the colours have been inverted and false colour added
by channel swapping in order to visualise blue with the fluorescent tags (B).
The scale bar represents 20µm.
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Figure 4.6. Adenoviruses used express the proteins coded for by their
constructs. Testing the viruses by immunocytochemically analysing
transcription factor expression in the nuclei of hepatocytes that have been
infected with adenoviruses coding for Pdx1 (A, red), Neurogenin3 (B, red),
NeuroD (C, green), Sox9 (D, red) and MafA (E, red). These were the only
transcription factors against which working antibodies were available. The
scale bar represents 10µm.
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Figure 4.13. A combination of Pdx1, Neurogenin3, NeuroD and Pax4
enhances the levels of insulin expression in de-differentiated hepatocytes.
Rat hepatocytes were isolated and cultured in the DS medium, infected with
the adenoviruses on day three and maintained for five more days. The
relative amount of insulin 1 and insulin 2 in de-differentiated hepatocytes
transduced with the combination of four transcription factors (Pdx1, Ngn3,
NeuroD and Pax4; each with individual M.O.I. of 10) compared to those
which were uninfected (normalised to 1) or infected with Pdx1 alone. n=3.
Figure 4.14. De-differentiated hepatocytes transduced with pancreatic
transcription factors synthesise insulin protein. Analysis for the levels of
insulin protein (INS) in de-differentiated hepatocytes was done by Western
blot analysis. The levels of insulin in de-differentiated hepatocytes are too
low to be detected by Western blot analysis. However after Pdx1 infection
and infection with the four viruses, the levels significantly increase. Protein
from RIN cells were used as a positive control. A Coomassie Blue Stain (CBS)
of totalprotein is shown to indicate equal loading.
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Figure 4.20. Immunodetectable levels of the insulin protein is not seen in
de-differentiated hepatocytes even after multiple pancreatic transcription
factor transductions. Immunocytochemistry for insulin expression in RIN-5F
cells (A), de-differentiated hepatocytes (B), de-differentiated hepatocytes
transduced with Pdx1 (C), de-differentiated hepatocytes transduced with
Pdx1, Ngn3, NeuroD and Pax4 (D) and de-differentiated hepatocytes
transduced with Pdx1, Ngn3, NeuroD, Pax4 and MafA (E). No immuno-
detectable insulin was seen by DAB staining in any of the samples except in
the RIN-5F positive control. The scale bar represents 10µm.
 
  
 
DISCUSSION 
One of the main problems with manipulating gene expression in adult 
hepatocytes maintained in primary culture is that it is difficult to transfect the 
cells with plasmid DNA constructs. Most of the transfection agents available 
commercially are targeted for immortal carcinoma cells and are often either 
incompatible with primary hepatocytes or the turnover of successful 
transformations is very low. Furthermore, transfection by electroporation of 
plasmid DNA requires intensive optimisation procedures each time so as not 
to cause extensive cell damage (Yao et al., 2002). However, the results 
confirm that adenoviral vectors are an excellent vehicle for gene delivery into 
primary hepatocytes with good efficiency and low cell mortality.  In addition to 
their safely, adenoviruses are attractive vectors as they are capable of 
transducing non-dividing cells, which is important if infecting differentiated 
hepatocytes maintained in the KS medium. Furthermore, genes delivered by 
adenoviral vectors do not integrate into the host genome, thus their 
expression is short-lived (Thomas et al., 2003, McConnell and Imperiale, 
2004). Therefore in theory, the use of adenoviral vectors would facilitate a ‘hit 
and run’ approach for molecular reprogramming, where reprogramming is 
initiated by the transduced gene, but then the cell could recruit its own 
molecular machinery of pancreatic transcription factors to maintain the newly 
acquired phenotype.  
The results of the experiments with the over-expression of Pdx1 alone, 
shows that Pdx1 can promote a hepato-pancreatic conversion by enhancing 
the expression of pancreatic genes. Transformation of primary hepatocytes 
using adenovirally transduced Pdx1 is not a new area of research. 
Adenovirus mediated transformation of hepatocytes into β-like cells has been 
previously achieved both by in vivo (Ferber et al., 2000, Ber et al., 2003, 
Kojima et al., 2003, Koizumi et al., 2004, Kaneto et al., 2005a, Kaneto et al., 
2005b, Imai et al., 2005, Shternhall-Ron et al., 2007) and in vitro (Sapir et al., 
2005, Meivar-Levy et al., 2007) approaches. Compared to the in vivo 
approaches, in vitro transformation of cells has the added advantage of 
overcoming the narrow tropism of the viruses especially for organs such as 
  
 
the liver. It also reduces vector toxicity by minimising systemic infections. 
When Pdx1 is directly introduced to the livers of rodents, it can trigger the 
expression of pancreatic exocrine genes and produce cells that secrete 
destructive enzymes such as amylase, trypsin, chymotrypsin and lipase 
(Kojima et al., 2003). Therefore, in vitro transformation of cells would also 
provide a greater quality control over the cells that can be selected especially 
if the transplantation of cells is desired. It has also been suggested that the 
induction of pancreatic genes by Pdx1 depends on an immune reaction to 
the adenoviral vector and is instead an artefact of viral infection (Wang et al., 
2007). Although this may hold true in vivo, the results reported in this chapter 
suggest that this is not the case in vitro. In the in vitro hepatocyte culture 
system, immune effects are likely to be minimal, but Pdx1 does enhance 
pancreatic gene expression. Furthermore any immune effects should also be 
shown by the various control viruses, but none of the other adenoviruses; 
null, protein coding or transcription factor coding, had the same effect as the 
Pdx1 coding adenovirus.  
The effect of Pdx1 has been proposed to be mediated by the suppression of 
C/EBPβ, which ultimately results in the loss of the hepatic phenotype 
(Meivar-Levy et al., 2007).  This could be true for the cells cultured in the KS 
medium where no pancreatic gene expression or hepatic gene 
downregulation is seen prior to Pdx1 transduction. However, in the DS 
medium cells de-differentiate and C/EBPβ expression is downregulated even 
without Pdx1 transduction. In this case, Pdx1 transduction merely acts to 
enhance the expression of the already induced pancreatic genes. Similarly, 
the de-differentiation process in terms of loss of hepatic epithelial 
morphology can be speeded up by over-expressing LIP which antagonises 
the activity of endogenous C/EBPβ. However, no enhancement of pancreatic 
gene expression was seen following the over-expression of LIP. Although 
C/EBPβ itself might be important for maintenance of hepatic gene 
expression, these results support a C/EBPβ-independent mechanism by 
which Pdx1 enhances pancreatic gene expression in the already de-
differentiated hepatocytes. Therefore de-differentiation synergises the 
reprogramming effects of Pdx1 although it is not a prerequisite for the 
  
 
molecular reprogramming process (as pancreatic genes can be induced by 
Pdx1 in differentiated hepatocytes as well).  
The mechanism by which de-differentiation potentiates Pdx1 action required 
some comment. A possible mechanism by which Pdx1 has a more 
augmented effect on cells cultured in DS medium as opposed to those in the 
KS medium could be the increased accessibility of Pdx1-target sites on 
pancreatic promoters by the changes in chromatin configuration that takes 
place during the de-differentiation process. The fact that the DNA 
demethylating agent, zebularine, did not enhance pancreatic gene 
expression does not rule out this possibility. The genome-wide effects of 
zebularine on global methylation patterns, including that of hepatic promoters 
could indeed have acted in favour of maintaining a hepatic phenotype, 
contrary to expectations. Therefore, if using DNA demethylating and histone 
acetylating agents for chromatin remodelling, a more targeted approach is 
necessary in the future. 
Insulin was used as the read-out in the screen for the transcription factor 
combination. The three transcription factors that gave any enhanced insulin 
expression on their own, compared to the uninfected control were Pdx1, 
Neurogenin3 and NeuroD. Pdx1 is a member of the homeodomain-
containing transcription factor family and it plays a crucial role in 
pancreogenesis as well as beta cell differentiation and function (Ohlsson et 
al., 1993, Jonsson et al., 1994, Holland et al., 2002). Neurogenin3 and 
NeuroD are both basic helix-loop-helix (bHLH) transcription factors that are 
downstream of Pdx1 in the endocrine developmental cascade and are 
essential for the differentiation of endocrine precursors and insulin gene 
expression in beta cells respectively (Schwitzgebel et al., 2000, Gradwohl et 
al., 2000, Naya et al., 1997, Naya et al., 1995). All of these transcription 
factors can directly or indirectly activate beta cell specific insulin gene 
expression. Pdx1 binds to the A-box enhancer element and NeuroD binds to 
the E-box region of the insulin promoter (German and Wang, 1994, Sharma 
and Stein, 1994, Cerf, 2006). However since the effects of adenoviral vectors 
are short-lived, any effect seen 5 days after transduction are presumably 
  
 
effects of molecular reprogramming rather than direct promoter activation. 
Previously, Neurogenin3 and NeuroD have both been used separately with 
Pdx1-VP16 to produce stable endocrine cells in the liver (Kaneto et al., 
2005b). The levels of insulin expression with each of the three transcription 
factors were different with Pdx1 being the strongest inducer of insulin 
expression followed by Neurogenin3. This could be so, because Pdx1 
binding to the A3/4 sites can synergise transcription factor binding to the E-
box (Glick et al., 2000, Ohneda et al., 2000b) and Neurogenin3 can in turn 
recruit NeuroD to the insulin promoter and also activate other transcription 
factors such as Pax4 (Naya et al., 1997, Smith et al., 2003, Cerf, 2006).  
In the rest of the screen where different combinations of transcription factors 
were used, no single combination gave a comparatively higher reading. One 
explanation for this is the possible competition between the different 
transcription factors to common binding sites on the insulin promoter. 
However, in addition to Pdx1, Neurogenin3 and NeuroD, Pax4 was the other 
transcription factor that frequently occurred in combinations that produced 
high insulin expression. Pax4 is a late-stage paired box transcription factor, 
that promotes beta cell differentiation and maturation, and is expressed 
downstream of NeuroD (Sosa-Pineda et al., 1997). Pax4 has previously 
been used in combination with Pdx1-VP16 to transform the pancreatic 
precursor cell line (WB-1) to cells with a gene expression profile similar to 
that of rat insulinoma INS-1 cells (Tang et al., 2006). However, thus far a 
combination of Pdx1, Neurogenin3, NeuroD and Pax4 has not been used for 
the in vitro molecular reprogramming of any cell type into pancreatic beta-like 
cells. However, recently a combination of Pdx1, Neurogenin3 and MafA were 
used for the in vivo reprogramming of differentiated adult murine pancreatic 
exocrine cells into beta-like cells. The reprogrammed cells were identified as 
extra-islet insulin-positive cells and they closely resembled endogenous islet 
beta cells in size, shape, ultrastructure, gene expression profile and function 
(Zhou et al., 2008). 
The results show that the combination of Pdx1, Neurogenin3, NeuroD and 
Pax4 was capable of producing higher levels of both insulin 1 and insulin 2 
gene expression as well as yielding comparatively higher levels of insulin 
  
 
protein. Unfortunately sequential infection of de-differentiated hepatocytes to 
mimic the development cascade of transcription factor expression was not 
possible due to high mortality of cells during sequential infections. One 
possible solution to this would be to design differentially inducible adeno- or 
lentiviruses that can be infected simultaneously but induced sequentially. 
The reason why MafA was chosen as the fifth transcription factor was 
because, like Pax4 it is a late-stage transcription factor during beta cell 
development and is important for beta cell functions such as glucose-
stimulated insulin secretions (Kataoka et al., 2002, Matsuoka et al., 2004, 
Matsuoka et al., 2007, Zhao et al., 2001). There are three conserved cis-
regulatory elements within the insulin promoter that are indispensable for 
proper beta cell specific insulin gene regulation. They are the E1 and A3 
elements to which Pdx1 and NeuroD bind to respectively and the RIPE3b/C1 
element to which MafA binds (Olbrot et al., 2002). Since neither, Pdx1, 
Neurogenin3, NeuroD nor Pax4 binds to the RIPE3b/C1 element, MafA 
would not need to compete with any other transcription factor for efficient 
insulin promoter binding thus making it an ideal candidate as the fifth 
transcription factor to further push the beta cell phenotype. However even 
with MafA, the levels of both insulin mRNA and protein expression was 
relatively low compared to RIN-5F cells as well as the adult rat pancreas.  
  
 
Chapter FIVE
The Use of Betacellulin
and other Extrinsic
Factors to Promote the 
Beta Cell Phenotype
 
  
 
BACKGROUND 
In addition to the transcription factors discussed in Chapter 4, a number of 
extrinsic signals play major roles in determining the fate adopted by the 
pancreatic epithelium. Such signals include growth factors, cytokines, 
hormones, circulating metabolites, nutrients, extracellular matrix components 
and membrane bound molecules, that interact with receptors and receptor 
complexes. The interactions are conveyed by intracellular signalling 
pathways to bring about changes in patterns of genes expression that 
ultimately controls the specification, proliferation, differentiation and 
programmed death of cells during development of the pancreas (Edlund, 
2002). Therefore, major efforts have been implemented to identify extrinsic 
factors, as well as to produce synthetic molecules, that mimic the function of 
such factors found in vivo, in order to enhance beta cell differentiation, 
maturation and function (see Table 5.1). Much of this information has been 
garnered by in vitro studies using pancreatic cell lines as well as organ 
culture models.  
The work described in this chapter comprises two parts. The first part will 
investigate the effects of the extracellular factor, betacellulin, on the 
differentiation of pancreatic cell types in an in vitro organ culture model. 
Betacellulin is a 32 kDa glycoprotein that has a widespread expression 
pattern. It has particularly high levels in the pancreas, liver and kidneys 
(Miyagawa et al., 1999). In the foetal pancreas, betacellulin has been 
immunohistochemically localised to the primitive duct cells and alpha cells 
and probably beta cells (Miyagawa et al., 1999). Although the physiological 
function of betacellulin is not definitely known, in various systems betacellulin 
has been shown to induce beta cell neogenesis and regeneration 
(Demeterco et al., 2000, Li et al., 2003). The second part of this chapter will 
focus on the effects of betacellulin and other extrinsic factors (see Table 5.1), 
on ability to enhance the pancreatic beta cell phenotype in reprogrammed 
hepatocytes. Analyses of the function of the beta-like cells generated by the 
over-expression of multiple key-regulatory pancreatic transcription factors 
and treatment with extracellular factors, will also be examined. 
  
 
Table 5.1. Some extrinsic factors and their known effects on beta cell 
proliferation, differentiation and function (amended from Soria et al., 2001).  
Factor Effect of beta cells References 
Activin A Induces the conversion of rat pancreatic cell 
line AR42J to insulin-secreting cells. 
(Mashima et al., 
1996) 
Betacellulin Facilitates beta cell differentiation in 
pancreatic buds. 
(Huotari et al., 1998, 
Thowfeequ et al., 
2007, Watada et al., 
1996) 
Epidermal Growth 
Factor (EGF)  
Stimulates islet growth. (Chatterjee et al., 
1986, Verme and 
Hootman, 1990) 
Exendin-4 An analogue of GLP1.  Is 10-fold more 
potent than GLP1 (see GLP1 below).  
(Zhou et al., 1999) 
Glucagon like 
peptide I (GLP1) 
Converts AR42J cells into endocrine 
hormone producing cells (insulin, glucagon 
and PP). 
(Zhou et al., 1999) 
FGF7 (KGF) Induces the formation of islet-like cell 
clusters from human embryonic stem cells. 
(Lumelsky et al., 
2001, Schuldiner et 
al., 2000) 
Gamma secretase 
inhibitors 
Blocks Notch activation and releases beta 
cell progenitors from differentiation arrest. 
(Murtaugh et al., 
2003) 
Glucose At high concentrations: increases beta cell 
replication. 
At low concentrations: increases insulin 
content of cells. 
(Bonner-Weir et al., 
1989, Soria et al., 
2000) 
Growth Hormone Increases beta cell mass during pregnancy. (Billestrup and 
Nielsen, 1991) 
Metformin Improves beta cell function by increasing the 
nuclear localisation of Pdx1. Used as a first 
line anti-diabetic drug for type 2 diabetes 
patients. 
(Richardson et al., 
2006) 
Nicotinamide Increase islet regeneration after partial 
pancreatectomy. Increases insulin content 
both at the DNA level as well as protein 
level. 
(Otonkoski et al., 
1993, Sjoholm et al., 
1994, Soria et al., 
2001, Sugiyama et 
al., 1991) 
PI3K inhibitors Increases the number of insulin producing 
cells as PI3K acts as an inhibitor of 
differentiation. 
(Ptasznik et al., 
1997) 
Prolactin Promotes cell proliferation in vitro. (Brelje et al., 1993, 
Moldrup et al., 1993) 
Sodium butyrate Inhibitor of histone deacetylases and a 
activator of gene expression. Increases 
insulin content. 
(Bartholomeusz et 
al., 1989, Philippe et 
al., 1987) 
Vascular 
Endothelial Growth 
Factor (VEGF) 
Upregulated during pancreatic regeneration 
after duct ligation. 
(Oberg-Welsh et al., 
1997) 
  
 
5.1 The expression of betacellulin and its receptors in the 
developing mouse pancreas. 
Betacellulin is an epidermal growth factor family protein that can bind to and 
signals through both ErbB-1 and ErbB-4 receptors (Miyagawa et al., 1999, 
Sasada et al., 1993). These two receptors belong to the ErbB family of 
transmembrane receptor tyrosine kinases. This class of receptors also 
encompasses ErbB-2 or Neu and ErbB-3 that bind similar ligands to 
betacellulin and maintain inter-receptor interactions through ligand-induced 
homo- and hetero-dimerisation (Dunbar and Goddard, 2000).  
Signalling through the ErbB receptors are known to be important for lineage 
determination during organogenesis (Huotari et al., 2002). In order to 
determine if betacellulin and its receptors were expressed in the developing 
pancreas, pancreata were isolated from E11.5 mouse embryos as described 
in Chapter 2 Section 2B.2.  The epithelium and mesenchyme were separated 
from pancreata (15 in total).  RNA was isolated from pooled pancreata and 
gene expression was analysed by RT-PCR (Fig. 5.1). Initially, the expression 
of the genes for the intermediate filament proteins cytokeratin 19 (CK19) and 
vimentin was analysed.  These were used as indicators of the purity of the 
mesenchymal and epithelial isolates respectively. Although the RNA isolated 
from the pancreatic epithelium contained considerable mesenchymal 
contamination (seen as vimentin expression), the RNA from the pancreatic 
mesenchyme did not have any significant epithelial contamination. Btc, the 
gene for betacellulin was expressed only in the pancreatic epithelium and not 
in the mesenchyme. The receptor genes ErbB-1 and ErbB-4 were both 
strongly expressed in the pancreatic epithelium but in a lower level in the 
mesenchyme. Erb-B1 seemed to be the predominant receptor type in the 
pancreatic mesenchyme. Despite some mesenchymal contamination in the 
epithelial isolate, the results were conclusive for the pattern of betacellulin 
expression being confined to the epithelium and its receptors being 
expressed in both the tissue types.  
 
  
 
5.2 The effect of betacellulin on the branching morphogenesis of the 
developing pancreas. 
Although the main interest was to determine the effects of betacellulin on 
beta cell differentiation, there were other changes in the pancreatic buds 
following culture with betacellulin. These changes are also worthy of 
comment.  ErbB receptor ligands are known to act as strong in vitro 
branching morphogens (Huotari et al., 2002, Li et al., 2003, Sakurai et al., 
1997). During the first few days of culture the epithelium became an 
extended branched structure, which can be observed under transmitted light 
conditions (Fig. 5.2A). Addition of betacellulin increased branching and 
dilation of the incipient pancreatic ducts (Fig. 5.2B). CK19, a cytoskeletal 
protein, is present in the incipient ductal cells of the pancreas as well as in 
developing acini (Bouwens et al., 1995). To confirm the increase in 
branching morphogenesis, control and betacellulin-treated cultures were 
immunostained with an anti-CK19 antibody. Betacellulin promoted branching 
morphogenesis based on the more extensive CK19 immunostaining (Fig. 
5.3). The differences in branching between the untreated and betacellulin-
treated buds were quantified by measuring the length along the CK19-
positive branches of the pancreatic ductal network. The results indicated that 
a 3.5-fold increase in branching was induced by betacellulin (Table 5.2). This 
implies a possible role for betacellulin in proliferation of the incipient ducts. 
To test this idea, the cell-proliferation marker phosphohistone-3 (PH3) was 
co-stained with CK19 in control and betacellulin-treated samples. However, 
no co-localisation of PH3 with CK19-positive cells was observed at any of the 
time-points examined (days 2, 3, 5 and 9), suggesting that proliferation of the 
ductal cells may take place prior to them becoming CK19-positive (Fig. 5.4A-
B). Instead, PH3-positive cells were mainly localised to the mesenchyme 
layer (Fig. 5.4C-D). Overall, betacellulin-treated samples contained 
increased numbers of PH3-positive cells compared with the controls (Table 
5.2).   
After 10 days of culture with betacellulin, pancreatic buds had a thicker and a 
wider area of mesenchyme in comparison with untreated buds which ties in 
with the increased mesenchymal proliferation (PH3-positive cells) 
  
 
observation following betacellulin treatment. The total area occupied by the 
epithelium and the mesenchyme was measured using E-cadherin and 
smooth muscle actin as their respective markers. The 
mesenchymal:epithelial ratio for control and betacellulin-treated buds is 
shown in Table 5.2. The results indicate that there was more than a 1.5-fold 
increase in the mesenchymal:epithelial ratio after betacellulin treatment. 
However it is not clear if the expansion of the mesenchyme following 
betacellulin treatment was a direct effect mediated via the ErbB receptors in 
the mesenchyme or an indirect effect due to a more elaborate ductal 
network. 
 
Table 5.2. Betacellulin regulates embryonic pancreatic development 
 Control Betacellulin n 
Mesenchymal:epithelial ratio 13.20±1.01 21.73±1.12
a 
3 
Length of the entire ductal network (×10
3 
µm) 2.40±0.25 8.43±0.53
b 
4 
Total area of amylase-positive cells (×10
3 
µm
2
) 32.11±3.41 1.73±0.45
b 
4 
Total area of insulin-positive cells (×10
3 
µm
2
) 72.75±8.26 235.60±29.34
a 
6 
Area of insulin-positive cells/no. of SS cells (
 
µm
2
) 439.7±43.24  398.0±33.59
c 
4 
Area of insulin-positive cells/no. of PP cells (µm
2
) 578.8±50.47 1,026.0±132.00
a 
4 
Area of insulin-positive cells/no. of ghrelin cells (µm
2
) 3,490±215.80 1,937±224.50
a 
4 
Total PH3-positive cell count 1,377±72.26 2,165±115.10
a 
4 
Maximum diameter of beta cells (µm) 13.91±0.24 13.61±0.17
c
 50 
a 
p=0.0286; 
b 
p=0.0079; 
c
 non-significant between control and betacellulin-treated 
 
5.3 Betacellulin reduces the pancreatic acinar cell population. 
Amylase-expressing cells were present in the control pancreatic organ 
cultures at day 7 and the numbers increased further by day 10. The amylase-
expressing cells were distributed around the periphery of the branches and 
were distinct from the endocrine cell populations (Fig. 5.5A,C). In contrast, 
the betacellulin-treated pancreatic tissue either completely lacked or had 
reduced numbers of amylase-expressing cells (Fig. 5.5B,D). Under 
transmitted light, the zymogen granules, which store the exocrine enzymes, 
were clearly visible in the control (Fig. 5.6A) but not in the betacellulin-treated 
  
 
(Fig. 5.6B). Overall, betacellulin treatment reduced the number of amylase-
positive cells (measured as the total area covered by amylase-positive cells) 
by 18.5-fold (Table 5.2). Western blot analysis confirmed this observation 
and showed the virtual absence of the amylase protein in betacellulin-treated 
samples (see Fig. 5.11). Furthermore, the pro-apoptotic protein caspase-3 
was observed in acinar tissue of betacellulin-treated samples (Fig. 5.7), 
whereas it was much more difficult to find caspase-3-positive cells in control 
buds. Therefore the reduction in amylase-positive cells may be mediated 
through apoptosis in betacellulin-treated samples. However, following the 
upregulation of activated caspase-3 in betacellulin-treated cultures, a 
concurrent decrease in the level of the transcription factor Ptf1a was also 
observed (Fig. 5.11). Since Ptf1a plays a vital role in early exocrine fate 
determination, the combined data suggest that the effect of betacellulin on 
the exocrine cells might in fact act at two different levels- before and after 
endocrine differentiation has taken place. On the other hand, hepatocyte 
nuclear factor (HNF) 4α, which is not known to play a pivotal role in either 
alpha or beta cell differentiation, was present at similar levels in both treated 
and untreated samples. 
 
5.4 The effects of betacellulin on the pancreatic endocrine lineages. 
One of the main aims of this chapter was to identify factors that promote beta 
cell differentiation.  To address this point, the effect of betacellulin on insulin-
expressing endocrine cells was investigated. In both betacellulin-treated and 
untreated samples, after 10 days of culture, insulin-positive beta cells 
outnumbered any other endocrine cell type. However, the distribution and 
organisation of the beta cells were noticeably different between treated and 
untreated samples. In the untreated pancreatic buds, there were greater 
numbers of beta cells clumped together in large islet-like structures (Fig. 
5.8A). In contrast, the betacellulin-treated buds had smaller clumps of beta 
cells that were dispersed throughout the organ culture (Fig. 5.8B). 
Additionally there were many individual cells or small islet-like cell clusters 
positive for insulin in the inter-islet regions and in close proximity to the 
  
 
ducts. Betacellulin induced an approximately three-fold increase in the 
number of beta cells (measured as the total area covered by insulin-positive 
cells) with no significant change in cell size (Table 5.2). This observation was 
further confirmed by western blotting for insulin protein (see Fig. 5.11). To 
test whether betacellulin increased the number of beta cells by increasing the 
proliferation of beta cells, the pancreatic buds were co-stained for insulin and 
the proliferation marker PH3. Betacellulin did not affect the proliferation of 
insulin-positive beta cells and only a few insulin-positive cells co-stained with 
PH3 (see Fig. 5.4A, B).  
In control samples, the classic islet morphology was preserved with 
glucagon-expressing cells present in the periphery and these cells 
outnumbered all other endocrine cell types except beta cells by day 10 of 
culture (Fig. 5.8A). However, in the betacellulin-treated samples, the number 
of glucagon-positive cells was reduced to just a few cells in each pancreas 
(Fig. 5.8B). Although glucagon protein was not detectable on the western 
blot, presumably because of its small size, the amount of the 18 kDa 
proglucagon peptide from which glucagon is derived was much higher in the 
untreated than betacellulin-treated pancreatic samples (Fig. 5.11).  
Since there was no evidence for changes of proliferative rate underlying the 
observed effects of betacellulin on the epithelial cell types it is more likely 
that the effects are due to an alteration in lineage determination of precursor 
cells. To examine this possibility, we determined the expression of pancreatic 
transcription factors by immunohistochemistry. By day 2 of culture, both 
control and betacellulin-treated samples showed high levels of Pdx1 (Fig. 
5.9). Pdx1 is a homeodomain protein that is expressed in the entire 
pancreatic anlagen at early stages of development. Normally, Pdx1 
expression declines during later embryonic stages in most of the pancreas 
but remains selectively expressed in the beta cells where it binds to and 
activates the insulin promoter. By day 5 of culture, the expression of Pdx1 
was indeed limited to insulin-positive cells in the untreated samples. In 
comparison, Pdx1 expression in the betacellulin-treated samples was not 
strictly confined to such insulin-positive cell clusters. Pdx1-positive cells in 
betacellulin-treated samples outnumbered all of the differentiated endocrine 
  
 
cells put together and the expression was more ubiquitous, extending to cell 
populations that might be acinar or ductal in nature (although this was not 
conclusively determined due to difficulty of co-staining acinar and ductal 
markers along with Pdx1). Pdx1 protein was also higher in betacellulin-
treated samples compared with controls (see Fig. 5.11). Pdx1 expression is 
normally downregulated in non-beta cells during late embryonic development 
(Stoffers et al., 1999) and prolonged expression of Pdx1 in the exocrine 
portion of the pancreas has been shown to cause acinar-to-ductal metaplasia 
mediated through activation of the signal transducer and activator of 
transcription-3 (Stat3) (Miyatsuka et al., 2006). This is very similar to what 
was observed, in that an increase of developing ducts relative to developing 
amylase-positive cells was seen. Therefore it was of interest to find out if 
Stat3 was activated following betacellulin treatment. Previously, Stat3 has 
been shown to be activated in cells of human pancreatic cancers (Greten et 
al., 2002, Scholz et al., 2003) and in the metaplastic cells that form ductal 
cells (Miyatsuka et al., 2006). When pancreata were cultured with and 
without betacellulin for 7 days activated Stat3 (phosphorylated on Tyr705) 
was found in betacellulin-treated samples (Fig. 5.11). Phosphorylated Stat3 
was absent in control samples at the time-point examined. A higher level of 
expression of the pro-endocrine transcription factor Sox9 (Fig. 5.11) was also 
seen following betacellulin treatment suggesting that endocrine progenitors 
may also contribute to the increases beta cell mass.  
The effects of betacellulin on the pancreatic polypeptide producing PP cells, 
somatostatin-containing delta cells and the ghrelin-containing cells were also 
investigated (Fig. 5.10). All these cell types were found in both the control 
and betacellulin-treated samples, but in smaller numbers compared with beta 
and alpha cells. PP cells were observed at a greater frequency in the 
untreated cultures than in the betacellulin-treated cultures (Table 5.2). 
Normally they are found clustered in or near the islets. In the betacellulin-
treated samples, clusters of PP cells were absent and they were found 
mostly individually, in pairs or as triplets (Fig. 5.10D). The frequency of 
occurrence of delta cells within islets was similar in both betacellulin-treated 
and untreated cultures (Table 5.2). The differences in cell numbers for delta 
  
 
cells were relative to the size of the pancreatic buds with and without 
treatment. This observation was also confirmed by western blot analysis for 
the amounts of SS protein normalised to the total amount of protein (Fig. 
5.11). Unlike PP cells, the delta cells did not cluster. Furthermore, as is 
typical in both treated and untreated samples, some of the SS-positive cells 
also co-expressed insulin (appears yellow on merged images; Fig. 5.10B). 
Ghrelin was the least abundant islet hormone in the pancreatic organ 
cultures (Fig. 5.10E, F). However, the number of cells expressing ghrelin was 
higher following betacellulin treatment (Table 5.2) and western blotting 
showed that the betacellulin-treated samples had considerably higher levels 
of ghrelin protein compared with the untreated samples (Fig. 5.11). Overall, 
betacellulin-treatment had an effect on most of the exocrine and endocrine 
cell types analysed; with a positive effect on beta cell differentiation as well 
as the numbers of ghrelin-positive cells and a negative effect on the numbers 
of alpha, acinar and PP cells. 
 
5.5 Screen for extrinsic factors that facilitate hepatic to beta cell 
conversion.  
For the induction of a beta cell phenotype in hepatocytes, de-differentiation 
and transcription factor over-expression alone was not sufficient to produce 
high levels of insulin expression. Cell differentiation and maturation can be 
expressed as functions of time, cell lineage and niche or milieu. Various 
extrinsic factors play an important role in providing this niche in which cells 
differentiate. Therefore it was necessary to resort to extrinsic factors to 
produce more as well as mature beta-like cells. The use of extrinsic factors 
for the in vitro differentiation of cells is not a new area of research. For 
example, interleukin-3 and interleukin-6 treatment can drive mouse ES cells 
into erythroid and lymphoid lineages respectively (Wiles and Keller, 1991). 
More recently, D’Amour et al., (2006) has developed a five stage protocol for 
generating pancreatic-hormone expressing cells from human ES cells. By 
altering media conditions (serum content and media compositions) along 
with media supplementation with growth factors, the procedure mimics 
  
 
normal pancreatic development by driving the cells through five identifiable 
endodermal intermediates en route to becoming hormone producing 
endocrine cells.  
A screen was carried out for extrinsic factors (including growth factors and 
factors that modify gene expression) that have previously been reported to 
either promote beta cell differentiation, proliferation, maturation and survival, 
or that increase levels of insulin expression and secretion (see Table 5.1). 
The rationale for using the diabetogenic agents, streptozotocin and alloxan, 
was based on reports that, elevated levels of insulin transcript and insulin 
positive cells were observed in the livers of streptozotocin-induced diabetic 
mice and not in non-diabetic mice (Kojima et al., 2003). For these 
experiments, hepatocytes were isolated from rats and cultured under DS 
conditions to facilitate de-differentiation. The de-differentiated hepatocytes 
were then transduced with a combination of viruses encoding Pdx1, 
Neurogenin3, NeuroD, Pax4 and MafA on day 3 after isolation (as described 
in Chapter 4). The treatments were initiated on day 3 after isolation (except 
for γ-secretase inhibitors which were added into the medium soon after cell-
attachment) and continued by supplementing the culture media with the 
relevant concentration of the extrinsic factors each time the media was 
changed daily. The treatments were followed for five days, before RNA 
isolation and analysis of insulin 1 expression by RT-PCR.  
Betacellulin, in accordance with the data above also increased the level of 
insulin expression in de-differentiated hepatocytes transduced with the 
combination of the five transcription factors (Fig. 5.12). On the first round of 
the experiments, similar high levels of insulin 1 expression was seen with 
nicotinamide and exendin-4 treatments as well as with a combination 
treatment of Activin A and betacellulin. All the other factors screened did not 
give any notable increase in the levels of insulin 1 expression compared to 
the untreated controls (Fig 5.12). The experiment was repeated for the four 
highest scoring treatments, however it is important to note that there was 
some variation in the response to the extrinsic factors. In the second and 
third rounds of the experiment, exendin-4 did not give notably high levels of 
insulin 1 expression, but betacellulin, Activin A and nicotinamide did. 
  
 
Ultimately, the highest level of insulin 1 expression was reproducibly seen 
with a combination of 10ng/ml betacellulin, 10nM Activin A and 20mM 
nicotinamide (Fig. 5.13). 
Addition of betacellulin to cultured embryonic pancreata enhanced the 
differentiation of some cells (e.g. beta cells) whereas it inhibited the 
production of others (e.g. alpha cells. The ability to enhance the 
differentiation of beta cells is instrumental in producing a homogenous 
population of beta-like cells for transplantation. Following de-differentiation 
and Pdx1 transduction alone, both pancreatic endocrine (insulin, SUR1, 
Kir6.2) and exocrine (amylase) markers were also induced. However, the 
inclusion of such exocrine enzyme secreting cell types, could lead to 
pancreatitis. When the expression of various endocrine hormone genes as 
well as exocrine genes were analysed after multiple viral transductions and 
extrinsic factor treatments, it was observed that the levels of the exocrine 
gene amylase was much reduced compared to untreated samples (Fig. 
5.14). Although glucagon, somatostatin and pancreatic polypeptide 
expression still remained, it was much more diminished after the extrinsic 
factor treatments. Significantly, both multiple transcription factor transduction 
(Pdx1, Neurogenin3, NeuroD, Pax4 and MafA) and extrinsic factor 
treatments (betacellulin, Activin A and nicotinamide) enhanced the levels of 
insulin gene expression. The next step was to assess the maturity of the 
beta-like cells generated by determining the performance of the beta-like 
cells in different functional assays. 
 
 5.6 Analysis of pro-insulin processing in beta-like cells. 
In functional beta cells, insulin hormone is produced from the pro-insulin 
precursor molecule by the action of proteolytic enzymes which include the 
prohormone convertases and the exoprotease, carboxypeptidase E. The 
type I (PC1/PC3) and type II (PC2) prohormone convertases are involved in 
the cleavage of the connecting peptide (C-peptide) from the pro-insulin 
molecule leaving the remaining A- and B-chains of the mature insulin 
molecule bound together by disulphide bonds. Both type I and type II 
  
 
prohormone convertases were induced in hepatocytes following de-
differentiation and further enhanced by Pdx1 and multiple transcription factor 
transduction (Fig 5.15A). The levels of PC2 were generally lower than the 
levels of PC1/3. Analysis of the expression of these proteolytic enzyme 
genes provides a clue as to whether cells are capable of processing pro-
insulin into its mature functional form. However, it does not serve as 
conclusive evidence to if pro-insulin processing takes place.   
Once cleaved, the C-peptide is stored together with insulin in mature 
granules until it is released intraportally with insulin, on an equimolar basis. 
But unlike insulin which undergoes a large hepatic extraction (~50%), C-
peptide can be detected in the peripheral circulation without appreciable 
extraction by the liver (Ferrannini and Cobelli, 1987). The level of C-peptide 
in the blood is hence often used as an indicator of how much insulin is made 
in the pancreas. Therefore the C-peptide content of cell lysates was 
measured using a Rat C-peptide enzyme-linked immunosorbant assay. De-
differentiated hepatocytes transformed with the four different transcription 
factors, Pdx1, Neurogenin3, NeuroD and Pax4, showed more efficient insulin 
processing capabilities indicated by a 1.6-fold increase in the amount of C-
peptide levels compared to those infected with just Ad-Pdx1 alone (Fig. 
5.15B). A further 1.6-fold enhancement of the levels of C-peptide was 
obtained following the inclusion of MafA in the transcription factor 
combination and a further augmention by the treatments with the 
combination of extrinsic factors- betacellulin, Activin A and nicotinamide. In 
contrary to the stoichiometry of the proteolytic reaction, the levels of insulin 
and C-peptide were not detected at the expected equimolar concentrations. 
The levels of insulin were consistently higher than the C-peptide levels. C-
peptide could be lost during the protein isolation protocol by acid-ethanol 
extraction.  C-peptide is a much smaller protein (2.75kDa) compared to 
insulin (5.81kDa).   
 
 
  
 
5.7 Assessing beta cell function by glucose-stimulated insulin 
secretion (GSIS). 
De-differentiated hepatocytes express genes encoding the glucose sensing 
and insulin release machinery. If beta-like cells generated from hepatocytes 
are to serve as surrogate beta cells they need to be able to secrete insulin in 
a glucose sensitive manner. Therefore the percentage of stored insulin 
released by the reprogrammed hepatocytes, in response to stimulation by 
25mM glucose was determined by measuring the levels of insulin in the cells 
and the media before and after a 1 hour period of stimulation with 25mM 
glucose. De-differentiated cells were able to respond to high glucose 
concentration by releasing more insulin into the medium. A somewhat higher 
constitutive insulin release was shown by de-differentiated cells after 
infection with Ad-Pdx1, and a further 2.8-fold increase was seen in response 
to the 25mM glucose (Fig. 5.16). The response was more regulated in de-
differentiated cells after infection with adenoviruses coding for Pdx1, 
Neurogenin3, NeuroD and Pax4. These cells showed a minimal basal level 
of insulin release at 5.5mM glucose but a 9.2-fold increase following glucose 
stimulation with 25mM glucose. The levels of basal insulin secretion 
remained low at around 2.7% (of the total insulin content of the cell being 
released) in 5.5mM glucose even with MafA over-expression and extrinsic 
factor treatments combined. Although the amount of insulin in the cells was 
more with the four transcription factors plus MafA (see Fig. 5.15B), the 
percentage released in response to the higher glucose concentration was 
lower than the combination without MafA. This is indicative of a more 
regulated secretion and a more mature beta cell phenotype brought about by 
MafA over-expression. A slight increase in the percentage of stored insulin 
released in response to glucose stimulation was observed following the 
extrinsic factor treatments. However, this does not necessarily mean a loss 
of maturity or the ability to regulate insulin secretion, but instead highlights 
the fact that betacellulin, nicotinamide and possibly Activin A can stimulate 
insulin release (Soria et al., 2001). The ability to secrete insulin following 
external glucose changes of this magnitude is a key aspect of the beta cell 
phenotype.  
  
 
5.8 Incretin responsiveness of beta-like cells. 
In addition to glucose, other factors such as the gut hormone glucagon like 
peptide 1 (GLP1) can act as insulin secreatgogues. GLP1 is also considered 
to act as an incretin by which it augments insulin secretion.  It is released into 
the circulatory system in response to ingestion of a meal (Ahren, 1998, 
Drucker, 2002). In vivo, the incretin effect is necessary to mediate the beta 
cell response to ingested glucose. It is therefore of interest to test the 
response of beta-like cells to incretins. We first determined, the expression of 
the GLP1 receptor (GLP1-R) by RT-PCR. GLP1-R was one of the pancreatic 
beta cell genes that was induced following de-differentiation (Fig. 5.17A). 
Similar to insulin and the other beta-specific cell genes, the level of GLP1-R 
expression was further increased by transcription factor over-expression as 
well as by the addition of extrinsic factor treatments. To test the 
responsiveness of the cells to incretins, the GLP1-R agonist and GLP1 
homolog, exendin-4 (at a 10nM final concentration) was added in the 
presence of 5.5mM and 25mM glucose and left for 1 hour. Addition of 
exendin-4 increased the levels of insulin secretion under both high and low 
glucose conditions. However, the changes in insulin following exendin-4 
addition were not statistically significant (5.17B). The insulinotropic properties 
of GLP1 are largely dose-dependent as well as glucose-dependent. 
Therefore more intricate adjustments to the incretin dose, length of 
stimulation and glucose concentration maybe necessary to achieve more 
overt GLP1 or exendin-4 responsiveness in reprogrammed hepatocytes.  
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
 
  
 
 
  
 
 
  
 
DISCUSSION 
While the complex transcription factor networks constitute the intracellular 
signals that control beta cell differentiation, the extrinsic factors are a means 
of mimicking intercellular communication. The interplay between these intra- 
and intercellular components is necessary for cell specification, 
differentiation as well as the patterning of virtually homogenous progenitor 
cell populations into the well-organised, complex, functional organs. Most of 
these extrinsic factors influence some the major signalling pathways involved 
in pancreatic development, including the TGFβ, Notch, hedgehog, FGF and 
EGF pathways (Kim and Hebrok, 2001). Further knowledge of how these 
extrinsic factors govern normal pancreatic development would serve as a 
platform for their use in cellular reprogramming. Therefore the effect of 
betacellulin on the development of the embryonic pancreas was investigated 
in detail. 
Addition of exogenous betacellulin induced multiple effects on embryonic 
pancreatic development. Betacellulin inhibited expression of amylase and 
glucagon, increased the expression of insulin and ghrelin and enhanced 
branching morphogenesis in an in vitro model of murine embryonic pancreas 
development. Betacellulin-null mice do not display any overt pancreatic 
defects, possibly due to functional redundancy and compensation by other 
EGFR ligands (Jackson et al., 2003). Pancreata of EGFR-deficient mice 
show impaired ductal branching, suggesting that this phenotype is mediated, 
in part, by the activation of a common EGFR downstream signalling pathway, 
possibly the MEK/ERK pathway (Miettinen et al., 2000, Rescan et al., 2005). 
To date, no study has examined the effects of betacellulin on branching 
morphogenesis in pancreatic explant cultures from E11.5d embryos. With 
CK19 as a marker of ductal cells, the results show that betacellulin increases 
branching morphogenesis. The mechanism of betacellulin action on ductal 
morphogenesis is probably mediated by increased differentiation from 
epithelial progenitors rather than by increased proliferation. This is 
reminiscent of the transdifferentiation of acinar cells to ductal cells that has 
previously been observed in culture (Rooman et al., 2000) and in transgenic 
  
 
mice over-expressing Pdx1 (Miyatsuka et al., 2006). Consistent with these 
studies an increase in the level of activated Stat3 is also seen. It is also 
probable that betacellulin is delaying or suppressing differentiation of the 
primordial duct-like epithelium into amylase-positive cells as a result of the 
continued expression of Pdx1. It is known that mesenchymal factors such as 
follistatin can regulate the proportion of exocrine and endocrine cell types 
(Miralles et al 1998). A reduction in the number of amylase-positive cells in 
the presence of mesenchymal proliferation was observed. Since the genes 
for ErbB1 and ErbB4 receptors are differentially expressed in both the 
mesenchyme and the epithelium, it is possible that the effect of betacellulin 
on both tissue types is independent rather than the change in amylase being 
brought about via a paracrine action emanating from the mesenchyme. 
Therefore the reduction in amylase-positive cells might also be mediated 
through apoptosis, since persistent upregulation of Pdx1 has previously been 
shown to destroy pancreatic acinar cells by the activation of the apoptotic 
pathways (Heller et al., 2001). It has also been observed that acinar 
apoptosis is associated with ductal proliferation after duct ligation (Abe and 
Watanabe, 1995). An upregulation of activated caspase-3 was seen, after 
betacellulin treatment and a concurrent decrease in the level of the 
transcription factor Ptf1a, which is necessary for early exocrine 
determination. One hypothesis to explain the pro-apoptotic action of 
betacellulin compared with other receptor tyrosine kinase ligands (e.g. EGF) 
is that it is acting through a different receptor or post-receptor events (Jones 
et al., 1999).  
Both by immunofluorescence microscopy and western blotting, it was seen 
that betacellulin enhances the number of insulin-positive beta cells and the 
overall levels of insulin in the developing pancreas. Betacellulin is reported to 
regulate the proportion of beta cells in other systems (Demeterco et al., 
2000, Huotari et al., 2002, Li et al., 2001). Three mechanisms might explain 
the increase in the number of beta cells. The additional beta cells could arise 
by: (1) the proliferation of existing beta cells; (2) the differentiation of 
endocrine precursor cells into beta cells rather than other endocrine cells; or 
(3) the conversion of exocrine and ductal cell types into beta cells. The first 
  
 
possibility can be ruled out because if the extra beta cells did arise due to the 
proliferation of existing beta cells, larger islets would be seen and an 
increased number of cells that show co-localisation for PH3 and insulin. 
However this was not the case. Similarly, the third possibility is unlikely as 
exocrine cell apoptosis was widespread in betacellulin treated samples. 
Huotari et al., (2002) described the modulation of endocrine lineages by 
different growth factors. In the absence of EGFR signalling, differentiation 
followed a default pathway towards alpha and PP cells. The reduction in the 
number of alpha and PP cells seen in the presence of betacellulin suggests 
that betacellulin might be influencing the fate choice made by the early 
endocrine precursor cells and shifting the balance towards a beta cell 
phenotype. All pancreatic endocrine cell types initially arise from common 
multipotent precursor cells that express Pdx1 but the continued expression of 
Pdx1 is only necessary for the development of beta cells and not other 
endocrine cell types (Jensen, 2004). The widespread late Pdx1 expression 
seen in the betacellulin-treated pancreata might therefore bias the 
commitment of endocrine precursors toward beta cells. Cell lineage studies 
have localised the endocrine progenitor cells close to the primitive ducts of 
the foetal pancreas (Ogata et al., 2004). The Pdx1 expression that is not 
restricted to the islets is seen in these regions after betacellulin treatment. 
During proliferation, duct cells have the potential to lose their ductal 
phenotype and revert back to multipotent cells (Bonner-Weir et al., 2000). 
This is achieved by the ductal cells expressing Pdx1, differentiating into beta 
cells, then migrating away from the ducts and clustering to form islets (Abe 
and Watanabe, 1995). The possibility of duct cell derived beta cells in this 
manner could explain the enhanced number of Pdx1-expressing cells in the 
ducts, the presence of islet-like cell clusters and the insulin-positive cells 
found in isolation. So, betacellulin is probably influencing beta cell formation 
both by increasing the proportion of endocrine cells and by increasing the 
proportion of endocrine precursors that become beta cells.  
Collectively the changes seen may largely be brought about by prolonged 
ubiquitous expression of Pdx1. Elevated Pdx1 expression suppresses early 
differentiation of the endodermal pancreatic precursor tissue and enhances 
  
 
branching and formation of beta cells. This makes betacellulin a hopeful 
candidate for stimulating beta cell regeneration in vivo, or increasing the 
proportion of beta cells in vitro in situations where beta cell differentiation is 
being sought with a view to transplantation.  
In light of such evidence, betacellulin transduction has been used in 
combination with NeuroD to trigger formation of insulin-secreting cells in the 
liver and completely reverse diabetes in STZ-treated mice (Kojima et al., 
2003). The result of treating reprogrammed hepatocytes with betacellulin 
was promising, giving a much more enhanced level of insulin expression 
compared to the other treatments. All the factors that were highlighted along 
with betacellulin in the screen (Activin A and nicotinamide) have all be shown 
to facilitate beta cell differentiation (eg:- Sjoholm et al., 1994, Mashima et al., 
1996, D'Amour et al., 2006) although not in combination nor from 
reprogrammed hepatocytes. Furthermore, nicotinamide has also been shown 
to protect beta cells against necrosis thereby proving useful for intervention 
trials undertaken to prevent type I diabetes in high risk subjects (Hoorens 
and Pipeleers, 1999). Factors such as betacellulin and nicotinamide have 
effects on both undifferentiated progenitors in terms of differentiation and on 
differentiated mature beta cells in terms of insulin secretion. The 
inconsistency of the results with the other extrinsic factors (that affects either 
progenitors or mature beta cells) could be in part due to the heterogeneity of 
the treated cell population, where the proportions of cells at each stage of 
differentiation are not identical each time. Therefore, a more directed 
stepwise differentiation protocol and prior selection might be necessary to 
see an effect with the other extrinsic factors rather than treating a 
heterogeneous population.  
The treatment with betacellulin, Activin A and nicotinamide following 
transcription factor transductions brings hepatocyte reprogramming a step 
closer to producing mature beta-like cells. Following the treatments and 
transcription factor over-expression, a propitious shift towards homogeneity 
and concurrent diminution of exocrine and ‘non-beta’ endocrine genes was 
observed. This is partly due the inclusion of transcription factors specific to 
mature beta cells such as MafA as well as the influence of betacellulin (and 
  
 
possibly Activin A and nicotinamide) in directing beta cell differentiation at the 
expense of other cell types as discussed above for the organ cultures.  
At the final stage of differentiation described here, the reprogrammed 
hepatocytes exhibited several properties of mature beta cells. The cells were 
capable of processing pro-insulin into mature insulin and were responsive to 
changes in external glucose concentrations. At a low external glucose 
concentration, the level of insulin secretion was present though minimal. 
However, this constitutive insulin secretion is paramount for beta cells to 
maintain their sensitivity to glucose as well as to amplify the glucose-
stimulated insulin response at higher glucose concentrations (Srivastava and 
Goren, 2003). The percentage of insulin secreted in response to high 
glucose by reprogrammed hepatocytes was above ~15%. Although a direct 
comparison was not made with bone-fide beta cells or isolated islets, based 
on the literature, the percentage of stored insulin released by beta cells in 
response to glucose is only 2-4%. The reason for this difference could either 
be because the reprogrammed hepatocytes exhibit only low levels of stored 
insulin compared to beta cells or are still immature and lack some of the 
molecular machinery needed for efficient regulated insulin secretion.  The 
latter reason could likewise explain the low response to incretins that was 
also observed.  
In summary, the extrinsic factor treatments proved beneficial in pushing the 
beta-like cells generated from reprogrammed hepatocytes towards maturity. 
It was not sufficient to produce cells that exactly mimic beta cell function; 
nonetheless many of the criteria were fulfilled.  Methods for further 
maturation will be needed and await elucidation. Although sequential 
transcription factor transduction of primary hepatocytes is not a reality at 
moment, such an approach may be redeemed in order to bring about a more 
directed differentiation towards mature beta-like cells using the transcription 
  
 
Chapter SIX
General Discussion  
  
 
GENERAL DISCUSSION AND CONCLUSION 
The molecular reprogramming of hepatocytes into insulin producing beta-like 
cells has challenged our view of the rigidity of the differentiated phenotype of 
cells. It has also brought us a step closer in producing extra-pancreatic 
surrogate beta cells for diabetes therapy. Overall the results reported in this 
thesis outline the stepwise development of a protocol for the generation of 
functional beta-like cells from hepatocytes by molecular reprogramming 
strategies. Firstly the phenomenon of de-differentiation, though long 
considered a hindrance for hepatocyte culture, in facts acts in favour of 
molecular reprogramming. De-differentiation of hepatocytes resulted in the 
induction of mature pancreatic and pancreatic progenitor-specific genes, 
while synergising the effects of the transduced Pdx1. However it can be 
semantically argued that this does not constitute a true transdifferentiation 
event as previously envisaged, as the change is mediated via a progenitor-
like de-differentiated intermediate instead of being a direct conversion. 
Furthermore, it is imperative that the mechanism behind this spontaneous 
gene induction be elucidated. It would be important to ascertain the changes 
taking place at the chromatin level in terms of switching off the hepatic genes 
and dictating the transcriptional activation of the pancreatic genes. This 
would enable us to bring about similar changes in gene expression through a 
more defined protocol- encompassing more specific chromatin remodelling 
agents, siRNA gene-silencing techniques as well as selecting the particular 
components of the DS media that are preponderant in the de-differentiation 
process.  
Although many approaches have been used in the past to generate beta-like 
cells from hepatocytes, those involving in vitro molecular reprogramming 
strategies are very limited. Furthermore, no other study has utilised a 
protocol integrating such a broad combination of transcription factors (Pdx1, 
Neurogenin3, NeuroD, Pax4 and MafA) along with a unique combination of 
extrinsic factors (betacellulin, nicotinamide and Activin A). However, it is 
important to note that the list of transcription factors screened while 
extensive was not exhaustive. It was based on the resources (in terms of 
  
 
adenoviral constructs) available at the time. Of late, there has been 
tremendous progress in revealing the emerging role of novel transcription 
factors (such as FoxO1) in beta cell differentiation and function (Glauser and 
Schlegel, 2007). Similarly several novel extrinsic factors and small molecules 
have been implied in beta cell differentiation, while the role of others have 
turned out to be more disputable (reviewed in Oliver-Krasinski and Stoffers, 
2008). Notwithstanding such emerging inconsistencies, the transcription 
factors and extrinsic factors used here have long been established as 
positive modulators of beta cell development and function.  
It is possible to generate insulin producing cells that are capable of 
processing pro-insulin and secreting insulin in a glucose-responsive manner. 
Despite this, a significant challenge that remains to be overcome is the 
overall low levels of insulin protein that was present, which was only a 
fraction (approximately 1/104) of the level in normal beta cells. A major part 
of continuing research should thus investigate means of intensifying the 
levels of insulin in the reprogrammed cells. Firstly, the extracellular factors 
during late-embryonic and neonatal beta cell development, of which we know 
little about, should be taken into consideration along with the indispensable 
importance of intercellular and epithelial-mesenchymal interactions. 
Secondly, the low levels of insulin could be due to the poor accessibility of 
the promoter targets for the transcription factors to have any effect. 
Therefore as already mentioned above, more efficient chromatin remodelling 
agents would be necessary to significantly improve the performance of the 
transcription factors themselves. Attaining immunodetectable levels of insulin 
would enable us to assess the efficiency of the reprogramming process in 
obtaining a potentially limitless source of stable and mature beta-like cells. 
This will in turn impinge on further improving the fidelity of the 
reprogramming protocol in a more systemic manner.  
Parallel studies also need to be carried out in assessing the in vivo 
functionality of the cells generated, in their competence to rescue 
hyperglycaemia in rodent models of diabetes. Surrogate beta cells can be 
transplanted into the liver via the hepatic vein, under the kidney capsule or 
into the epididymal fat pads of alloxan or steptozotocin-induced 
  
 
hyperglycaemic SCID or NOD/SCID mice. In light of recent evidence, it might 
not be necessary to delay transplantation until fully mature beta cells are 
obtainable by the reprogramming protocol. For instance, when deriving 
insulin-expressing cells from human ES cells, transplanting progenitor-like 
pancreatic endodermal cells enable them to mature in vivo into single-
hormone expressing endocrine cells more effectively, compared to 
transplantation of cells from later stages of the differentiation protocol 
(D'Amour et al., 2006, Kroon et al., 2008). Therefore the transplantation of 
more immature, endocrine or islet progenitor-like cells derived from de-
differentiated hepatocytes, into a diabetic environment could facilitate their 
differentiation into mature beta cells more efficiently under conditions 
otherwise irreproducible in vitro. 
Beta-like cells generated from hepatocytes by molecular reprogramming 
might not be capable of recapitulating all the functions of bone fide beta cells. 
Yet it would be beneficial in generating in vitro, a quality controlled and 
carefully selected source of cells to complement the inadequate supply of 
islets and pancreata available for transplantation. Moreover, it serves as a 
general paradigm for treating type 1 diabetes by cell-based therapies utilising 
beta cells generated in vitro. 
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Appendices
 
  
 
Appendix A :  List of all commercial suppliers of chemicals and antibodies. 
 
COMPANY DISTRIBUTER LOCATION INFORMATION 
Abcam Cambridge, UK www.abcamplc.com 
AbD Sero Tec Oxford, UK www.ab-direct.com 
AbGene Epsom, UK www.abgene.com 
Acris Herford, Germany www.acris-antibodies.com 
Amersham Biosciences Little Chalfont, UK www.gelifesciences.com 
Autogen-Bioclear Calne, UK www.autogenbioclear.com 
Baxter Healthcare Newbury, UK www.baxterhealthcare.co.uk  
BD Biosciences Cowley, UK www.bdbiosciences.com 
Beckman High Wycombe, UK www.beckmancoulter.co.uk  
Biogenesis Poole, UK www.biogenesis.co.uk 
BioRad Hemel Hempstead, UK www.bio-rad.com 
Calbiochem San Diego, CA www.calbiochem.com 
Cell Signalling Danvers, MA www.cellsignal.com 
Chemicon Chandlers Ford www.chemicon.com 
Clontech Laboratories Basingstoke, UK www.clontech.com/clontech 
Cypex Dundee, UK www.cypex.co.uk 
DAKO Ely, UK www.dako.co.uk 
Epitomics Burlingame, CA www.epitomics.com 
Fisher Scientific Loughborough, UK www.fisher.co.uk 
Gibco see Invitrogen see Invitrogen 
Invitrogen Paisley, UK www.invitrogen.org.uk 
Lab Vision Newmarket, UK www.labvision.com 
Leica Wetzler, Germany www.leica-microsystems.com 
Mercodia (Diagenics) Milton Keynes, UK www.diagenics.co.uk 
Millipore Bedford, UK www.millipore.co.uk 
MWG Primers see Invitrogen www.mwg-biotech.com 
Phoenix Pharmaceuticals Gloucester, UK www.phoenixpeptide.com 
Promega Southampton, UK www.promega.com/uk 
R&D systems Abingdon, UK www.rndsystems.com 
Roche Mannheim, Germnay www.roche.com 
Santa Cruz Biotech. Santa Cruz, CA www.scbt.com 
Sigma(-Aldrich) Poole, UK www.sigmaaldrich.com 
Thermo Scientific Winsford, UK www.thermo.com 
Transduction Labs see BD Biosciences see BD Biosciences 
Upstate Biotech. Lake Placid, NY see Chemicon 
Vector Laboratories Peterborough, UK www.vectorlabs.com 
VWR International Leighton Buzzard, UK uk.vwr.com 
Zymed Cambridge, UK www.zymed.com 
 
  
 
Appendix B 
 
• No primary controls were used to detect autoflorescence of secondary 
antibodies. Below are two examples. DAPI was used to stain the nuclei. 
  
NOTE: All scale bars 
represent 20µm. 
Antibody: go anti rb FITC 
Tissue: rat liver section 
Antibody: ho anti mo Texas Red 
Tissue: hepatocytes 
 
 
• Positive controls for the primary antibodies used.  Scale bar indicates 20µm. 
   
Antibody: rb anti-AFP 
Tissue: foetal rat liver 
Antibody: rb anti-Amylase 
Tissue: mouse panc. explant 
Antibody: rb anti-ChrA 
Tissue: adult rat pancreas 
   
Antibody: mo anti-CK19 
Tissue: mouse panc. explant 
Antibody: mo anti-CK20 
Tissue: mouse panc. explant 
Antibody: rb anti-C-peptide 
Tissue: adult rat pancreas 
  
 
   
Antibody: DBA-FITC 
Tissue: mouse panc. duct 
Antibody: mo anti-Glucagon 
Tissue: mouse panc. explant 
Antibody: rb anti-Glut2 
Tissue: rat hepatocytes 
   
Antibody: rb anti-HNF4 
Tissue: rat hepatocytes 
Antibody: gp anti-Insulin 
Tissue: mouse panc. explant 
Antibody: mo anti-Insulin 
Tissue: mouse pancreas 
   
Antibody: mo anti-OV6 
Tissue: Dex-treated B13 cells 
Antibody: rb anti-Pdx1 
Tissue: mouse panc. explant 
Antibody: rt anti-PECAM-1 
Tissue: mouse glomerulus 
   
Antibody: rb anti-PGP9.5 
Tissue: mouse panc. explant 
Antibody: rb anti-PH3 
Tissue: proliferating 
hepatocytes 
Antibody: mo anti-SMA-Cy3 
Tissue: embryonic 
mesenchyme 
  
 
   
Antibody: rb anti-Sox9 
Tissue: rat testes 
Antibody: rb anti-Thy1 
Tissue: E11.5 mouse liver 
Antibody: mo anti-Vimentin 
Tissue: mouse skin section 
KEY:  ho- horse; go-goat; gp-guinea pig; mo- mouse; rb- rabbit; rt-rat. 
  
 
Appendix C  
 
Full list of data for the transcription factor combination experiments for all 
combinations of seven (
7
C10). The values shown are the ∆∆CT values (x10
-6
 
normalised to Ins1RIN=1.0).  Highlighted are the 9 combinations that gave a value 
above the chosen threshold of 20.  
 
1.            Pdx1,Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax4,Pax6 11.70 
2.            Pdx1,Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax4,IA1 16.59 
3.            Pdx1,Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax4,Sox9 9.53 
4.            Pdx1,Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax4,p48 6.85 
5.            Pdx1,Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax6,IA1 11.95 
6.            Pdx1,Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax6,Sox9 6.43 
7.            Pdx1,Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax6,p48 13.09 
8.            Pdx1,Ngn3,NeuroD,Nkx2.2,Nkx6.1,IA1,Sox9 8.01 
9.            Pdx1,Ngn3,NeuroD,Nkx2.2,Nkx6.1,IA1,p48 0.00 
10.        Pdx1,Ngn3,NeuroD,Nkx2.2,Nkx6.1,Sox9,p48 0.00 
11.        Pdx1,Ngn3,NeuroD,Nkx2.2,Pax4,Pax6,IA1 11.07 
12.        Pdx1,Ngn3,NeuroD,Nkx2.2,Pax4,Pax6,Sox9 10.15 
13.        Pdx1,Ngn3,NeuroD,Nkx2.2,Pax4,Pax6,p48 0.37 
14.        Pdx1,Ngn3,NeuroD,Nkx2.2,Pax4,IA1,Sox9 22.31 
15.        Pdx1,Ngn3,NeuroD,Nkx2.2,Pax4,IA1,p48 15.32 
16.        Pdx1,Ngn3,NeuroD,Nkx2.2,Pax4,Sox9,p48 14.40 
17.        Pdx1,Ngn3,NeuroD,Nkx2.2,Pax6,IA1,Sox9 24.93 
18.        Pdx1,Ngn3,NeuroD,Nkx2.2,Pax6,IA1,p48 16.66 
19.        Pdx1,Ngn3,NeuroD,Nkx2.2,Pax6,Sox9,p48 24.01 
20.        Pdx1,Ngn3,NeuroD,Nkx2.2,IA1,Sox9,p48 12.11 
21.        Pdx1,Ngn3,NeuroD,Nkx6.1,Pax4,Pax6,IA1 10.67 
22.        Pdx1,Ngn3,NeuroD,Nkx6.1,Pax4,Pax6,Sox9 22.11 
23.        Pdx1,Ngn3,NeuroD,Nkx6.1,Pax4,Pax6,p48 24.79 
24.        Pdx1,Ngn3,NeuroD,Nkx6.1,Pax4,IA1,Sox9 15.68 
25.        Pdx1,Ngn3,NeuroD,Nkx6.1,Pax4,IA1,p48 200.45 
26.        Pdx1,Ngn3,NeuroD,Nkx6.1,Pax4,Sox9,p48 5.88 
27.        Pdx1,Ngn3,NeuroD,Nkx6.1,Pax6,IA1,Sox9 0.53 
28.        Pdx1,Ngn3,NeuroD,Nkx6.1,Pax6,IA1,p48 4.19 
29.        Pdx1,Ngn3,NeuroD,Nkx6.1,Pax6,Sox9,p48 2.42 
30.        Pdx1,Ngn3,NeuroD,Nkx6.1,IA1,Sox9,p48 0.78 
31.        Pdx1,Ngn3,NeuroD,Pax4,Pax6,IA1,Sox9 1.77 
32.        Pdx1,Ngn3,NeuroD,Pax4,Pax6,IA1,p48 0.54 
33.        Pdx1,Ngn3,NeuroD,Pax4,Pax6,Sox9,p48 2.30 
34.        Pdx1,Ngn3,NeuroD,Pax4,IA1,Sox9,p48 0.30 
  
 
35.        Pdx1,Ngn3,NeuroD,Pax6,IA1,Sox9,p48 20.15 
36.        Pdx1,Ngn3,Nkx2.2,Nkx6.1,Pax4,Pax6,IA1 0.60 
37.        Pdx1,Ngn3,Nkx2.2,Nkx6.1,Pax4,Pax6,Sox9 0.32 
38.        Pdx1,Ngn3,Nkx2.2,Nkx6.1,Pax4,Pax6,p48 0.00 
39.        Pdx1,Ngn3,Nkx2.2,Nkx6.1,Pax4,IA1,Sox9 0.39 
40.        Pdx1,Ngn3,Nkx2.2,Nkx6.1,Pax4,IA1,p48 0.49 
41.        Pdx1,Ngn3,Nkx2.2,Nkx6.1,Pax4,Sox9,p48 0.00 
42.        Pdx1,Ngn3,Nkx2.2,Nkx6.1,Pax6,IA1,Sox9 0.16 
43.        Pdx1,Ngn3,Nkx2.2,Nkx6.1,Pax6,IA1,p48 0.96 
44.        Pdx1,Ngn3,Nkx2.2,Nkx6.1,Pax6,Sox9,p48 1.40 
45.        Pdx1,Ngn3,Nkx2.2,Nkx6.1,IA1,Sox9,p48 17.76 
46.        Pdx1,Ngn3,Nkx2.2,Pax4,Pax6,IA1,Sox9 46.69 
47.        Pdx1,Ngn3,Nkx2.2,Pax4,Pax6,IA1,p48 1.39 
48.        Pdx1,Ngn3,Nkx2.2,Pax4,Pax6,Sox9,p48 6.10 
49.        Pdx1,Ngn3,Nkx2.2,Pax4,IA1,Sox9,p48 1.17 
50.        Pdx1,Ngn3,Nkx2.2,Pax6,IA1,Sox9,p48 2.53 
51.        Pdx1,Ngn3,Nkx6.1,Pax4,Pax6,IA1,Sox9 0.37 
52.        Pdx1,Ngn3,Nkx6.1,Pax4,Pax6,IA1,p48 0.81 
53.        Pdx1,Ngn3,Nkx6.1,Pax4,Pax6,Sox9,p48 1.06 
54.        Pdx1,Ngn3,Nkx6.1,Pax4,IA1,Sox9,p48 3.99 
55.        Pdx1,Ngn3,Nkx6.1,Pax6,IA1,Sox9,p48 0.11 
56.        Pdx1,Ngn3,Pax4,Pax6,IA1,Sox9,p48 1.98 
57.        Pdx1,NeuroD,Nkx2.2,Nkx6.1,Pax4,Pax6,IA1 34.88 
58.        Pdx1,NeuroD,Nkx2.2,Nkx6.1,Pax4,Pax6,Sox9 15.65 
59.        Pdx1,NeuroD,Nkx2.2,Nkx6.1,Pax4,Pax6,p48 3.22 
60.        Pdx1,NeuroD,Nkx2.2,Nkx6.1,Pax4,IA1,Sox9 2.48 
61.        Pdx1,NeuroD,Nkx2.2,Nkx6.1,Pax4,IA1,p48 1.79 
62.        Pdx1,NeuroD,Nkx2.2,Nkx6.1,Pax4,Sox9,p48 11.32 
63.        Pdx1,NeuroD,Nkx2.2,Nkx6.1,Pax6,IA1,Sox9 17.97 
64.        Pdx1,NeuroD,Nkx2.2,Nkx6.1,Pax6,IA1,p48 1.02 
65.        Pdx1,NeuroD,Nkx2.2,Nkx6.1,Pax6,Sox9,p48 10.42 
66.        Pdx1,NeuroD,Nkx2.2,Nkx6.1,IA1,Sox9,p48 1.15 
67.        Pdx1,NeuroD,Nkx2.2,Pax4,Pax6,IA1,Sox9 15.57 
68.        Pdx1,NeuroD,Nkx2.2,Pax4,Pax6,IA1,p48 1.61 
69.        Pdx1,NeuroD,Nkx2.2,Pax4,Pax6,Sox9,p48 8.08 
70.        Pdx1,NeuroD,Nkx2.2,Pax4,IA1,Sox9,p48 2.60 
71.        Pdx1,NeuroD,Nkx2.2,Pax6,IA1,Sox9,p48 2.98 
72.        Pdx1,NeuroD,Nkx6.1,Pax4,Pax6,IA1,Sox9 9.52 
73.        Pdx1,NeuroD,Nkx6.1,Pax4,Pax6,IA1,p48 4.27 
74.        Pdx1,NeuroD,Nkx6.1,Pax4,Pax6,Sox9,p48 1.24 
75.        Pdx1,NeuroD,Nkx6.1,Pax4,IA1,Sox9,p48 10.42 
76.        Pdx1,NeuroD,Nkx6.1,Pax6,IA1,Sox9,p48 6.67 
  
 
77.        Pdx1,NeuroD,Pax4,Pax6,IA1,Sox9,p48 2.73 
78.        Pdx1,Nkx2.2,Nkx6.1,Pax4,Pax6,IA1,Sox9 5.06 
79.        Pdx1,Nkx2.2,Nkx6.1,Pax4,Pax6,IA1,p48 4.07 
80.        Pdx1,Nkx2.2,Nkx6.1,Pax4,Pax6,Sox9,p48 0.00 
81.        Pdx1,Nkx2.2,Nkx6.1,Pax4,IA1,Sox9,p48 0.00 
82.        Pdx1,Nkx2.2,Nkx6.1,Pax6,IA1,Sox9,p48 4.18 
83.        Pdx1,Nkx2.2,Pax4,Pax6,IA1,Sox9,p48 0.00 
84.        Pdx1,Nkx6.1,Pax4,Pax6,IA1,Sox9,p48 1.32 
85.        Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax4,Pax6,IA1 5.85 
86.        Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax4,Pax6,Sox9 3.81 
87.        Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax4,Pax6,p48 4.66 
88.        Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax4,IA1,Sox9 0.00 
89.        Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax4,IA1,p48 2.86 
90.        Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax4,Sox9,p48 0.81 
91.        Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax6,IA1,Sox9 5.66 
92.        Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax6,IA1,p48 1.10 
93.        Ngn3,NeuroD,Nkx2.2,Nkx6.1,Pax6,Sox9,p48 6.10 
94.        Ngn3,NeuroD,Nkx2.2,Nkx6.1,IA1,Sox9,p48 1.69 
95.        Ngn3,NeuroD,Nkx2.2,Pax4,Pax6,IA1,Sox9 0.00 
96.        Ngn3,NeuroD,Nkx2.2,Pax4,Pax6,IA1,p48 2.22 
97.        Ngn3,NeuroD,Nkx2.2,Pax4,Pax6,Sox9,p48 2.68 
98.        Ngn3,NeuroD,Nkx2.2,Pax4,IA1,Sox9,p48 3.61 
99.        Ngn3,NeuroD,Nkx2.2,Pax6,IA1,Sox9,p48 2.91 
100.    Ngn3,NeuroD,Nkx6.1,Pax4,Pax6,IA1,Sox9 2.52 
101.    Ngn3,NeuroD,Nkx6.1,Pax4,Pax6,IA1,p48 5.00 
102.    Ngn3,NeuroD,Nkx6.1,Pax4,Pax6,Sox9,p48 1.93 
103.    Ngn3,NeuroD,Nkx6.1,Pax4,IA1,Sox9,p48 5.11 
104.    Ngn3,NeuroD,Nkx6.1,Pax6,IA1,Sox9,p48 4.96 
105.    Ngn3,NeuroD,Pax4,Pax6,IA1,Sox9,p48 3.11 
106.    Ngn3,Nkx2.2,Nkx6.1,Pax4,Pax6,IA1,Sox9 1.24 
107.    Ngn3,Nkx2.2,Nkx6.1,Pax4,Pax6,IA1,p48 2.01 
108.    Ngn3,Nkx2.2,Nkx6.1,Pax4,Pax6,Sox9,p48 0.87 
109.    Ngn3,Nkx2.2,Nkx6.1,Pax4,IA1,Sox9,p48 0.54 
110.    Ngn3,Nkx2.2,Nkx6.1,Pax6,IA1,Sox9,p48 0.98 
111.    Ngn3,Nkx2.2,Pax4,Pax6,IA1,Sox9,p48 1.04 
112.    Ngn3,Nkx6.1,Pax4,Pax6,IA1,Sox9,p48 1.01 
113.    NeuroD,Nkx2.2,Nkx6.1,Pax4,Pax6,IA1,Sox9 3.04 
114.    NeuroD,Nkx2.2,Nkx6.1,Pax4,Pax6,IA1,p48 0.00 
115.    NeuroD,Nkx2.2,Nkx6.1,Pax4,Pax6,Sox9,p48 0.99 
116.    NeuroD,Nkx2.2,Nkx6.1,Pax4,IA1,Sox9,p48 0.46 
117.    NeuroD,Nkx2.2,Nkx6.1,Pax6,IA1,Sox9,p48 2.49 
118.    NeuroD,Nkx2.2,Pax4,Pax6,IA1,Sox9,p48 1.76 
  
 
119.    NeuroD,Nkx6.1,Pax4,Pax6,IA1,Sox9,p48 2.08 
120.    Nkx2.2,Nkx6.1,Pax4,Pax6,IA1,Sox9,p48 0.00 
 
 
Repetition of the 9 combinations that gave a value above 20 along with a randomly 
chosen combination that gave a lower value (combination 54). Each value is a mean 
of a triplicate. N1 and N2 were two different PCR reactions from the same cDNA 
sample and N3 was repeated with cDNA newly synthesised from RNA from a 
different experiment. 
†- indicates an anomalous result. 
 
 N1 N2 N3 
54.        Pdx1,Ngn3,Nkx6.1,Pax4,IA1,Sox9,p48 3.99 6.32 4.56 
14.        Pdx1,Ngn3,NeuroD,Nkx2.2,Pax4,IA1,Sox9 22.31 24.72 20.93 
17.        Pdx1,Ngn3,NeuroD,Nkx2.2,Pax6,IA1,Sox9 24.93 22.51 29.47 
19.        Pdx1,Ngn3,NeuroD,Nkx2.2,Pax6,Sox9,p48 24.01 29.1 24.89 
22.        Pdx1,Ngn3,NeuroD,Nkx6.1,Pax4,Pax6,Sox9 22.11 32.06 24.64 
23.        Pdx1,Ngn3,NeuroD,Nkx6.1,Pax4,Pax6,p48 24.79 28.6 26.31 
25.        Pdx1,Ngn3,NeuroD,Nkx6.1,Pax4,IA1,p48 200.45
† 
30.44 28.01 
35.        Pdx1,Ngn3,NeuroD,Pax4,IA1,Sox9,p48 20.15 22.51 19.64 
46.        Pdx1,Ngn3,Nkx2.2,Pax4,Pax6,IA1,Sox9 46.69 38.26 29.4 
57.        Pdx1,NeuroD,Nkx2.2,Nkx6.1,Pax4,Pax6,IA1 34.88 19.23 24.15 
 
  
 
 
  
 
 
  
 
 
  
 
 
